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ABSTRACT 
There is substantial evidence to suggest that independent of conventional BP, LV 
mass (LVM) is higher in African-Americans than in European-Americans a difference that 
may translate into a higher prevalence of cardiovascular diseases. In the present thesis I 
assessed whether LVM is similarly elevated in groups of African descent living in Africa, 
and subsequently whether 24-hour, day or night BP or indices of arterial stiffness could 
explain the variability in LVM beyond conventional BP in this population group. As there 
is considerable controversy as to whether 24-hour BP measurements are better 
predictors of the regression of LVH than conventional BP and whether antihypertensive 
agents that target the renin-angiotensin system (RAS) regress LV hypertrophy (LVH) 
independent of BP in groups of African descent, in the present thesis I therefore also 
assessed these questions. 
In 141 healthy adult participants obtained from a random sample of nuclear 
families (n=399) of African ancestry living in Soweto, I determined that LVM adjusted for 
body surface area to the first power was an appropriate allometric signal to account for 
growth effects on LVM. The allometric signals established in other populations 
considerably over-adjusted for LVM in the group that I studied with marked negative 
relations noted. After adjusting for body surface area I noted upper thresholds of LVM 
index (LVMI) of 134 g/m2 for men and 112 g/m2 for women. As compared to thresholds 
described for other population samples these thresholds were noted to be modestly 
higher. 
In 187 women from randomly recruited nuclear families of African ancestry, after 
appropriate adjustments, conventional BP was as closely associated with LVMI as 24-
hour BP, and daytime BP was as closely associated with LVMI as night-time BP in 
women. However, in 110 men from randomly recruited nuclear families of African 
ancestry, after appropriate adjustments, only night-time BP was associated with LVMI, 
an effect that was independent of conventional BP (r=0.21, p<0.05). Indices of nocturnal 
decreases in BP were not associated with LVMI in either gender group. Furthermore, in 
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randomly recruited nuclear families of African ancestry, after appropriate adjustments, 
including systolic BP or pulse pressure, pulse wave velocity (an index of arterial stiffness 
assessed using applanation tonometry) was independently associated with LVMI in 
women (n=204, r=0.25, p<0.0005), but not in men (n=123, r=-0.07). 
In 173 hypertensive patients of African descent of whom 64 were previously 
untreated and 109 were previously treated, I assessed whether ambulatory BP is a 
better predictor of on-treatment decreases in LVMI over a 4 month treatment period. In 
the previously untreated patients, the regression in LVMI correlated to a similar degree 
(p<0.09) with decreases in conventional (r=0.34; p<0.005) and 24-hour (r=0.26; p<0.04) 
systolic BP. In this same study sample followed prospectively for 25 months, accounting 
for effects on ambulatory BP at each time point, the use of the angiotensin-converting 
enzyme inhibitor, enalapril, was not associated with LVMI, whereas, on-treatment 
conventional systolic BP (p=0.01) and night-time systolic BP (p=0.01) were associated 
with LVMI. 
In a further study conducted in 87 patients of African ancestry with hypertension 
and LVH, I showed that changes in systolic ambulatory BP (daytime, r=0.46, p=0.006) 
were predictive of changes in LVMI after 2 months of treatment with an angiotensin II 
receptor blocker (candesartan), ACE-I (ramipril) and the diuretic agent, 
hydrochlorothiazide. Moreover, in a final study I showed that in hypertensive patients of 
African ancestry, initiating therapy with the diuretic, indapamide SR and then adding the 
ACE-I, perindopril 4 mg (n=42), was equally as effective as amlodipine (calcium channel 
blocker) (n=44) therapy at reducing ambulatory BP and LVMI. 
Thus, in conclusion, groups of African descent living in Africa have only 
marginally higher thresholds for LVM than other population groups. Moreover, in this 
population group, nocturnal BP has a conventional BP-independent effect on LVMI in 
men, but not in women, whereas arterial stiffness has a conventional BP-independent 
effect on LVMI in women, but not in men. Further, in this population, reductions in LVM 
produced by antihypertensive therapy appear to be equally as closely related to 
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conventional as ambulatory BP and in contrast to findings in groups of European 
ancestry, where RAS blockers produce unique benefits on LVM beyond conventional BP 
reductions, in groups of African ancestry in Africa, RAS blockers produce no BP-
independent reductions in LVM. Moreover, in this population, decreases in LVM in 
patients with LVH produced by RAS blockers are related to ambulatory BP changes and 
despite the ineffectiveness of RAS blockers on BP when used as monotherapy in this 
population, RAS blockers together with diuretics are equally as effective in decreasing 
BP and LVM as compared to a class of antihypertensive agents with established efficacy 
(calcium channel blockers). Hence when compelling indications for RAS blockade exist, 
RAS blocker-diuretic combinations are effective therapy in patients of African descent 
living in Africa. 
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PREFACE 
Left ventricular hypertrophy (LVH) is recognised as a risk factor of cardiovascular 
morbidity and mortality independent of conventional blood pressure (BP) in populations 
of Caucasian and African origins. Moreover, there is now compelling evidence to indicate 
that LV mass (LVM) is increased in African as compared to European Americans, an 
effect that is independent of conventional BP. However, the mechanisms responsible for 
conventional BP-independent ethnic differences in LVM have not been determined, but 
may relate to ethnic differences in 24-hour BP profiles or to arterial stiffness. These 
questions prompted me to assess whether, as compared to other population samples, 
thresholds for LVM are greater in a group of healthy individuals recruited in large 
randomly selected population of African descent living in Africa. Further, I assessed 
whether either ambulatory BP or an index of arterial stiffness (pulse wave velocity) 
predict LVM better than or independent of conventional BP in this population sample and 
whether ambulatory BP is a better predictor of on-treatment regression of LVM than 
conventional BP in hypertensive patients of African ancestry. These studies are 
described in chapters 2-5 of the present thesis. 
Although in groups of European descent the use of blockers of the renin-
angiotensin system (RAS) regress LVH beyond BP effects, current thinking is that this 
effect may not occur in groups of African descent. This prompted me to assess, in a ~2 
year study described in chapter 6, whether the use of an angiotensin-converting enzyme 
inhibitor was associated with changes in LVM beyond ambulatory BP in hypertensives of 
African ancestry. Moreover, in a further study described in chapter 7 I assessed whether 
there is indeed an association between the regression of LVH and ambulatory BP in 
hypertensives of African descent. Last, as there are compelling indications for the use of 
RAS blockers, including the presence of LVH, but calcium channel blockers are far more 
effective antihypertensive agents in hypertensives of African ancestry than RAS 
blockers, I assessed whether a diuretic/ACE-I combination was as effective as a calcium 
 xx 
channel blocker at decreasing ambulatory BP and LVM in hypertensives of African 
ancestry. These data are described in chapter 9. 
 In this thesis I have first reviewed the scientific literature that relates to LVM and 
LVH with a specific focus on what is known about LVM in groups of African descent. This 
review is the content of chapter 1 and is meant to lead the reader through a series of 
arguments that support the hypotheses tested in this thesis. At the end of chapter 1 I list 
the aims of the thesis. Chapters 2-8 consist of semi-independent chapters, each divided 
into an “abstract”, “introduction”, “methods”, “results” and “discussion” sections. Although 
these chapters are separated from each other as they deal with specific hypotheses, 
there is overlap between chapters and the progression of arguments from chapter-to-
chapter has been underscored.  
In support of this thesis I am either first author or a co-author on three papers 
published to-date (Skudicky, Sareli, Libhaber et al, Circulation 2002;105:830-836, 
Libhaber et al Am J Hypertens 2004;17:5,428-443 and Libhaber et al, Journal of Human 
Hypertension 2005;19:959-961) and a number of papers that are presently being 
prepared for publication. In addition other components of this thesis have been 
presented at international congresses (Libhaber et al 21st Annual Scientific Meeting of 
the American Society of Hypertension. May 16-18, 2006 New York. USA, Libhaber et al. 
World Congress of Cardiology 2006. September 2-6 2006. Barcelona. Spain). 
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Chapter 1 
 
 
            INTRODUCTION 
 
 
 
Left ventricular hypertrophy: Current knowledge, 
controversies and outstanding issues with particular reference 
to persons of African descent 
 2 
1.0 Introduction 
 
Cardiovascular (CV) diseases (CVD) including strokes, myocardial infarction (MI), 
renal failure, heart failure, sudden cardiac death and peripheral vascular disease (PVD), 
share similar risk factors. Cardiovascular diseases are amongst the leading causes of 
death in adults in both developed (reviewed by guidelines committees including World 
Health Organization, International Society of Hypertension Writing Group. [Whitworth 
2003]; European Society of Hypertension-European Society of Cardiology Guidelines 
Committee 2003; Chobanian et al 2003; Williams et al 2004) and developing (Kahn et al 
1999) countries. A significant proportion of the risk of developing CVD is attributed to 
hypertension, smoking, diabetes mellitus, dyslipidaemias, aging and excess adiposity 
(reviewed by guidelines committees including World Health Organization, International 
Society of Hypertension Writing Group. [Whitworth 2003]; European Society of 
Hypertension-European Society of Cardiology Guidelines Committee 2003; Chobanian 
et al 2003; Williams et al 2004). In the present thesis I have studied one of the principle 
risk factors for CVD in groups of African descent, namely hypertension. The main aim of 
the present thesis was to attempt to clarify some of the outstanding issues that relate to 
the development and regression of a target organ change in hypertension, namely left 
ventricular hypertrophy (LVH), in groups of African descent. As will be underscored the 
identification of LVH is of major clinical importance in any population group. However, 
the factors that drive the development of LVH and its changes with therapy still remain 
uncertain. This is particularly obscure in groups of African descent.   
 
1.1 The prevalence of hypertension in groups of African ancestry 
 
With respect to pathological LVH, its prevalence is generally perceived to depend 
on the prevalence of hypertension and excess adiposity. Consequently, it is first worth 
considering epidemiological issues that relate to hypertension prevalence in groups of 
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African descent. Importantly, the prevalence of hypertension in non-African countries has 
previously been reported to be twice as high in black as compared to Caucasian 
communities (Comstock 1957, Stamler et al 1975, Meade et al, 1978, Chaturvedi et al 
1993), a difference that still persists despite a better awareness and treatment of the 
condition, Indeed, the latest analysis of the National Health and Nutrition Examination 
Surveys (NHANES) in the United States of America (USA) indicates that the prevalence 
of hypertension in those of African descent is 40.5% as compared to 27.4% in those of 
European descent (Glover et al 2005). These are quite extraordinary differences and 
represent an increasing rather than decreasing difference in prevalence than that 
previously reported on (Ashaye and Giles, 2003). Yet more and not less hypertensives of 
African than European descent in the USA are aware of their condition (70.3 vs 62.9%) 
and at least the same proportion have blood pressures (BP) controlled to target levels 
(29.8 vs 29.8%)(Glover et al 2005). Even in the context of equivalent health promotion 
services between ethnic groups, subjects of African ancestry between the ages of 45-to-
64 years are still 5.6 times more likely to be hospitalised for hypertension than their 
Caucasian counterparts (Holmes et al 2005). Moreover, higher prevalence rates of 
hypertension persist in those of African descent in the USA when adjusting for income 
and educational level (Howard et al 2000). Thus, under conditions of equivalent care, 
awareness, income and education, the higher prevalence rates of hypertension in 
individuals of African descent are sustained. In South Africa about one-fifth to one-
quarter of groups of African descent have hypertension and a large proportion of these 
subjects have BPs that are not at target levels (Steyn et al 1996; Steyn et al 2001; 
Alberts et al 2005). 
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1.2 Cardiovascular disease in groups of African descent: Hypertension as a 
major risk factor 
 
As a consequence of the high prevalence of hypertension in groups of African 
descent, there is inevitably an increased risk for CVD. Indeed, in developed countries 
there is a greater prevalence of some CVD in ethnic groups of African origins. In the 
USA, the prevalence of strokes is greatest amongst groups of African origins (Gillum 
1999; Hollar et al 2004; McGruder et al 2004; Jamerson 2004; Howard 2001, Sacco et al 
2001). In developing countries in Africa, there is some evidence to indicate that stroke is 
highly prevalent in rural communities (Seedat et al 1998, Connor et al 2006) and 
presumably also in urban communities. Although until recently ischaemic heart disease 
(IHD) was thought to be a rare entity in sub-Saharan Africa, based on hospital 
admissions, the prevalence is thought to be increasing at a dramatic level. Moreover, the 
risk of coronary artery disease may be just as high in patients of African ancestry with 
stroke as it is in patients of European ancestry with stroke (Joubert et al 2000). As stroke 
is a common cause of morbidity and mortality in sub-Saharan Africa it may therefore be 
argued that IHD is also common in these countries, but that it goes largely undetected or 
is not expressed as an important clinical phenotype. However, true prevalence data for 
IHD in these countries has yet to be reported on. 
 
1.3 Left ventricular hypertrophy in risk stratification: Outstanding issues still 
remain 
 
In the management of hypertension, to predict the risk for stroke and other CV 
events, it is now widely acknowledged that identifying target organ damage, such as 
LVH, is important in risk stratification (see section 2.1 below) (reviewed by guidelines 
committees including World Health Organization, International Society of Hypertension 
Writing Group. [Whitworth 2003]; European Society of Hypertension-European Society of 
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Cardiology Guidelines Committee 2003; Chobanian et al 2003; Williams et al 2004). 
Moreover, a therapeutic aim of antihypertensive therapy is to regress LVH (see section 
2.4 below). However, with respect to LVH, there are many questions that remain 
unanswered, and of particular importance to countries like South Africa there are ethnic 
differences in LV mass (LVM) reported in non-African countries, with higher LVM values 
noted in groups of African descent (Drazner et al 2005) (also see section 3.0 below). 
Moreover, there are data that indicate important ethnic differences in the response of 
LVM to antihypertensive agents (see section 5.2 below). Yet the clinical relevance of 
these ethnic differences remains uncertain. 
The ethnic difference in LVM in groups of African as opposed to European 
descent (Drazner et al 2005) has largely been attributed to the well recognized 
relationship between BP and LVM. In other words, the greater prevalence of 
hypertension in groups of African ancestry would predictably translate into more target 
organ changes. However, even after adjusting for conventional BP values, groups of 
African ancestry appear to have a higher LVM (Drazner et al 2005, see section 3.0 
below). Moreover, conventional BP accounts for a relatively small portion of the 
variability in LVM in any population (see section 4.1 below). Thus the mechanisms that 
explain ethnic differences in LVM or remodeling and differences in response to therapy 
have not been entirely resolved. The purpose of this thesis was therefore in-part to 
attempt to ascertain whether LVM is indeed particularly high in groups of African descent 
living in Africa, and if so to identify any unique characteristics of the factors that may 
explain LVM in this group. Moreover, an additional purpose of this thesis was to further 
understand the potential ethnic differences in therapeutic responses of the LV to 
antihypertensive therapy. 
In this chapter I will therefore review the evidence to support the notion that LVM 
and its regression predicts CV events in Caucasians and groups of African descent. I will 
subsequently attempt to explain the relationship between LVM and adverse CV 
outcomes. I will then summarize the evidence to indicate that persons of African ancestry 
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have a higher LVM. I will also discuss the mechanisms that explain increases in LVM in 
any population and whether the characteristics of any one of these mechanisms could 
contribute toward the higher prevalence of an increased LVM in groups of African 
descent. I will further highlight the apparent ethnic disparities in the BP and LVM 
responses to antihypertensive therapy and indicate the unresolved issues in this regard. 
 
2.0 Left ventricular hypertrophy: Compensatory change or cardiovascular risk 
factor? 
 
For many years LVH was considered a compensatory response to a chronic 
pressure load on the LV. In accordance with the law of Laplace, where wall tension 
(stress) is proportional to the product of pressure and internal radius and inversely 
proportional to wall thickness, an increased wall thickness in LVH maintains a normal LV 
wall stress in the face of increments in pressure generated within the LV cavity. Based 
on the principle that LV geometry and wall thickness change to maintain systolic stress 
within normal limits (Grossman et al 1975), LVH was considered an adaptive reaction to 
a pressure overload with a more favorable outcome predicted (Grossman et al 1975, 
Gaash et al 1978). However, LVH can no longer be considered a compensatory change. 
Indeed, epidemiological data indicate that LV mass (LVM) is an independent risk factor 
for CV events, including MI, stroke, congestive heart failure, sudden cardiac death, renal 
failure and peripheral vascular disease. The following outlines the evidence to support 
this notion. 
 
2.1 Left ventricular hypertrophy predicts cardiovascular risk independent of 
conventional BP in Caucasian populations 
 
Many studies now support the notion that LVH is a predictor of CV risk 
independent of conventional BP measurerments (Casale et al 1986, Levy et al 1990, 
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Levy et al 1994, Verdecchia et al 1996, Ghali et al 1998, Gardin et al 2001, Verdecchia 
et al 2001, Drazner et al 2004). In the Framingham Heart study conducted largely in a 
Caucasian population, LVM corrected for height was associated with the incidence of 
death from CVD with a higher relative risk noted in women than in men after adjusting for 
treatment for hypertension (Levy et al 1990). Even in the absence of arterial 
hypertension, LVM in Caucasian groups is an independent risk factor for CV events 
(Gardin et al 2001). In the Italian Multicenter and Prospective Study (Massa Ventricolare 
sinistra nell’ Ipertensione arteriosa) (MAVI) conducted in a largely Caucasian population 
with essential hypertension, irrespective of baseline conventional BP and treatment for 
hypertension, the presence of LVH doubled the risk for CV events such as cardiac death, 
MI, stroke, transient ischemic attack, heart failure, unstable angina, arterial occlusive 
disease and renal failure (Verdecchia et al 2001). Even after adjusting for other 
traditional CV risk factors (age, diabetes mellitus and smoking), the CV risk of an 
increased LVM persisted (Verdecchia et al 2001). In a cohort of Caucasians of the 
Cardiovascular Health Study (CHS) followed for 5 years, LVH was also associated with a 
decrease in left ventricular ejection fraction (LVEF) or diastolic function independent of 
traditional risk factors including conventional BP (Drazner et al 2004). Thus, LVH 
predicts the transition to cardiac dysfunction. 
The conventional BP-independent relationship between LVM/LVH and CV 
outcomes is perhaps not surprising as an occasional conventional BP measurement may 
not predict actual BP changes over a prolonged period. Indeed, even over a 24-hour 
period, BP varies considerably over time (Mancia et al 1999). Thus, LVM and hence CV 
risk could be the product of BP over a prolonged period. If this argument holds, then it 
should be obvious that LVM would be a better predictor of CV events than the occasional 
BP measurement. As an extension to this argument, it may also be argued that during 
antihypertensive therapy, measurements of BP over prolonged time periods, rather than 
an occasional conventional BP measurement should predict CV events equally as well 
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as changes in LVM over time. However, as shall be seen there is considerable 
controversy over this issue (see section 4.1.4 and later discussion). 
 
2.2 Left ventricular hypertrophy also predicts cardiovascular risk in 
populations of African descent 
 
Are there ethnic-specific effects of LVH as a predictor of CVD? The BP-
independent predictive power of LVH as a risk factor for CVD as described in Caucasian 
populations is not specific for this ethnic group. Indeed, a number of studies conducted in 
groups of African ancestry support a similar conclusion. In a cross-sectional study in 
hypertensive African-American males, LVH was associated with the severity of coronary 
disease independent of conventional BP (Robinson et al 1993). Moreover, among an 
African-American cohort, independent of conventional BP, LVH was associated with a 
greater relative risk of coronary multivessel disease, LV dysfunction and an adverse 
survival rate (Liao et al 1995). In a bi-racial population (20% were African Americans)-
based study with mean follow-up of 6.5 years, LVH conferred a 2-to-3 times higher 
adjusted hazard ratios for incident coronary heart disease and congestive heart failure 
(CHF) independent of hypertension status (Gardin et al 2001). In  the Atherosclerosis 
Risk In Communities  (ARIC) study, a prospective epidemiologic study conducted in an 
African-American population, LVH as detected by echocardiography and/or 
electrocardiography was a precursor of premature cardiovascular morbidity and mortality 
across all ethnic groups, even after adjusting for conventional risk factors including BP 
(Nunez et al 2005). Thus LVH appears to predict CVD in both groups of European and 
African ancestry. However, without exception these studies have been performed in 
population groups outside of Africa. Whether the same effects would be noted in groups 
of African descent living in developing communities in Africa has never been assessed. 
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2.3 Regression of left ventricular hypertrophy reduces cardiovascular risk 
 
Clearly if LVH predicts the risk of future CVD, then regression of LVH should 
predict a reduced risk of CVD. One method of reducing LVM and decreasing the 
prevalence of LVH and concentric remodeling is through antihypertensive treatment 
(Wachtell et al 2002). It is now well recognized that regression of LVH with 
antihypertensive therapy is associated with reduced risk of CV morbidity and a decrease 
in coronary heart disease (CHD) and CV death rates (Heyden Hypertension Detection 
and Follow-up Program Cooperative Group, 1985, Levy et al 1994). Importantly 
however, there is now evidence to indicate that the impact of therapeutic agents on 
either ECG-determined LVH or echocardiographically-determined LVM and the 
associated CVD risk reduction is partly independent of office BP changes (Mathew et al 
2001; Okin et al 2004; Devereux et al 20042). These studies have therefore produced 
further provocative evidence to indicate that the relationship between LVM and 
associated CVD risk in hypertension may not be as tightly linked to BP changes as 
would normally have been predicted. In other words, LVM appears to predict a CV 
change that cannot simply be attributed to BP as measured using conventional 
techniques alone. Nevertheless, as will be discussed in subsequent sections, this 
conventional BP-independent effect may still be related to BP, but simply not that well 
predicted by conventional BP measurements. In other words, measures or indices that 
inform us of BP over prolonged periods, or in areas of large vessels closer to the heart 
than the brachial artery, may be better predictors of LVM. 
 
2.4 Why is left ventricular hypertrophy associated with worse clinical outcomes 
independent of blood pressure? 
 
Assuming that the relationship between LVM and CV outcomes is not simply 
because LVM is an index of the sum of all BP changes over time, then how could LVM 
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increase CVD risk? As LVH decreases LV wall stress, but yet is still associated with 
adverse CV outcomes, it is important to consider the potential reasons for these worse 
outcomes. The potential cardiac changes that may influence cardiac-related CV 
outcomes have been summarized by Messerli (1996). Left ventricular hypertrophy could 
lead to an impaired filling of the LV through both a decreased early-diastolic relaxation 
and a reduced late-diastolic compliance, changes that result in diastolic dysfunction. 
This, in-turn, may increase cardiac filling pressures, augment myocardial transmural 
pressures during diastole and reduce coronary flow (reduced coronary reserve) (Lorell et 
al 1987). Left ventricular hypertrophy could also result in an impaired LV pump function 
through a number of mechanisms including chamber dilatation (Norton et al 2002) and a 
decreased myocardial contractility (Malik et al 1974). Further, the increased tissue bulk 
of the myocardium may increase myocardial oxygen demand (Kannel et al 1970, Ghali et 
al 1991) an effect that may not be accompanied by the expected increase in coronary 
flow because of reductions in coronary reserve. Alterations in myocardial oxygen 
demand-to-supply ratios could result in programmed cell death (apoptosis) (Liu et al 
2000) and necrosis (Tsotetsi et al 2001). Further, LVM is associated with neurohormonal 
activation and excessive myocardial sympathetic effects (Drazner et al 2004, Schlaich et 
al 2003), which could promote the transition to heart failure (Badenhorst et al 2003; 
Veliotes et al 2005). 
Although there are many potential mechanisms that may explain the impact of 
LVH on myocardial pathology, the relationship between LVH or its regression and 
strokes (Di Tullio et al 2003, Okin et al 2004; Devereux et al 20042) is more difficult to 
understand. It is possible that increased filling pressures in the LV and hence in the left 
atrium may result in atrial fibrillation and mural thrombus formation, an effect that could 
result in an embolic phenomenon. However, many strokes in patients with LVH are not 
from emboli from the heart. It is possible that LVH may predict early endothelial 
dysfunction and structural changes in large and small vessels (Muiesan et al 2004). 
Indeed, there is an association between vascular damage in small resistance arteries 
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and concentric hypertrophy (Palatini et al 1998, Wachtell et al 2000,  Treasure et al 
1993, Muiesan et al 2002). These changes in the brain or extracranial vessels, which 
would occur in conjunction with LVH, could lead to strokes. 
 
3.0 Ethnic disparities in left ventricular mass and geometry 
 
Whilst data from some early studies have suggested that after adjusting for BP, 
ethnicity is not associated with an increased prevalence of LVH (Hammond et al 1984, 
Gottdiener et al 1994) other early studies indicated that LVM index is increased in 
African-Americans as compared to Caucasians after BP adjustments (Dunn et al 1983) 
and that concentric LVH occurs more frequently in elderly African Americans with 
hypertension as compared to Caucasians (60% as compared to 39%) (Savage et al 
1987). However, as will be discussed, uncertainties raised by these relatively 
inconsistent findings in earlier studies have nevertheless been resolved in more recent 
studies and in studies with large or relatively larger study samples. 
It is now well documented that LVH is more prevalent amongst subjects of 
African ancestry than in Caucasian subjects (Koren et al 1993, Gardin et al 1995, 
Zabalgoitia et al 1998, Skelton et al 2003, Lorber et al 2003, Kizer et al 2004, Rodriguez 
et al 2004, Drazner et al 2005). Of particular relevance, in the Dallas Heart Study, 
conducted in over 2000 individuals, where more accurate methods of assessment of 
LVM were utilized (magnetic resonance imaging) than the usual method of 
echocardiography, African-Americans had an increased LVM even after adjustments for 
other determinants of LVM, including fat mass, fat-free mass, systolic BP, age, gender 
and measures of socioeconomic status (Drazner et al 2005). These findings are in 
agreement with the Hypertension Genetic Epidemiology Network Study, where over 
1000 African-Americans had a greater LVM and LV relative wall thickness than 580 
Caucasians after adjustment for confounding variables (Kizer et al 2004). In a study 
comparing African-American to European-American youth, ethnicity effects on LVM 
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appeared in early adolescence, and persisted even when controlling for anthropometric 
factors, haemodynamic variables and socioeconomic status (Dekkers et al 2002). 
Moreover, in a small study sample of African-Americans (n=82) and Caucasians (n=63), 
where ethnicity, gender, 24-hour BP, adiposity indices, plasma lipid concentrations, apo-
lipoprotein concentrations and fasting insulin were included in the regression model, 
ethnicity was the most powerful predictor of LVM index (El -Gharbawy  et al 2001). 
Studies performed on groups of African descent recently emigrated from Africa also 
support the notion that groups of African ancestry have a greater prevalence of 
concentric LVH (Abassade et al 19961; Abassade et al 19962). 
With respect to the LV remodeling process associated with LVH, in previously 
untreated patients with essential hypertension relative wall thickness was noted to be 
greater in African-American subjects as compared to Caucasians (Mayet 1994). More 
recent studies clearly support this view. Indeed, a 6-fold higher prevalence of concentric 
remodeling has been reported in African-Americans as compared to Caucasians 
(Olutade et al 1998).  
Despite the overwhelming evidence to indicate that LVM is greater in groups of 
African as compared to European ancestry, whether this effect is because of biological 
differences or because of differences in environmental factors has not been established. 
The impact of ethnicity on LVM appears to be stronger in subjects with higher BP values 
(Drazner et al 2005), suggesting that BP may still be the major factor influencing the 
impact of ethnicity on LVM. However, there are no studies that have been conducted in 
groups of African descent living in Africa that have attempted to determine whether LVM 
is characteristically higher in these groups as well. A higher LVM in subjects of African 
origins living in Africa would support a biological difference. This prompted me to define 
thresholds (partition values) for LVM in clinically normal individuals from randomly 
selected families in an urban developing community of African descent in South Africa. 
These data and the implications thereof are discussed in chapter 2 of this thesis. 
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4.0 Determinants of left ventricular hypertrophy 
 
Many would still argue that the disparities between ethnic groups with respect to 
LVM and remodeling could be accounted for by co-morbidities or factors that may or may 
not be considered in epidemiological studies. Consequently, it is worth discussing some 
of the major determinants of LVM and the potential factors that could cause LVH. 
Together with normal growth-related changes, there are several consistent 
factors that influence the development of LVH such as systemic BP, adiposity and body 
size, age and male gender. Left ventricular hypertrophy has also been associated with 
physical activity, genetic factors and arterial stiffness (Post et al 1994). The following 
outlines the evidence to support a role for some of these factors and the potential ethnic 
differences that may exist. 
 
4.1 Blood Pressure 
 
As indicated in earlier sections of this chapter, if BP in systemic arteries and 
hence the LV increases, the LV wall hypertrophies. An increase in systemic BP 
(hypertension) is a major cause of increases in LV pressures during the ejection phase 
of the cardiac cycle. Thus, not surprisingly, systemic hypertension is a primary 
determinant of LVH. However, some time ago it was recognized that the correlation 
between conventional BP and LVM is not as consistent as one would expect (Devereux 
et al 1987). This relationship may be so poor as to be undetectable in some groups. 
Indeed, in previous studies conducted in Caucasian hypertensives and normotensives 
(Bauwens et al 1991, Cerasola et al 1991, Polonia et al 1992) and in a recent study 
conducted in Congolese hypertensive patients of African ancestry (Lepira et al 2006), the 
relationship between conventional BP and LVM or LVH was almost absent or indeed 
was absent. A potential explanation for these unusual findings is that the haemodynamic 
load on the LV cannot be predicted from office or clinic (conventional) BP 
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measurements, measurements obtained at a single point in time (Devereux et al 1987). 
Indeed, early studies conducted at this time showed that LVH correlated better with BP 
measured during normal activity than at rest (Devereux et al 1987) and that the best 
correlation with LVM in Caucasians was with daytime BP (Frohlich et al 1992). 
Based on the premise that BP measured during activity may be a better predictor 
of LVM than resting BP values, a number of studies have been conducted to test the 
hypothesis that ambulatory BP is a better predictor of LVM than conventional BP. 
Moreover, these studies explored whether daytime or night-time BP values are better 
predictors of LVM and whether the nocturnal decline in BP contributes toward the 
variability in LVM. These studies will be described in the following sections. 
 
4.1.1 Ambulatory or conventional BP: Which is better correlated with left 
ventricular mass in cross-sectional studies? 
 
Many cross-sectional studies with small or relatively small sample sizes have 
reported on the superiority of ambulatory BP over conventional BP when predicting LVM 
(reviewed by Fagard et al 19951). The majority of these studies were conducted in study 
samples which ranged from small to reasonably large (n=12-to-235). An analysis of the 
relationship between the correlation coefficients of the office BP-LVM and ambulatory 
BP-LVM relations of many of these studies has been particularly revealing (Fagard et al 
19951). This analysis supported a conclusion that some clinic BPs may predict LVM as 
well as ambulatory BP, rather than a conclusion that ambulatory BP is indeed superior to 
clinic BP in predicting LVM (Fagard et al 19951). In this regard, multiple visits may be 
required to obtain a better assessment of the relationship between conventional BP and 
LVM (Prisant and Carr 1990). Moreover, the assessment of conventional BP in a quiet 
room may produce just as close a correlation with LVM as ambulatory BP (Ganau et al 
1990). The use of the same observer and multiple conventional BP measurements (5 at 
each visit) at two visits in a quiet room at a similar time of day was also associated with 
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similar correlation coefficients between conventional and ambulatory BP and LVM 
(Fagard et al 1992). Thus, there is still no real consensus as to whether ambulatory BP is 
superior to conventional BP in predicting LVM in cross-sectional studies. This is a 
particularly important question in developing communities where access to ambulatory 
BP monitoring in minimal resource settings is almost non-existent. Hence, as part of my 
thesis, I studied in a relatively large community-based sample, whether ambulatory BP is 
superior to conventional BP. These data and the implications thereof are reported on in 
chapter 3 of this thesis. 
 
4.1.2 Diurnal variations in BP and the impact on left ventricular mass 
   
It is still not clear which component of the 24-hour BP profile best predicts LVM or 
CVD. An attenuated nocturnal decrease in BP or nocturnal rather than daytime BP per 
se has been associated with lacunar infarcts (Yamamoto et al 1998), cardiovascular 
outcomes in the elderly with isolated systolic hypertension (Staessen et al 1999), in 
hypertensives in general (Verdecchia et al 1994, Zweiker et al 1994), in the general 
population (Ohkubo et al 1997, Kikuya et al 2005) and in type II diabetes mellitus 
(Nakano et al 1998) independent of conventional BP values. Some studies have 
suggested that night-time, but not daytime systolic BP predicts LVM in normotensives 
and hypertensives (Mayet et al 1998, Verdecchia et al 1994, Morfis et al 2002). 
Moreover, other reports have indicated that an attenuated nocturnal fall in BP or “non-
dipping” is associated with LVH (Verdecchia et al 1990, Verdecchia et al 1992, 
Schmieder et al 1995). However, there is also considerable controversy in this regard as 
others have demonstrated no relationship between nocturnal decreases in BP and LVM 
(Schulte et al 1993, Boley et al 1997, Roman et al 1997). Moreover, a meta-analysis 
revealed that daytime BP is an equivalent predictor of LVM as compared to night-time 
BP, and that the differences between day and night-time BP explain only 15% of LVM 
index (Fagard et al 19952). Moreover, more recent studies have also indicated that 
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daytime BP is an equivalent predictor of both echocardiographic and electrocardiograph 
indices of LVM as compared to night-time BP in untreated hypertensive patients (Feola 
et al 1998; Cicconetti et al 2003, de la Sierra et al 2002). However, what has not been 
appropriately addressed is whether daytime, night-time or day-night differences in BP 
are of particular relevance as predictors of LVM in groups of African descent. 
Importantly, all of the large or relatively studies assessing the relative impact of day, 
night or day-night differences in BP on LVM have been conducted in groups largely of 
European descent. However, as compared to groups of European ancestry it is groups 
of African ancestry who have attenuated nocturnal decreases in BP (Profant and 
Dimsdale 1999; Wang et al 2006). It is therefore possible that disparities in LVM between 
ethnic groups may be accounted for by an impact of diurnal variations in ambulatory BP. 
Indeed, conventional BP assessment may underestimate the severity and duration of a 
high BP especially amongst subjects of a lower social economic status (Rodriguez et al 
2004). It is well recognized that groups of African descent, through ethnic discrimination, 
generally have a lower mean socioeconomic status. 
In contrast to the number of studies assessing the impact of day, night or day-
night differences in BP on LVM in groups of European descent, few such studies have 
been conducted in groups of African descent. Some studies suggest that nocturnal 
rather than daytime systolic BP influences LVM in groups of African descent (El-
Gharbawy et al 2001, Mayet et al 1998, Hinderliter et al 2004). However, these studies 
were generally performed in small sample sizes (n=46-to-88) (El-Gharbawy et al 2001, 
Mayet et al 1998, Hinderliter et al 2004). Moreover, other large studies (n=426 subjects 
of African descent) have suggested that daytime rather than nocturnal BP is associated 
with LVM in groups of African descent (Chaturvedi et al 1994). Nevertheless, in this 
study (Chaturvedi et al 1994), the investigators only used two hours of BP 
measurements to describe each of daytime and nocturnal BP. No study with a large 
sample size conducted in groups of African descent and with appropriate ambulatory BP 
values has specifically reported on relationships between day-night differences in BP 
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and LVM. Consequently, as part of the present thesis I also studied the relative impact of 
day, night and day-night differences in ambulatory BP on LVM in a large community-
based sample of a group of African descent. These data and the implications thereof are 
described in chapter 3 of the present thesis. 
 
4.1.3 Ambulatory or conventional BP: Which is better correlated with the 
regression of left ventricular hypertrophy in groups of European descent? 
 
With respect to the relative impact of conventional or ambulatory BP on the 
regression of LVH, some studies conducted in Caucasians indicate that ambulatory BP 
is either superior to conventional BP in predicting treatment-induced changes in LVM or 
adds to the value of predicting treatment-induced changes in LVM (Koren et al 1991, 
Fagard et al 19973, Mancia et al 1997, Redon et al 1998, Mancia et al 2003). Moreover, 
in a recent meta-analysis that compared office BP to ambulatory BP in assessing the 
response of LVM to antihypertensive treatment, ambulatory BP was superior to office BP 
(Mancia et al 2004). However, controversy exists as to which BP measurement 
(conventional or ambulatory) best predicts changes in LVM with antihypertensive 
treatment (Fagard et al 19973). In this regard, large studies are multicentric, which makes 
the standardization of conventional BP measurements more difficult to achieve. 
In contrast to data that indicate that ambulatory BP is a better predictor of 
changes in LVM with treatment, in the Pressione Arteriose Monitorate E Loro 
Associazioni (PAMELA) study, if patients achieved BP control, LVM index was markedly 
decreased regardless of whether the BP was assessed by office, home or ambulatory 
measurements (Mancia et al 2002). Moreover, in the PAMELA study, ambulatory and 
conventional BP predicted CVD equally as well (Sega et al 2005). Nevertheless, the 
PAMELA study also demonstrated that the addition of nocturnal BP to the regression 
model which included conventional BP improved the strength of the relationship with CV 
events (Sega et al 2005). 
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As indicated in the above discussion (section 4.1.2), as compared to groups of 
European ancestry, groups of African ancestry have attenuated nocturnal decreases in 
BP (Profant and Dimsdale 1999, Wang et al 2006). It is therefore possible that 
decreases in nocturnal BP may translate into a closer relationship between changes in 
ambulatory BP and LVM, than between changes in conventional BP and LVM in groups 
of African ancestry receiving antihypertensive treatment. Prior to the studies reported on 
in this thesis there were no prospective studies assessing whether ambulatory BP is a 
better predictor of on-treatment LVM than conventional BP in groups of African descent. 
These studies were conducted as part of my thesis and the outcomes reported on in 
chapters 5 and 6. 
 
4.1.4 Diurnal variations in BP: Impact on the regression of left ventricular 
hypertrophy 
 
With respect to day versus night BP effects on the regression of LVH in groups of 
European ancestry, in the Study on Ambulatory Monitoring of Pressure and Lisinopril 
Evaluation (SAMPLE), daytime and night-time BP were equally important in predicting 
the reduction in LVM (Mancia et al 1997). These data are also supported by a smaller 
study demonstrating a similar impact of day and night BP on treatment induced changes 
in LVM (Fagard et al 19973). Moreover, day-night differences in BP were not associated 
with on-treatment changes in LVM (Mancia et al 1997, Fagard et al 19973). However, this 
does not preclude a potentially important role for diurnal variations in BP as contributing 
toward changes in LVM over time. Indeed, antihypertensive treatment decreases rather 
than increases day-night differences in BP (Fagard et al 19973). Moreover, it is difficult to 
control for absolute BP changes over time when assessing the relationship between day-
night differences in BP and LVM. Hence, longitudinal studies designed to resolve the role 
of diurnal variations in BP as determinants of LVM are difficult to conduct. Nevertheless, 
as part of the present thesis, although I did not aim to assess the importance of day-night 
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differences in BP on treatment-induced changes in LV mass, I did evaluate the relative 
impact of sequential day and night BP values on LVM in hypertensives on treatment. 
This is particularly important considering that some small studies have suggested that 
nocturnal rather than daytime systolic BP influences LVM in groups of African descent 
(El-Gharbawy et al 2001, Mayet et al 1998, Hinderliter et al 2004) and as indicated in the 
above discussion, that groups of African descent have an attenuated nocturnal decline in 
BP (Profant and Dimsdale 1999, Wang et al 2006). 
 
4.2 Body size 
 
Body size is the most consistent determinant of LVM. The strong relationship 
between body size and LVM is supported by a number of studies with large sample sizes 
(Lauer et al 1991, Lauer et al 1992, de Simone et al 1992, Gottdiener et al 1994, Urbina 
et al 1995, Gardin et al 1995, Sherif et al 2000; Lorber et al 2003; Fox et al 2004). 
Importantly, in large cohorts of mild-to-moderate hypertensive patients, body mass index 
(BMI) is the strongest predictor of LVM (Lauer et al 1992, Gottdiener et al 1994). The 
effects of body size may be through either the impact of adiposity and muscularity, 
effects which are accounted for by indexing LVM for body surface area, or simply by 
growth effects, which are in-turn, accounted for by indexing LVM for height. The effects 
of adiposity are thought to be through the effects of fat-free mass (Drazner et al 2005). 
However, the relationship between body size and LVM may not be restricted to lean 
body mass only. Indeed, in healthy young Caucasian and African-American adults of the 
Coronary Artery Risk Development in Young Adults (CARDIA) cohort study, a strong 
correlation was found between LVM and subscapular skin-fold thickness in both genders 
and ethnic groups (Gardin et al 1995). Similarly, in pre-menopausal American women 
LVM index correlated with indexes of central adiposity (Sherif et al 2000). 
Importantly, when indexing LVM for height to account for growth but not adiposity 
effects, the relationship between height and LVM is an exponential function (de Simone 
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et al 1992, de Simone et al 1995). Hence a power function is used to adjust for the 
exponential relationship with the power function generally used being height2.7 (de 
Simone et al 1992, de Simone et al 1995). Based on CV outcomes, normal values for 
LVM indexed for allometric height signals have been described in populations of 
European ancestry and African descent originating from West Africa (Nunez et al 2005). 
Both of these population groups are nevertheless taller than those noted in groups of 
African descent living in South Africa (see chapter 2). Whether the relationship between 
LVM and height in shorter populations fits the same exponential function as that in taller 
groups has not been established. One study conducted in groups of African descent with 
a shorter stature has indicated that adjustment for height to the first power rather than to 
the power of 2.7 eliminates LVM/height-height relations (Jaggy et al 2000). Indexing for 
height2.7, may therefore underestimate LVM thresholds in groups of African descent with 
a shorter stature. Consequently, in the present thesis I evaluated the relationship 
between LVM and allometric (growth) signals in a community of African descent living in 
Africa with mean values for height lower than those described for other populations. This 
study was conducted in order that thresholds for LVM index could be defined for healthy 
adults of African descent living in South Africa using an appropriate index, and these 
thresholds could then be compared against thresholds defined for other population 
groups. These data and the implications thereof are described in chapter 2 of the present 
thesis. 
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4.3 Arterial stiffness and its relationship with cardiovascular disease and left 
ventricular mass 
 
It is now well recognized that changes in the characteristics of the wall of large 
arteries (wall thickness and compliance) are predisposing factors for CVD (Blacher et al 
1999, Black et al 1999, de Simone et al 1999, Laurent et al 2001, Boutouyrie et al 2002, 
London et al 2001, Safar et al 2002, Guerin et al 2001, Saba et al 1993; Blacher et al 
2005; Chaturvedi et al 2004, Dolan et al 2006). Indices of aortic stiffness are 
independent predictors of CV events in patients with hypertension (de Simone et al 
1999, Laurent et al 2001, Boutouyrie et al 2002), in patients referred to tertiary care 
centres (Dolan et al 2006) and in patients with end stage renal disease (London et al 
2001, Safar et al 2002, Guerin et al 2001, Nitta et al 2004). These effects are 
independent of conventional or ambulatory (Dolan et al 2006) BP measurements. 
Moreover, indices of arterial stiffness are associated with pump dysfunction in chronic 
heart failure (Tartiere et al 2006), with a concentric LV geometry in hypertension 
(Palmieri et al 2003) and with LV diastolic dysfunction in hypertension (Palmieri et al 
2003), effects that are also independent of conventional BP. 
Arterial stiffness contributes toward CVD, in-part through the impact of early 
reflective waves on central aortic pressures, a pressure that is not accurately predicted 
by brachial artery BP measurements (Karamanoglu et al 1993, Williams et al 2006). The 
effects on the heart could be through an increased LV afterload and a decreased 
coronary perfusion subsequent to the development of LVH (see section 2.4 above). 
However, although preclinical studies provide evidence to suggest that central rather 
than peripheral BP predicts LV remodelling (Kobayashi et al 1996), as shall be 
discussed, whether a conventional BP-independent relationship between arterial 
stiffness and LVM exists is unclear. 
Although many studies have shown that indices of arterial stiffness are 
associated with LVM (Tatchum et al 1995, Kobayashi et al 1996, Bouthier et al 1985, 
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Boutouyrie et al 1995, Roman et al 1996, Chen et al 1998, Roman et al 2000, Baguet et 
al 2000, Iketani et al 2000, Deague et al 2001, Gates et al 2003, Leoncini et al 2006) in 
this regard, much of the evidence indicates that measures of arterial stiffness do not 
provide information beyond that afforded by measures of brachial artery (peripheral) 
systolic BP. Only two human studies suggest that arterial stiffness effects on LVM are 
independent of brachial artery BP (Lekakis et al 2004, Leoncini et al 2006), one of which 
was conducted in a very small study sample (Lekakis et al 2004), and another was a 
study relating the less well recognized ambulatory arterial stiffness index with LVM 
(Leoncini et al 2006). In contrast, a number of papers have indicated that the relationship 
between indices of arterial stiffness and LVM is dependent on conventional BP 
measured at the brachial artery (Bouthier et al 1985, Roman et al 1996, Chen et al 1998, 
Roman et al 2000, Baguet et al 2000, Deague et al 2001). Nevertheless, clinical studies 
assessing the relationship between arterial stiffness and LVM have largely been 
conducted in groups of European descent (Bouthier et al 1985, Boutouyrie et al 1995, 
Roman et al 1996, Chen et al 1998, Roman et al 2000, Baguet et al 2000, Iketani et al 
2000, Gates et al 2003, Deague et al, 2001, Lekakis et al 2004, Leoncini et al 2006). 
However, arterial stiffness appears to be higher in people of African ancestry as 
compared to Caucasians (Din-Dzietham et al 2004; Shiburi et al 2006; Chaturvedi et al 
2004). The question therefore arises as to whether the impact of arterial stiffness on 
LVM in groups of African descent is in-part independent of BP measured at the brachial 
artery. If this is so, this may partly explain the increased LVM noted in groups of African 
ancestry. Therefore as part of the present thesis I also aimed to assess whether indices 
of arterial stiffness are associated with LVM and geometry independent of conventional 
BP in a relatively large, randomly selected population sample of African descent. These 
data are presented in chapter 4 of this thesis. 
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5.0 Class-specific effects of therapeutic agents on the regression of left 
ventricular hypertrophy 
 
As indicated in section 2.4 above, there is evidence to indicate that the impact of 
therapeutic agents on LVM and the associated CV risk reduction is partly independent of 
conventional BP changes (Mathew et al 2001; Okin et al 2004; Devereux et al 20042). 
The notion that specific antihypertensive classes of agents may have unique beneficial 
properties on target organ effects originally arose from animal studies demonstrating that 
non-specific vasodilators, such as minoxidil and hydralazine have little effect on LVM in 
animal models of hypertension, despite producing profound antihypertensive effects (e.g. 
Tsotetsi et al 2001). This notion was further extended in a number of human studies that 
were subsequently formally reviewed in a series of systematic reviews and meta-
analyses of these smaller studies. In this regard, two meta-analyses, which included 
uncontrolled studies in the analysis, revealed therapeutic class-specific effects. In a 
meta-analysis by Dahlof including 109 treatment studies, angiotensin-converting enzyme 
inhibitors (ACE-Is) and calcium channel blockers (CCBs) were noted to produce a more 
pronounced reduction of LVH than other drug classes (Dahlof et al 1992). Moreover, in a 
meta-analysis conducted by Schmieder et al (1998) with 89 randomized double-blind 
studies included in the analysis, ACE-Is and CCBs were noted to produce a greater 
decrease in LVH than beta-blockers or diuretics. In contrast however, a meta-analysis 
conducted by Fagard3 (1995) which included 21 controlled treatment studies, the 
reduction of LVM produced by antihypertensive agents was similar across the drug 
classes studied including diuretics, CCBs, beta-blockers and/or ACE-Is (Fagard 19953). 
Based on the notion that some classes of antihypertensive agents may be 
superior to others in their ability to reduce LVM in hypertension, further large studies 
were conducted with direct comparisons made between specific classes of agents. In the 
Losartan Intervention for Endpoint Reduction in Hypertension (LIFE) study, the 
angiotensin II receptor blocker, losartan, produced a greater regression of LVM than did 
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a beta-adrenergic receptor blocker, atenolol, after adjusting for conventional BP effects 
(Devereux et al 20041). This class-specific effect of losartan was mainly mediated by a 
decrease in LV septal and posterior wall thickness, rather than through changes in 
internal dimensions (Devereux et al 20041). The specific conventional BP-independent 
benefits of losartan on LVM in the LIFE study were also associated with a class-specific 
effect on CV risk reduction. As compared to the beta-blocker treated group, the overall 
greater CV risk reduction in hypertensive patients with LVH, treated with losartan, was 
13% (Dahlof et al 20021). The risk reduction was achieved for the composite end-point of 
CV death, stroke and MI, and especially for fatal and non fatal stroke (Dahlof et al 
20021). The data from the LIFE study are further supported by a study conducted with a 
similar design, where the angiotensin II receptor blocker, losartan, was also found to be 
superior to the beta-blocker atenolol at regressing LVH despite comparable effects on 
conventional BP (Zanchetti et al 2002). 
Although there is now substantial evidence to indicate that agents that block the 
renin-angiotensin system (RAS), such as angiotensin II receptor blockers, may reduce 
LVM in hypertensives to a greater degree than beta-adrenergic receptor blockers 
independent of conventional BP measurements, RAS blockers may still produce 
equivalent effects as compared to other antihypertensive agents such as CCBs. Indeed, 
in the Prospective Randomized Enalapril Study Evaluating Regression of Ventricular 
Enlargement (PRESERVE) Trial, ACE-Is and CCBs (with the addition of diuretics) 
produced similar effects on LVM in patients with hypertension and LVH (Devereux et al 
2001). 
 
5.1 Potential mechanisms of class-specific effects of therapeutic agents on the 
regression of left ventricular hypertrophy 
 
There are several explanations why blockers of the RAS may have a superior 
effect on the regression of LVH, whilst beta-blockers may not perform as well after 
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adjusting for conventional BP values. Blockers of the RAS may reduce the accumulation 
of collagen in large vessels and subsequently increase arterial compliance to a greater 
extent than other antihypertensive agents (Safar et al 1986). As indicated in section 4.3 
above, the effect of changes in arterial compliance on central BP may not be detected at 
the brachial artery (Karamanoglu et al 1993, Williams et al 2006). Although this issue is 
controversial (Weinberg et al 1997), blockers of the RAS may also reduce the effect of 
angiotensin II on the growth of cardiac myocytes independent of BP effects (Weinberg et 
al 1997).Therefore blocking angiotensin II production may favor the regression of LVH 
irrespective of BP effects (Ji et al 2003; Cagalinec et al 2006). However, the 
conventional-BP independent effect of RAS blockers on LVM may still be through BP 
effects. Indeed, blockers of the RAS may also produce a greater reduction in 24-hour BP 
than other classes of agents (Dahlof et al 1992). Clearly adjusting for conventional BP as 
opposed to ambulatory BP when assessing class-specific effects on LVM, is likely to 
have no impact if therapeutic agents have different ambulatory but the same 
conventional BP effects. 
As will be argued, the class-specific effect of RAS blockers on the regression of 
LVH in groups of African descent is in-question. Hence, as part of the present thesis I 
studied whether on-treatment LVM index is more closely related to the use of an ACE-I 
or to BP in South Africans of African ancestry with mild-to-moderate hypertension over a 
two-year treatment period. This study is described in chapter 6 of the present thesis. As 
it is possible that RAS blocker-specific effects on LVM may be through a greater 
reduction in 24-hour BP than other classes of agents (Dahlof et al 1992) in this study I 
employed ambulatory BP monitoring to assess BP effects on LVM. 
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5.2 Ethnic differences in class effects of therapeutic agents on the regression 
of left ventricular hypertrophy and cardiovascular outcomes 
 
In contrast to data obtained from meta-analyses in Caucasian groups (Dahlof et 
al 1992, Schmieder et al 1998), ACE-Is and diuretics appear to produce a similar 
reduction in LVM in South Africans of African ancestry (Middlemost et al 1994). In 
addition, when used as monotherapy, CCBs are superior to the ACEI, enalapril, in 
reducing LVM in severe and in mild-to-moderate hypertensive patients of African descent 
(Radevski et al 1999; Skoularigis et al 1994). Moreover, in the Baragwanath 
Hypertension Study, a relatively large single-centre study conducted in South African 
hypertensives of African ancestry, we were able to show that the decrease in LVM index 
produced by CCB, diuretic and ACE-I treatment groups did not differ between these 
different therapeutic classes over four months of therapy (Sareli et al 2001). Thus in 
South Africans of African descent at least, there is evidence to indicate that agents that 
block the RAS have no greater benefits over other antihypertensives when assessing 
their effects on LVM. However, this still requires clarity as maximal regression of LVH 
with antihypertensive agents may take up to two years to achieve (Devereux et al 2002).  
The inability of agents that block the RAS to produce a greater degree of 
regression of LVM as compared to other agents in black South Africans is reflected by 
data obtained in African-Americans. Indeed, in the LIFE study, a greater propensity of 
the angiotensin II receptor blocker, losartan to decrease LVM as compared to atenolol 
was noted in Caucasians, but not in other ethnic groups. Indeed, in a small cohort of 
other ethnic groups a significant decrease in LVM was not achieved with losartan 
(Devereux et al 20041). The lack of ability of losartan to decrease LVM to a greater 
extent than atenolol in the LIFE study was also mirrored by an inability of losartan to 
produce greater effects on CV outcomes as compared to atenolol in African-Americans 
patients (Julius et al 2004). Indeed the overall analysis on CV outcomes favored atenolol 
as opposed to losartan (Julius et al 2004). The ethnic-specific effects of agents that block 
 27
the RAS on CV outcomes were also noted in the Antihypertensive and Lipid-Lowering 
Treatment to Prevent Heart Attack Trial (ALLHAT). In the ALLHAT study, in which 35% 
of the patients enrolled were African-Americans, a significant interaction between ethnic 
group and treatment was noted when comparing the ACE-I, lisinopril, to the diuretic 
treatment group with respect to stroke and CVD (Julius et al 2004). 
The lack of consensus as to whether RAS blockers produce effects on LVM 
independent of BP changes in groups of African descent prompted my colleagues and I, 
as part of my thesis to extend the Baragwanath Hypertension Study from four months to 
two years. In this study I evaluate whether the use of an ACE-I confers benefits on 
changes in LVM beyond that produced by BP effects. This study and the implications 
thereof are described in chapter 6. 
 
5.3 Potential explanations for the impact of ethnicity on class effects of 
antihypertensive agents on left ventricular mass and other target organs 
 
A number of factors could explain the distinct ethnic differences in the RAS class 
effects of antihypertensive agents on LVM and other target organs. One potential 
explanation is that the BP response of hypertensives of African descent may differ for 
some treatment regimens (Cushman et al 2000, The ALLHAT Officers and Coordinators 
for the ALLHAT Collaborative Research Group 2002). Indeed, in the ALLHAT study, the 
reduction in systolic BP (4 mmHg) in the lisinopril (ACE-I)-treatment group was lower in 
African–Americans as compared to Caucasians and other ethnic groups (The ALLHAT 
Officers and Coordinators for the ALLHAT Collaborative Research Group 2002) a finding 
that has been widely incorporated into guidelines (Chobanian et al 2003, Williams et al  
2004). These data are consistent with what is presently known to occur in South Africans 
of African descent. It is well recognized that ACE-Is, when used as monotherapy, have 
little antihypertensive effect in South Africans of African ancestry, an effect that appears 
to be genetically pre-determined (Woodiwiss et al 2006). 
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Importantly however, the class-specific effect of ACE-Is on LVM may still occur in 
South Africans of African ancestry. Indeed, a similar reduction in LVM in South Africans 
of African ancestry in response to ACE-Is as compared to diuretics may occur even 
without a BP effect (Middlemost et al 1994). Thus in South Africans of African ancestry at 
least, there is still question as to whether agents that block the RAS have a BP-
independent effect on LVM regression, and if so whether this effect masks the BP-
dependent effects of antihypertensive agents on LVM. If antihypertensive agents 
produce therapeutic benefits on LVM and hence presumably other target organs without 
a significant BP effect, then there is question as to whether BP can be used as a 
surrogate measure of target organ effects. This is an important question in groups of 
African ancestry, in whom electrocardiograph criteria are poor indicators of LVH (Lee et 
al 1992), thus necessitating the use of other clinical indicators of regression of LVH. With 
the present resource constraints in the public health sector, it is not possible to offer 
routine echocardiography during antihypertensive therapy. If neither echocardiograph 
nor electrocardiograph indices of LVH are either available or useful, the only surrogate of 
the regression of LVH is a measure of BP. If the regression of LVH with RAS blockers in 
patients of African descent is not closely associated with BP, then we are faced with the 
conundrum of having no clinical index which will inform us of target organ effects in 
groups of African descent. Consequently, as part of the present thesis I studied whether 
there is indeed a relationship between BP changes and changes in LVM following the 
administration of agents that block the RAS to black South Africans with hypertension. 
These data and the implications thereof are presented in chapter 7 of this thesis. 
 
5.4 What is the best approach to the use of antihypertensive therapy in groups 
of African descent? 
 
As indicated in the above discussion there is indeed an ethnic-specific effect of 
antihypertensive therapy in groups of African descent. These effects are for both BP 
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(Cushman et al 2000, The ALLHAT Officers and Coordinators for the ALLHAT 
Collaborative Research Group 2002) and for LVM (Devereux et al 20041, Sareli et al 
2001, Radevski et al 1999; Skoularigis et al 1994). How does this potentially impact on 
the management of hypertension in groups of African ancestry? The South African 
Hypertension Society and the Seventh Report of the Joint National Committee on 
Prevention, Detection, Evaluation and Treatment of High Blood Pressure (JNC 7) 
guidelines recommend thiazide diuretics as initial therapy for the treatment of 
uncomplicated hypertension (Hypertension Society of Southern Africa, [Seedat et al 
2006], The Joint National Committee on Prevention, Detection, Evaluation, and 
Treatment of High Blood Pressure 2003). As the major ethnic-specific effect of 
antihypertensive therapy appears to apply to ACE-Is and angiotensin II receptor 
blockers, and not to diuretics, this ethnic-specific effect of antihypertensive therapy may 
not impact on management decisions in groups of African descent. 
However, there are many compelling indications for the use of RAS blockers in 
the treatment of hypertension, one of which is hypertension with LVH (Hypertension 
Society of Southern Africa, Seedat et al 2006, The Joint National Committee on 
Prevention, Detection, Evaluation, and Treatment of High Blood Pressure 2003). As LVH 
is likely to be highly prevalent in groups of African descent (see section 3.0 above), the 
ethnic-specific effects of RAS blockers may pose a management decision problem. 
However, a potential solution to this dilemma is to start patients requiring RAS blockers 
on a diuretic and then to add a RAS blocker, a combination that is thought to be as 
efficacious as in other ethnic groups. However, low-dose thiazide diuretic agents do not 
achieve ambulatory BP control in patients of African descent (Skoularigis et al 1995). 
Moreover, in a multi-arm combination trial, a dihydropyridine calcium channel blocker 
(CCB) when used as monotherapy was shown to be more efficacious than other classes 
of antihypertensive agents including low dose hydrochlorothiazide (HCTZ) (12.5-25 mg 
daily), a thiazide diuretic, as determined from 24 hour ambulatory BP monitoring in 
patients of African ancestry (Sareli et al 2001). Thus, it appears at least from a BP 
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perspective, that efficacious first-line therapy in groups of African descent may not be 
diuretic agents, but rather CCBs. 
Nevertheless, using ambulatory BP monitoring to assess efficacy, our group have 
recently demonstrated that monotherapy with the diuretic indapamide was superior to 
low dose HCTZ (Radevski et al 2002) in the management of hypertension in black 
African patients with mild-to-moderate hypertension. Whether indapamide used as initial 
therapy, with an ACE-I added as additional therapy, mediates equivalent 
antihypertensive actions and beneficial effects on LVM when compared to 
dihydropyridine CCB therapy in groups of African descent has not been evaluated. 
Therefore, as part of this thesis I compared the effect of indapamide plus an ACE-I to the 
dihydropyridine CCB, amlodipine on ambulatory BP and LVM in black patients with mild-
to-moderate hypertension. This study and the implications thereof are described in 
chapter 8 of the present thesis. 
 
6.0 Aims 
 
The aims of the present thesis were therefore as follows: 
 
a) To determine whether allometric growth signals (based on relationships between LVM 
and height) presently used to account for growth effects on LVM in taller populations are 
appropriate for a community of African descent living in Africa with a relatively short 
stature (chapter 2). 
 
b) To assess threshold values for LVM in clinically normal individuals from a randomly 
selected cross-sectional sample of nuclear families in a community of African descent 
living in Africa and consequently to compare these thresholds with other population 
samples (chapter 2). 
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c) To determine whether ambulatory BP is more closely associated with LVM than 
conventional BP or associated with LVM independent of conventional BP in a randomly 
selected cross-sectional sample of nuclear families in an urban, developing community 
of African descent (chapter 3). 
 
d) To determine the relative impact of day, night and day-night differences in BP on LVM 
in a randomly selected cross-sectional sample of nuclear families in an urban, 
developing community of African descent (chapter 3). 
 
e) To determine whether indices of arterial stiffness are associated with LVM 
independent of conventional BP in a randomly selected cross-sectional sample of 
nuclear families in an urban, developing community of African descent (chapter 4). 
 
g) To determine whether the regression of LVM in hypertensives of African origins is 
more closely associated with ambulatory than conventional BP over 4 months of 
antihypertensive treatment in newly diagnosed patients (chapter 5) and over 2 years in a 
combination of newly diagnosed and previously treated patients (chapter 6). 
 
h) To determine whether the use of RAS blockers confers specific benefits over other 
agents in reducing LVM in hypertensives of African origins (chapter 6) and whether RAS 
blockers mask the BP-dependent effect of antihypertensives on the regression of LVM in 
hypertensives of African origins (chapter 7). 
 
i) To determine whether a diuretic-ACEI combination is equally effective as a CCB in 
regressing LVM in hypertensives of African descent (chapter 8). 
 
 
 
 32
 
 
                                                    
 
                                                              
 
 
                                        Chapter 2 
 
 
Partition Values for Left Ventricular Mass in Subjects of 
African Descent in South Africa. 
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ABSTRACT 
Left ventricular (LV) hypertrophy is an independent risk factor for CVD. 
Population thresholds for LV mass (LVM) have been almost exclusively defined in 
groups residing in non-African countries. Unlike other population samples where growth 
exponentially impacts on LVM, in Southern Africa LVM may be linearly related to growth. 
Thresholds for LVM indices in populations where LVM is linearly related to growth have 
not been determined. In healthy participants (n=141) of randomly selected nuclear 
families of African descent living in an urban, developing community in South Africa 
(Soweto)(n=399 participants older than 16 years) I determined the appropriate 
adjustments of LVM for body size and subsequently assessed the thresholds for LVM 
indexed to these growth signals. The relationship between height and LVM was 
markedly different from that reported on in other population groups. LVM was related to 
body weight to the first power (r=0.42, p<0.001), body surface area (BSA) to the first 
power (r=0.46, p<0.001) and height to the first power (r=0.39, p<0.0001). No residual 
relation of LVM/BSA to BSA (r=0.04, p=0.61) was noted, whereas an inverse relation 
between LVM/body weight and body weight and a positive relation between LVM/height 
and height was noted. Expressing LVM for growth signals determined in other population 
groups (height2.7), overadjusted LVM, with a negative relationship noted between 
height2.7 adjusted LVM and height (r=-0.24, p=0.003) and BSA1.5 adjusted LVM and BSA 
(r=-0.19, p=0.02). Partition values for LVM adjusted for BSA to the first power were only 
marginally higher than in studies conducted in ethnic groups of non-African descent or 
ethnic groups of African descent living in other African countries. These data suggest 
that in South Africans of African descent, allometric signals used to adjust for growth in 
other population groups overadjust LVM. Moreover, in groups of African descent living in 
South Africa, thresholds for LVM appropriately indexed for growth are only marginally 
greater than in other population samples of non-African ancestry or of African ancestry 
living in Africa. 
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2.1 INTRODUCTION 
 
 The importance of LVM as a determinant of CVD is now well established (Casale 
et al 1986; Levy et al 1990; Koren et al 1991; Levy et al 1994; Verdecchia et al 1996; 
Ghali et al 1998; Devereux et al 20042; Okin et al 2004). In this regard, a number of 
recent studies with large sample sizes conducted in groups living outside of Africa 
indicate that LVM and the prevalence of LVH is considerably greater in groups of African 
than of European descent, and that ethnicity is a strong risk factor for LVH independent 
of all other factors including conventional BP, fat mass and fat-free mass (Skelton et al 
2003, Lorber et al 2003, Kizer et al 2004, Rodriguez et al 2004, Drazner et al 2005). 
These ethnic differences in LVM may translate into an increased prevalence of CVD. 
Thresholds for LVM have been almost exclusively defined in groups residing 
outside of Africa. There is considerable uncertainty as to whether LVM is indeed 
increased in groups of African descent in Africa. Difficulty in assessing whether LVM is 
increased in groups of African descent living in Africa occurs because growth relations 
with LVM may differ in these population groups. Unlike most population samples, where 
residual correlations between LVM and height are eliminated with the use of power 
functions (height2.0 or 2.7)(Lauer et al 1994, de Simone et al 1992, 1995), in groups of 
African descent living in Africa, where a shorter stature may occur, LVM indexed for 
height to the first power has been reported to eliminate residual correlations between 
LVM and height (Jaggy et al 2000). Unlike African-American groups that have been 
reported to have prevalence rates of LVH when adjusting LVM for height2.7 of ~36-49% 
(Nunez et al 2005), groups of African descent living in Africa have LVH prevalence rates 
based on LVM indexed for height, of ~9% (Jaggy et al 2000). It is therefore possible that 
unlike in African-Americans, groups of African descent living in Africa do not have an 
increased LVM. In the present study I therefore aimed to identify the most appropriate 
relationships between growth and LVM in subjects of African ancestry living in an urban, 
developing community in South Africa, to subsequently identify thresholds for LVM 
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indexed for appropriate growth signals in healthy individuals in this community, and to 
compare thresholds for LVM indices obtained in healthy individuals against other 
population samples. 
 
2.2 METHODS 
 
2.2.1 Study group. 
 
The study protocol was approved by the University of the Witwatersrand 
Committee for Research in Human Subjects (approval number: M02-04-72). To ensure 
quality control of the present study, investigators were trained at the University of Leuven 
in Belgium. In the present study, subjects of African ancestry were recruited from the 
township of Soweto (a metropolitan area of Johannesburg). Random recruitment of 
spouses and siblings living in households from formal dwellings (Figure 2.1) represented 
in the last census conducted (2001) was performed. Households were allocated 
numbers and numbers were selected from a random number generator. People residing 
in informal dwellings or institutions/homes were not recruited. The minimum age for 
participation in the study was 16 years, but there was no upper age limit. A lower age 
limit was included to avoid the impact of rapid growth effects. 
Recruitment for the present study was initiated in October 2003 and data 
obtained up until November 2006 were used for the present thesis. The study design has 
been described in brief in a recent publication (Shiburi et al 2006). Substantially more 
participants have been recruited subsequent to this original analysis (Shiburi et al 2006). 
Of the 1058 subjects that were invited to be part of the study, 656 subjects (62%) agreed 
to participate. Of the 656 participants enrolled in the study, 418 (64%) agreed to 
echocardiograph assessments. I discarded 15 because echocardiograms were of poor  
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Figure 2.1. Examples of formal dwellings in the suburban region where people were 
recruited for this study. 
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quality and a further 8 who did not have conventional BP measurements obtained on 
three separate occasions as part of this study. Thus, in total 399 subjects were assessed 
in this study. 
The subjects recruited were from the Nguni (Zulu, Xhosa, Ndebele, Swati), Sotho 
(South Sotho, North Sotho and Tswana) and Venda chiefdoms. The groups largely 
consisted of Nguni and Sotho chiefdoms. The lack of representation from the Venda 
chiefdom reflects a lack of individuals of this chiefdom residing in these areas of 
Johannesburg. No subjects of mixed, Asian, or European ancestry were recruited and no 
Khoi-San subjects were recruited. All subjects gave written, informed consent to 
participate in the study. 
 
2.2.2 Questionnaire 
 
Subjects completed a standard questionnaire. In order to avoid translational 
errors, the questionnaire was not translated into an African language, but study 
assistants familiar with all languages spoken in these townships and whom have either 
previously lived in Soweto or currently reside in Soweto, assisted with the completion of 
each questionnaire. Only same-sex assistants were used to assist each family member 
with the completion of the questionnaire. Assistance was only provided when requested. 
The majority of subjects were reasonably proficient in English. Study assistants first 
visited homes of subjects that agreed to participate in the study in order to develop a 
trusting relationship. The questionnaire was only completed at a subsequent clinic visit 
and then ambiguities checked by performing a follow-up home visit. If family members 
were absent at follow-up home visits, data was checked with them personally via 
telephonic conversations whenever possible. Ambiguities in answers to the 
questionnaire were detected by an independent observer prior to the second home visit. 
A pilot study was conducted in 20 subjects to ensure that data obtained in the 
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questionnaires were reproducible when obtained with the assistance of two separate 
study assistants. 
The questionnaire requested specific answers to date of birth, gender, previous 
medical history, the presence of hypertension, diabetes mellitus and kidney disease, 
prior and current drug therapy (analgesic use included), prior and current occupation, 
level of education, smoking status (including the number of cigarettes smoked in the past 
and at the present time), daily alcohol consumption (beer, traditional beer or other forms 
of alcohol and the daily quantity), caffeine consumption (number of cups of tea or coffee 
and whether they are decaffeinated and the number of cola’s a day), exercise frequency 
and family history of hypertension and cardiovascular events. For females, menstrual 
history, history of pregnancies and oral contraceptive use was evaluated. Although many 
of the questions simply required a “yes”-“no” answer, understanding was assessed by 
requesting some short answers. Although daily distances walked were requested, it was 
noted that perceptions of distance were largely overestimated and hence these data 
were not analysed. If subjects were unable to provide the name of medication taken 
these were obtained on the second home visit. Although a crude assessment of SE 
status (SES) was calculated from the combined levels of education, present occupations 
and annual income, these data were not analysed as this approach has not been 
validated in South Africa. 
 
2.2.3 Conventional blood pressure measurements 
 
Trained observers measured BP using a standard mercury sphygmomanometer 
during two home visits and a clinic visit. These were neither doctors, nor nursing sisters 
as both are perceived by the community as being in positions of authority and hence 
may elicit “white-coat” effects. After being trained in the procedure, including being 
shown pitfalls of BP measurement (positioning of the cuff, positioning of the arm, first 
estimating systolic BP using a radial pulse measure in order to avoid increasing cuff 
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pressures too high, detecting auscultatory gaps, releasing valve pressure at the correct 
speed, using the correct cuff size, etc.), assistants had to demonstrate an ability to 
perform the procedure on 20 subjects. The study assistants were then tested on their 
ability to measure BP in two ways. First they were asked to measure BP on a separate 
group of 20 subjects including patients with hypertension and their readings had to be 
within 4 mm Hg of a doctors/nursing sister’s readings obtained with a stethoscope with 
two ear pieces. Second, study assistants were asked to watch a video showing a 
simulated mercury column with Korotkoff sounds where observers were tested on their 
ability to detect phase I and V sounds under different circumstances including in the 
presence of a wide auscultatory gap and where phase V Korotkoff was taken as a 
“muffling” rather than a “disappearance” of sounds (Blood Pressure Measurement, 
British Medical Journal, BMA House London). To qualify as observers all their readings 
(n = 20) had to be within 4 mm Hg of the reference standard. Those assistants who failed 
on the assessment the first time were given more time to practise on subjects and then 
asked to repeat the tests.  
Home visits were conducted 3-to-4 weeks apart and the clinic visit occurred 
between the two home visits. A standard cuff with a 12 × 24 cm inflatable bladder was 
used, but if upper arm circumference exceeded 31 cm, larger cuffs with a 15 × 35 cm 
inflatable bladder were used. After 10 minutes of rest in the sitting position, five 
consecutive BP readings were taken 30 to 60 seconds apart with the subject in a sitting 
position, followed by a pulse rate count. The cuff was deflated at approximately 2 mm Hg 
per second and phase I (systolic) and phase V (diastolic) BP recorded to the nearest 2 
mm Hg according to the recommendations of the European Society of Hypertension 
(O’Brien et al 2003). The mean of the five measurements taken at the first home visit 
was recorded as the home BP.  Between the two home visits subjects were invited to the 
School of Physiology Hypertension Clinic where the same observers, following the same 
procedure as the first home visit, measured the subject’s blood pressure under 
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comfortable surroundings. The average of the five readings was taken as the office 
(conventional) BP. Office rather than home measurements were used to define the 
presence or absence of hypertension in untreated subjects. 
In the present study quality control of conventional BP assessments was 
assessed as previously described (Kuznetsova et al 2002). Only 0.23% of visits had 
fewer than the planned BP recordings. The frequency of identical consecutive recordings 
was 1.15% for systolic BP and 2.08% for diastolic BP. The occurrence of BP values 
recorded as an odd number was 0.02 %. Of the 8722 systolic and diastolic BP readings, 
26% ended on a zero (expected =20%). A diagnosis of hypertension was made if 
subjects were receiving antihypertensive therapy and/or if the average of the mean 
values for the clinic readings was ≥140/90 mm Hg. 
 
2.2.4 Anthropometric Measurements 
 
Body height and weight were measured during the clinic visit by a trained 
observer. Height and weight were measured with the participants standing and wearing 
indoor clothes with no shoes. Body mass index was calculated as weight in kilograms 
divided by the square of height in meters. Body surface area in meters2 (m2) was 
calculated as (0.0001) x (71.84) x (weight in kg)0.425 x (height in cm)0.725. 
 
2.2.5 Blood measurements 
 
 Blood samples were obtained on the day of the clinic visit and sent to the South 
African National Health Systems Laboratories (NHSL) to perform a full blood count and 
differential count, to measure urea, creatinine and electrolyte concentrations, to assess 
liver function (from alanine transaminase, aspartate transaminase, gamma glutamyl 
transferase, alkaline phosphatase, albumin, total protein and plasma albumin, total 
bilirubin, and conjugated and unconjugated bilirubin concentrations) and plasma urate 
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concentrations, to obtain a lipid profile (total cholesterol, LDL cholesterol, HDL 
cholesterol and TG concentrations), a blood glucose measurement, an HbA1c and an 
FSH in females. These data were used to identify medical conditions and syndromes. A 
“spot” urine analysis was also performed to screen for major clinical conditions, such as 
diabetes mellitus and renal pathology. The NHSL was utilised for blood measurements to 
ensure reproducibility and reliability as these laboratories have been accredited as 
fulfilling all criteria of “good laboratory practise”. In those subjects without a prior history 
of diabetes mellitus, an HbA1c rather than a fasting blood glucose concentration was 
utilised in the APOGH study to assess blood glucose control. 
 
2.2.6 Echocardiography. 
 
Echocardiographic measurements were performed using previously described 
methods (Sareli et al 2001). Briefly, two-dimensional guided M-mode echocardiography 
was performed using a pulse color Doppler Hewlett Packard model 5500 recorder 
coupled to a 2.5 MHz transducer. Data obtained in the short axis view were analyzed 
according to the American Society of Echocardiography (ASE) convention (Sahn et al 
1978). During recordings the transducer was placed perpendicular to the chest wall or 
pointed slightly inferiorly and laterally at the end of the long axis (Sahn et al 1978). All 
measurements were recorded on videotape and analyzed off-line by an experienced 
investigator (CL), who was unaware of the clinical condition of the subjects. The 
interventricular septal wall thickness (IVS) at end diastole, the posterior wall thickness 
(PWT) at end diastole and the end diastolic internal dimensions of the left ventricle were 
measured only when appropriate visualization of both the right and the left septal 
surfaces was obtained (Sahn et al 1978). Figure 2.2 shows echocardiography being 
performed and a representative M-mode image. Left ventricular mass was derived 
according to an anatomically validated formula (Devereux et al 1986) (appendix 1). For 
comparison purposes with studies that have utilized the ASE convention without
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Figure 2.2. Upper panel illustrates the Hewlett Packard model 5500 utilised to assess 
left ventricular dimensions in the study sample. The lower panel shows an M-Mode 
image. 
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corrections for over-estimations, or the Penn convention, LVM was also calculated using 
these formulae (see appendix 1). Left ventricular relative wall thickness (RWT) was 
calculated as (LV diastolic posterior wall thickness x2)/LV end diastolic diameter (Ganau 
et al 1992). Left ventricular mean wall thickness was determined from the mean of LV 
septal and posterior wall thickness. 
 
2.2.7 Data analysis. 
 
For database management and statistical analysis, SAS software, version 9.1 
(SAS Institute Inc., Cary, NC) was employed. Proportions were compared using χ2-
statistics and comparisons between gender groups were performed using an unpaired 
Student’s t-test. To generate a healthy sample of subjects, a total of 258 subjects were 
excluded, because of hypertension (receiving antihypertensive therapy or a conventional 
BP140/90 mm Hg, n = 188), diabetes (receiving oral or insulin therapy) or impaired 
blood glucose control (an HbA1c >7%) (n = 35), obesity (body mass index 30kg/m2) (n 
= 170) or because they had previous or concomitant cardiovascular disease, including 
coronary heart disease, heart failure, transient ischemic attack, or intermittent 
claudication (n = 8). The overall number of participants statistically analysed totaled 141. 
 Relations of LVM to measures of body size were assessed using linear 
regression analysis. Thresholds for LVM were determined in sex-specific groups from 
linear regression analysis relating indexed LVM to age. Departure from normality was 
evaluated by Shapiro-Wilk’s statistic (Shapiro and Wilk 1965) and skewness by the 
computation of the coefficient of skewness, i.e. the third moment about the mean divided 
by the cube of the standard deviation (Snedecor and Cochram 1980). The normal 
distribution was used to determine the significance of the coefficient of the skewness 
(Snedecor and Cochram 1980). For the purposes of comparisons with other population 
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samples, thresholds for LVM indices were generated for indices with appropriate growth 
signals only.  
2.3 RESULTS 
 
2.3.1 Characteristics of the Participants 
 
Table 2.1 gives the characteristics of the healthy participants by gender. Mean 
age was 29.2±12.4 years. Women had a higher body mass index than men, with 35/82 
women (43%) and 19/59 men (32%) being overweight (BMI25kg/m2). Of the 141 
healthy participants, 26 men (18%) and 9 women (6%) were smokers and 22 men (16%) 
and 13 women (9%) reported alcohol consumption. Among smokers, median tobacco 
use was 7 cigarettes per day (range, 1–23). Among regular drinkers, median alcohol 
consumption was 19.8 grams per day (range, 2–117.5). Men had higher values for all 
measurements of LV structure. 
 
2.3.2 Relationships between left ventricular mass and measures of body size 
 
Figures 2.3-to-2.5 show the relations between LVM and each measure of body 
size (body weight, body surface area and height)(upper panels) and the relations 
between LVM normalised to each measure of body size to the first power versus each 
measure of body size (lower panels). All of the relations essentially fitted a linear function 
(upper panels). Minimal residual correlations were noted after adjustments of LVM for 
body surface area (lower panel of Figure 2.4). In contrast, a marked negative relationship 
between LVM adjusted for body weight to the first power and body weight was noted 
(Figure 2.3) and a positive relationship between LVM adjusted for height to the first 
power and height was noted (Figure 2.5). 
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Table 2.1 Characteristics of the healthy participants 
 
                  Men            Women  p-value 
Number        59      82   
Age, years    30.1±13.0  28.5±12.0 =0.47 
 
Anthropometic measurements 
 
Height, cm    170.3± 7.9  158.8± 7.4 <0.0001 
 
Weight, kg    66.4±11.4  60.7±9.5 =0.002 
 
Body mass index, kg/m2  22.9± 3.6  24.1±3.4 =0.04 
 
Body surface area, m2  1.77± 0.16  1.62± 0.1 <0.0001 
 
Blood Pressure (mm Hg)   
 
Systolic    118± 9   112±10  =0.0007 
 
Diastolic    78±8   75± 8   =0.03 
 
Smoking habits (%)     44     11  <0.0001 
 
Alcohol intake (%)     37     16   =0.02 
 
Left ventricular (LV) measurements 
 
End diastolic diameter (cm)  4.96± 0.45  4.51± 0.43 <0.0001 
 
Posterior wall thickness (end  0.98± 0.10  0.90± 0.07 <0.0001 
 
diastole)     
 
Septal wall thickness (end diastole) 1.01± 0.12  0.93± 0.09 <0.0001 
 
LV mass (g)    180±38  138±27 <0.0001 
 
LV mass index (g/m2)   102±20  85±16  <0.0001 
 
LV mass index (g/m)   106±22  87±17  <0.0001 
 
LV mass index (g/m2.7)   43±10   40± 8   =0.028 
 
LV RWT    0.40± 0.05  0.40± 0.05  =0.71 
 
Values are mean ± SD or number (%). P-values are comparisons between men and 
women. 
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Figure 2.3. Relationship between left ventricular mass (LVM) and body weight (upper 
panel) and between LVM normalised to body weight to the first power and body weight 
(lower panel). Correlation coefficients for the relationships are indicated in the figures.  
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Figure 2.4. Relationship between left ventricular mass (LVM) and body surface area 
(upper panel) and between LVM normalised to body surface area to the first power and 
body surface area (lower panel). Correlation coefficients for the relationships are 
indicated in the figures. 
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Figure 2.5. Relationship between left ventricular mass (LVM) and height (upper panel) 
and between LVM normalised to height to the first power and height (lower panel). 
Correlation coefficients for the relationships are indicated in the figures. 
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2.3.3 Impact of adjustments of LVM for allometric signals generated in other 
populations. 
 
 When adjusting for allometric signals generated in other population groups (body 
surface area1.5 and height2.7 (Lauer et al 1994, de Simone et al 1992, 1995), inverse 
relations were noted between adjusted LVM and either body surface area or height 
(Figures 2.6-2-7). Thus, allometric signals generated in other population groups 
markedly over-adjusted for LVM in the present community sample.  
 
2.3.4 Distribution of left ventricular mass 
 
Figure 2.8 shows the distributions of LVM and LVM indexed for body surface 
area. The distributions departed from normality and were positively skewed (p<0.001). 
The coefficients of skewness were 0.81 for LVM and 0.50 for LVM indexed for body 
surface area. 
 
2.3.5 Proposal for diagnostic thresholds for left ventricular mass index 
 
To determine diagnostic thresholds of LVM index for men and women in this 
community, the 95th prediction bands (Figure 2.9) for the approximate mean age of the 
participants (30 years) was rounded downwards to the nearest value ending in zero, or 
integer for LVM indexed for body surface area. This procedure yielded the following 
thresholds: 134 g/m2 for LVM indexed for body surface area for men and 112 g/m2 for 
LVM indexed for body surface area for women. LVM index tended to increase with age, 
although this did not reach statistical significance (Figure 2.9). Per decade of life, the 
aforementioned thresholds may therefore be altered by approximately 1.2 g/m2 for LVM  
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Figure 2.6. Relationship between left ventricular mass (LVM) normalised to body surface 
area1.5 and body surface area. The correlation coefficient for the relationship is indicated 
in the figure. 
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Figure 2.7. Relationship between left ventricular mass (LVM) normalised to height2.7 and 
height. The correlation coefficient for the relationship is indicated in the figure. 
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Figure 2.8. Distributions of left ventricular mass (LVM) and LVM indexed for body 
surface area in healthy subjects. 
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Figure 2.9. Sex-specific relations of left ventricular mass (LVM) indexed for body surface 
area with age in study subjects. Each panel shows the regression line and the 95% 
prediction bands for mean and individual values of LVM index. 
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indexed for body surface area for men, and 1.4 g/m2 for LVM indexed for body surface 
area for women. 
 
2.3.6 Comparison of diagnostic thresholds with other populations 
 
 Table 2.2 shows thresholds for LVM indexed to body surface area obtained in the 
present population sample and in those reported on for other population groups. 
Thresholds defined for LVM calculated from the American Society of Echocardiograpy 
convention (both corrected for LVM overestimations [Devereux et al 1986] and 
uncorrected) and the Penn convention are shown. These have been included for 
comparative purpose with other population samples where different methods for 
calculating LVM have been employed. Irrespective of the method of calculation of LVM, 
LVM indexed to body surface area was noted to be marginally higher than in studies 
conducted in other population groups. 
 
2.4 DISCUSSION 
 
The main findings of the present study are as follows. First, in a healthy group of 
participants of African ancestry living in South Africa, the relationship between LVM and 
body size appears to differ from that noted in other populations. Unlike other populations 
where adjusting LVM for power functions of either body surface area (body surface 
area1.5) or height (height2.7) is required to eliminate residual relations between LVM and 
body size, the use of these allometric signals resulted in marked overadjustments of LVM 
in the present study. The most appropriate index to adjust LVM for body size in the 
present study was LVM adjusted for body surface area to the first power, which 
eliminated residual relations between LVM and body size. Second, in the absence of an 
outcome-driven reference frame for the present population, our study suggests thresholds 
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Table 2.2. Thresholds for echocardiographic LVM indexed to body surface area as 
determined from confidence intervals or means and standard deviations (SD) in the 
present and in other populations. 
 
Study    Population              Threshold 
        Men    Women 
_______________________________________________________________________ 
Present   African ancestry  168#   140# 
134†   112† 
        158*              130* 
Levy et al 1987   Caucasian   150#   120# 
        131*   100* 
Lauer et al 1994  Caucasian   130*     96* 
Savage et al 1987  Caucasian   131*   100* 
Devereux et al 1984  Caucasian   134*   110* 
Chaturverdi et al 1994 Mixed    123†   111† 
de Simone et al 1992  Caucasian   117†   105† 
de Simone et al 1995  Caucasian   117†   104† 
_____________________________________________________________________ 
# From the ASE criteria without corrections for over-estimation (Devereux et al 1986); † 
From the American Society of Echocardiography convention; * From the Penn 
convention. Bold and italix are all data from the Framingham Heart study. 
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for normal LVM indexed to body surface area in this population. Third, in comparison to 
other population-based studies, the thresholds noted in healthy individuals in the present 
study for LVM indexed to body surface area are marginally higher than in other population 
samples (Table 2.2). 
Although measurements of LVM using echocardiography have been established 
as being useful in predicting CVD (Casale et al 1986; Levy et al 1990; Koren et al 1991; 
Levy et al 1994; Verdecchia et al 1996; Ghali et al 1998; Devereux et al 20042), there has 
been some debate as to how best to adjust for growth effects on LVM, changes that are 
of physiological but not pathological relevance. Presently there are several methods to 
normalize LVM using different measures of body size (height, weight, body surface 
area)(de Simone et al 1992, Lauer et al 1994, Urbina et al 1995, de Simone et al 1995, 
Bella et al 1998), but the most appropriate growth signals for LVM appear to be power 
functions (height2.7 and body surface area1.5)(de Simone et al 1992, Lauer et al 1994, de 
Simone et al 1995). Indeed, power functions (height2.7 and body surface area1.5) appear 
to elimate residual correlations between LVM and body size (de Simone et al 1992, Lauer 
et al 1994, de Simone et al 1995). However, studies conducted that define appropriate 
growth signals for LVM have been conducted in groups of European ancestry. 
Appropriate growth signals for LVM have not been formally identified in groups of African 
ancestry. 
In the present study conducted in healthy participants of African ancestry, I have 
demonstrated that indexing LVM for height2.7 produces overadjustments of LVM as 
indicated by inverse correlations between height2.7 adjusted LVM and height (r=-0.24, 
p=0.003). Similarly, indexing LVM for body surface area1.5 produces overadjustments of 
LVM as indicated by inverse correlations between body surface area1.5 adjusted LVM and 
body surface area (r=-0.19, p=0.04). These inverse relations between height2.7 adjusted 
LVM and height have been noted in other population groups, but they have been modest 
at best and consistent with inverse relations between LVM/bodyweight versus body 
weight relations (de Simone et al 1992). In contrast, in the present study, the inverse 
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relation between height2.7 adjusted LVM and height was distinct and represents a clear 
overadjustment for body size effects on LVM. Rather, of all the indexes used to-date, 
indexing LVM for body surface area to the first power was noted to be the most 
appropriate method of eliminating residual correlations between LVM and body size 
(Figure 2.4, lower panel). 
Unlike the present study, one previous study conducted in 65 men and 99 women 
of African descent living in Southern Africa (Mauritius) suggested that adjustment of LVM 
for height to the first power does indeed eliminate the correlation between LVM and 
height (Jaggy et al 2000). Although in the present study adjustments of LVM for height to 
the first power reduced the correlation between LVM and height (Figure 2.5, lower panel), 
this did not eliminate the correlation. Consequently, it is likely that a power function for 
height is still required to adjust LVM for height effects in the population sampled. 
However, as the most appropriate height signal in the present population is unlikely to 
represent a signal previously described for indexing LVM, it has no value when 
comparing thresholds derived in the present population with thresholds generated in other 
population samples. 
An explanation for the distinct differences in the relationship between LVM and 
body size in Southern African groups of African descent (this study and Jaggy et al 2000) 
and in other population groups (de Simone et al 1992, Lauer et al 1994, de Simone et al 
1995) should be considered. In both the present and a previous study (Jaggy et al 2000), 
the mean height of the study subjects was lower than that generally noted to occur in 
Caucasian and African-American groups. A reduced height but a similar degree of 
muscularity achieved may significantly modify the relationship between LVM and either 
height or body surface area. As muscularity was not measured in the present study, this 
potential explanation remains speculative. Importantly, differences in the degree of 
adiposity cannot explain the discrepancies in the relationship between LVM and body size 
in Southern African groups of African ancestry and population groups elsewhere. Indeed, 
in all studies (this study and Jaggy et al 2000, de Simone et al 1992, Lauer et al 1994, de 
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Simone et al 1995) obese subjects were excluded from the groups assessed and a 
similar mean BMI was noted. 
 Thresholds for LVM have more recently been defined from outcome-based 
studies. Outcome-based studies have appropriately described thresholds for LVM 
indexed to height2.7. However, as indicated by the present study, height2.7 is an 
inappropriate index for the population studied. Thus, it is important to define thresholds 
for the present population using appropriate allometric signals. In the absence of 
outcome-based studies, the present study suggests thresholds for LVM indexed to an 
appropriate allometric signal, as defined from clinically healthy individuals. Importantly, in 
the present study, thresholds of LVM index obtained in healthy individuals do not appear 
to be strikingly greater than those described in largely Caucasian populations (see Table 
2.2). However, the fact that the relations between LVM and growth signals are not the 
same in the present as in other populations, comparing LVM index thresholds obtained in 
the present with those defined in other population samples, may be a spurious 
comparison. 
 In summary the present study provides evidence to suggest that growth signals 
for LVM in populations of African ancestry living in South Africa are different from other 
population groups. Further, the present study suggests that thresholds for LVM index in 
an apparently healthy group of African descent are not strikingly higher than in other 
population studies. 
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                                        Chapter 3 
 
 
Diurnal Blood Pressure Profiles and the Prediction of Left 
Ventricular Mass Beyond that of Conventional Blood 
Pressures in Subjects of African Descent 
 - 60 -
ABSTRACT 
 Whether an attenuated nocturnal decline in blood pressure (BP) in subjects of 
African descent translates into a greater left ventricular mass (LVM) independent of 
conventional BP is uncertain. In the present study, I examined whether ambulatory BP 
(SpaceLabs, model 90207) is associated with LVM indexed to body surface area 
(LVMI)(echocardiography) better than or independent of conventional BP and whether 
diurnal BP profiles determine LVMI in a randomly selected population sample (n=399) of 
a group of African ancestry. Conventional BP (standardized and non-physician 
determined) was determined from the mean of 5 measurements. 22% were receiving 
antihypertensive treatment. Adjustments were made for sex, age, body mass index, non-
independence of family members, antihypertensive treatment, and the presence of 
diabetes mellitus or an HbA1c>7.0%. Neither the ratio of night-to-day BP, nor differences 
in night-to-day BP were associated with LVMI. After adjustments, conventional, 24-hour, 
daytime and night-time systolic BP (SBP) were associated with LVMI, with equivalent 
relations noted for conventional (r=0.21, p<0.0005) and 24 hour (r=0.17, p<0.005) SBP 
and for daytime (r=0.17, p<0.005) and night-time (r=0.16, p<0.01) SBP. Diastolic BP was 
not independently related to LVMI. With conventional BP included as a covariate, neither 
24-hour, daytime nor night-time BP were independently associated with LVMI in the 
whole group. Similar outcomes were noted in untreated subjects. However, in sex-
specific analysis, night-time BP was associated with LVMI independent of conventional 
BP in men (n=110, r=0.21, p<0.05). In conclusion, in persons of African descent, diurnal 
BP profiles do not contribute to LVMI and neither 24-hour, nor daytime BP predict LVMI 
beyond conventional BP. However, nocturnal BP may contribute to LVMI in men, but not 
in women, independent of conventional BP. 
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3.1   INTRODUCTION  
 
As summarized in chapter one, LVM is a strong independent predictor of CVD 
(Casale et al 1986; Levy et al 1990; Koren et al 1991; Levy et al 1994; Verdecchia et al 
1996; Ghali et al 1998; Devereux et al 20042; Okin et al 2004). Moreover, groups of 
African ancestry living outside of Africa have a higher LVM than groups of European 
descent, changes that are independent of conventional BP, fat mass and fat-free mass 
(Skelton et al 2003, Lorber et al 2003, Kizer et al 2004, Rodriguez et al 2004, Drazner et 
al 2005). These conventional BP-independent ethnic differences in LVM may translate 
into an increased prevalence of CVD. However, the exact mechanisms responsible for an 
increased LVM in groups of African ancestry have not been reported on. 
Several cross-sectional studies conducted in Caucasian groups have reported 
that ambulatory blood pressure is more closely associated with LVM than conventional 
BP (reviewed by Fagard et al 19951, Verdecchia et al 1999, Fagard and Staessen 2002). 
There are a number of explanations for the differences in the association of conventional 
and ambulatory BP with LVM. One potential explanation is that unlike conventional BP 
measurements, ambulatory BP accounts for 24-hour and nocturnal BP loads. In this 
regard, groups of African descent are thought to have an enhanced 24-hour BP load for 
any given daytime BP, as they have an attenuated nocturnal decrease in BP (Profant and 
Dimsdale 1999, Wang et al 2006). However, as studies with small sample sizes, poor 
quality ambulatory and possibly conventional BP data, and with inconsistent outcomes 
have addressed the issue of whether attenuated nocturnal decreases in BP translate into 
an enhanced LVM in groups of African ancestry (Murphy et al 1991, Fumo et al 1992, 
Chatuvedi et al 1994, Olutade et al 1998, Mayet et al 1998, Palmieri et al 1999, 
Harshfield et al 2002, Hinderliter et al 2004) this question still remains unanswered. 
Moreover, none of the studies evaluating the role of nocturnal decreases in BP as a 
determinant of LVM in groups of African descent have assessed whether indices of 
nocturnal decreases in BP, 24-hour BP, daytime BP or nocturnal BP predict LVM beyond 
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that provided by conventional BP. In the present study I therefore assessed the 
relationship between nocturnal decreases in BP and LVM in a relatively large community-
based sample of randomly recruited nuclear families of African descent. I also assessed 
whether 24-hour BP, daytime BP or nocturnal BP predict LVM either better than or 
independent of conventional BP in subjects of African ancestry.  
 
3.2 METHODS 
 
3.2.1 Study group, demographic and clinical data, conventional blood pressure 
measurements and echocardiography. 
 
The community sampled and the sampling approach has been described in full in 
chapter 2 of the present thesis. Of the 656 subjects recruited for the present study, 399 
subjects had high quality echocardiograms (see chapter 2) and 297 subjects had both 
high quality echocardiograms and 24-hour ambulatory BP values that met pre-specified 
quality control criteria (see below for description). Demographic and clinical data and 
conventional BP and echocardiographic measurements were obtained as described in 
chapter 2. 
 
3.2.2   Ambulatory blood pressure. 
 
On the same day as conventional BP measurements were obtained, 24-hour 
ambulatory BP monitoring was performed using oscillometric monitors (Spacelabs, model 
90207) (see Figure 3.1). Ambulatory monitors were calibrated monthly against a mercury 
manometer. The non-dominant arm was selected for BP monitoring. The size of the cuff 
was the same as that used for conventional BP measurements. The monitors were 
programmed to measure BP at 15-minute intervals from 06:00 to 22:00 h and at 30-
minute intervals from 22:00 to 06:00 h. Subjects kept a diary card for the duration of the 
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recordings to note the time of going to bed in the evening and getting up in the morning. 
Subjects were also asked to record the time when taking medication in those receiving 
medication and any times when they either smoked or took caffeine containing or 
alcoholic beverages. Subjects were asked to pursue their normal daily activities and to 
keep the cuff arm steady during measurements. Considering the patterns of diurnal 
activities, daytime and night-time were defined as ranging from 09:00 to 19:00 h and from 
23:00 to 05:00 h, respectively. These fixed clock-time intervals were defined in order to 
eliminate the transition periods (evening and morning) during which BP changes rapidly in 
most subjects (Thijs et al 1992). On completion of the recording, the data were 
transferred to a computer for analysis. Intra-individual means of the ambulatory 
measurements were weighted by the time-interval between successive recordings (Thijs 
et al 1992). Of the participants enrolled in the study, we discarded 67 from the analysis, 
because the ambulatory BP measurements did not meet pre-specified quality criteria 
(more than 20 hours of recordings and more than 10 and 5 readings for the computation 
of daytime and night-time means respectively). The degree of nocturnal decreases in BP 
was assessed by expressing data as either the day-night difference or the ratio of night-
to-day BP.   
 
3.2.3 Statistical analysis 
 
Database management and statistical analysis were performed using SAS 
software versions 9.1 (SAS Institute Inc.) The definitions for hypertension and diabetes 
mellitus or abnormal blood glucose control are provided in chapter 2. LVM was calculated 
as described in chapter 2. I have previously demonstrated that indexing LVM for body 
surface area eliminates residual correlations between LVM and body surface area 
(chapter 2). Moreover, I have shown that alternative indices used to adjust for height or 
body surface area (height2.7 and BSA1.5) described in other populations, considerably 
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Figure 3.1. Spacelabs model 90207 ambulatory BP monitors (upper panel) and 
representative data obtained for analysis purposes (lower panel). 
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overadjust LVM (chapter 2). Consequently, LVM was indexed for body surface area 
(LVMI) to the first power rather than to power functions described for other population 
samples. Pearson correlation coefficients for the relationships between BP (or indices of 
nocturnal decreases in BP) and LVM indexed for body surface area were determined.  
 Means and proportions were compared by the large-sample z-test and the χ2-
statistic, respectively. Linear regression analysis with adjustments for sex (except when 
sex-specific analysis was performed), age, BMI, antihypertensive treatment (except in 
untreated subjects), and the presence of diabetes mellitus/abnormal blood glucose 
control, was used to determine the relation between conventional or ambulatory BP and 
LVMI. For statistical analysis of the relations and the derivation of probability values, 
further adjustments were made for non-independence of family members. To determine 
whether 24-hour BP was more closely associated with LVMI that conventional BP, or 
whether nocturnal BP was more closely associated with target organ effects than daytime 
BP, adjusted correlation coefficients were compared. When assessing the conventional 
BP–independent relationship between ambulatory BP and target organ changes, 
conventional BP was included as an adjustor. Sensitivity analysis was performed in 
subjects not receiving antihypertensive therapy and in sex-specific groups. 
 
3.3 RESULTS 
 
3.3.1 Population characteristics. 
 
Table 3.1 gives the demographic and clinical characteristics of the subjects. As 
subjects were not specifically selected as a healthy cohort of the sample, the 
characteristics of the study sample were different to the cohort of healthy individuals 
described in chapter 2. The mean age was 43.9±18.1 years. Women had a higher body 
mass index than men, with 142 women (76%) and 59 men (54%) being overweight or 
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  Table 3.1 Demographic, and clinical characteristics of study subjects 
 
  All subjects  Women  Men 
 
Number                    297  187             110   
Age (years)   43.9 ± 18.1           42.9 ± 17.5        45.6 ± 19.0 
Body Weight (kg)   76.0 ± 17.9           77.3 ± 18.3        73.8 ± 17.0 
Body Height (cm)  161.8 ± 8.4           158.0 ± 6.6       168.3 ± 7.0** 
BMI (kg/m2)    29.1 ± 7.1            31.0 ± 7.3          26.0 ± 5.7** 
Current antihypertensive  
medication n,(%)    66 (22)  47 (25)  19 (17)     
n,(%) with hypertension    121(41)  77(41)   44(40) 
n,(%) with diabetes mellitus    19 (7)   8 (5)   11(10) 
Blood pressures 
Conventional (mm Hg)           130±21/84±12        129±22/84±12         132±19/85±11 
24-hour (mm Hg)                    119±15/73±10        117±16/72±11         121±13*/74±10   
Daytime (mm Hg)                   123±15/78±10        122±15/77±11         126±13*/79±10 
Night-time (mm Hg)                112±17/65±12        111±18/65±12         114±15/66±12 
Night-day (mm Hg)                 -11±11/-12±9   -10.6±10.4/-12.1±7.9  -12.1±10.8/-12.8±9.6 
Night/day                             0.9±0.08/0.8±0.1  0.91±0.08/0.84±0.10   0.91±0.09/0.84±0.12 
BMI, body mass index; *p<0.05 , ** p<0.001 versus women. 
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obese (BMI25kg/m2). 41% of the sample was hypertensive, and 7% had type II diabetes 
mellitus, with more men than women noted to have diabetes mellitus. 22% of the sample 
were receiving antihypertensive therapy. 
Table 3.2 gives the echocardiographic data. As compared to women, men had 
increased LV dimensions for all parameters. 
 
3.3.2 Relationship between conventional and ambulatory BP. 
 
A strong correlation was noted between conventional systolic BP and 24-hour 
(r=0.71, p<0.0001), day (r=0.69, p<0.0001) and night-time (r= 0.66, p<0.0001) systolic 
BP. Moreover, a strong correlation was noted between conventional diastolic BP and 24-
hour (r= 0.61, p<0.0001), day (r=0.63, p<0.0001) and night-time (r=0.53, p<0.0001) 
diastolic BP. Similar relations between conventional and either 24-hour, day or night-time 
systolic and diastolic BP were noted in both gender groups (men; conventional systolic 
BP versus 24 hour, r=0.68, p <0.0001, versus day, r=0.60, p<0.0001, versus night, r=0.61     
, p< 0.0001: women;  conventional systolic BP versus 24 hour, r=0.73, p <0.0001, versus 
day, r=0.73, p<0.0001, versus night, r=0.67, p<0.0001). 
 
3.3.3 Unadjusted associations between BP and LVMI. 
 
LVMI positively correlated with conventional, 24-hour, daytime and night-time 
systolic and diastolic BP in the whole group (Figure 3.2 and Table 3.3, unadjusted 
associations) and in untreated subjects (Table 3.4, unadjusted associations). Importantly, 
no correlations were noted between night-day differences in systolic or diastolic BP or in 
the night-to-day ratio of systolic and diastolic BP and LVMI (Tables 3.3 and 3.4). No 
differences in the relationships between conventional BP and LVMI and either 24-hour or 
daytime BP and LVMI were noted (comparison of correlation coefficients, conventional 
versus 24-hour or daytime, p>0.05). Moreover, no differences in the relationships 
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Table 3.2. Echocardiographic characteristics of study subjects. 
 
                                                          All subjects              Women                   Men 
                                                               297                        187                        110          
____________________________________________________________________ 
LVED diameter (cm)                           4.77±0.52            4.63±0.49              5.00±0.47*    
LVED posterior wall thickness (cm)   0.98± 0.13             0.96±12               1.02±0.15*    
LVED septal thickness (cm)               1.03±0.16            1.00±0.14            1.07±0.17* 
LV mass (g)                                        175±52                  161±43                199±57* 
LV mass index (g/m2)                           98±26                   92±23                109±26* 
 
LV, left ventricle; LVED, LV end diastolic. * p<0.001 versus women. 
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Figure 3.2. Relationships between conventional, 24-hour, daytime and night-time systolic 
blood pressure (SBP) and left ventricular mass index (LVMI)(g/m2) in South Africans of 
African descent. Correlation coefficients are shown in Table 3.3. 
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Table 3.3. Correlations between blood pressure and left ventricular mass index in all 
study subjects. 
           Systolic BP             Diastolic BP 
    Correlation        p value  Correlation           p value 
                    coefficients (r)             coefficients (r) 
_______________________________________________________________________   
                                   Unadjusted correlations with left ventricular mass index (n=297) 
Conventional BP     0.31         <0.0001       0.14          =0.015 
24-hour BP      0.27†        <0.0001       0.13†          =0.028 
Daytime BP      0.27†        <0.0001       0.11†          =0.058 
Night-time BP      0.26#        <0.0001       0.15#          =0.009 
Night-day      0.05           0.42       0.08          =0.20 
Night/day      0.08           0.16       0.09          =0.14 
 
            Adjusted* correlations with left ventricular mass index (n=297) 
Conventional BP     0.21         <0.0005       0.07          =0.27 
24-hour BP      0.17†        <0.005       0.02          =0.82 
Daytime BP      0.17†        <0.005       0.02          =0.81 
Night-time BP      0.17#        =0.007       0.05          =0.51 
Night-day     -0.005        =0.99       0.03          =0.57 
Night/day     -0.0004        =0.99       0.02          =0.73 
 
* adjusted for sex, age, body mass index, antihypertensive treatment and the presence of 
diabetes mellitus/abnormal blood glucose control (+ for 24-hour BP in indexes of 
nocturnal decreases in BP). Probability values were calculated with additional 
adjustments for non-independence of family members. # p>0.05 vs daytime values, † 
p>0.05 vs conventional BP values. 
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Table 3.4. Correlations between blood pressure and left ventricular mass index in 
untreated subjects only. 
           Systolic BP             Diastolic BP 
    Correlation        p value  Correlation           p value 
                    coefficients (r)             coefficients (r) 
_______________________________________________________________________ 
   Unadjusted correlations with left ventricular mass index (n=231) 
Conventional BP     0.35         <0.0001       0.24          =0.0003 
24-hour BP      0.34†        <0.0001       0.22†          =0.0009 
Daytime BP      0.36†        <0.0001       0.21†          =0.001 
Night-time BP      0.31#        <0.0001       0.22#          =0.001 
Night-day     -0.03           0.67       0.04          =0.60 
Night/day      0.02           0.81       0.06          =0.37 
   
             Adjusted* correlations with left ventricular mass index (n=231) 
Conventional BP     0.29         <0.0001       0.17          =0.02 
24-hour BP      0.25†        =0.0002       0.09          =0.19 
Daytime BP      0.26†        <0.0001       0.09          =0.19 
Night-time BP      0.22#        <0.002       0.10          =0.13 
Night-day     -0.05         =0.44       0.03          =0.77 
Night/day     -0.05                    =0.49       0.01          =0.99 
 
*adjusted for sex, age, body mass index, and the presence of diabetes mellitus/abnormal 
blood glucose control (+ for 24-hour BP in indexes of nocturnal decreases in BP). 
Probability values were calculated with additional adjustments for non-independence of 
family members. # p>0.05 vs daytime values † p>0.05 vs conventional BP values. 
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between daytime BP and LVMI and night-time BP and LVMI were noted (comparison of 
correlation coefficients, daytime versus night-time, p>0.05) (Figure 3.2 and Tables 3.3 
and 3.4). 
 
3.3.4 Adjusted associations between BP and target organ changes. 
 
Tables 3.3 (all subjects) and 3.4 (untreated subjects) also summarize the 
correlation coefficients between BP and LVMI after adjusting for sex, age, BMI, 
antihypertensive treatment (Table 3.3 only) and the presence of diabetes 
mellitus/abnormal blood glucose control, with non-independence of family members 
include as an adjustor when determining probability values, and 24-hour BP included as 
an adjustor when evaluating relationships between indexes of nocturnal decreases in BP 
and LVMI. Both conventional and ambulatory systolic BP were independently associated 
with LVMI. However, diastolic BP was not independently associated with LVMI. 
Conventional BP correlated equally as well with LVMI as 24-hour or daytime BP 
(comparison of correlation coefficients, conventional versus 24-hour or daytime, p>0.05). 
Daytime systolic BP correlated equally as well with LVMI as night-time systolic BP 
(comparison of correlation coefficients, daytime versus night-time, p>0.05). No 
associations were noted between night-day differences in BP or night-to-day ratio of BP 
and LVMI. 
 
3.3.5 Adjusted associations between BP and target organ changes in sex-specific 
groups. 
 
Table 3.5 summarizes the correlation coefficients between BP and LVMI in sex-
specific groups after adjusting for age, BMI, antihypertensive treatment and the presence 
of diabetes mellitus/abnormal blood glucose control, with non-independence of family 
members include as an adjustor when determining probability values, and 24-hour BP 
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included as an adjustor when evaluating relationships between indexes of nocturnal 
decreases in BP and LVMI. Both conventional and ambulatory systolic BP were 
independently associated with LVMI in women. However, in men, only nocturnal BP was 
independently associated with LVMI. Diastolic BP was not independently associated with 
LVMI in either group. 
In women conventional BP correlated equally as well with LVMI as 24-hour or 
daytime BP (comparison of correlation coefficients, conventional versus 24-hour or 
daytime, p>0.05). Moreover, in women, daytime systolic BP correlated equally as well 
with LVMI as night-time systolic BP (comparison of correlation coefficients, daytime 
versus night-time, p>0.05). Although in men nocturnal BP, but neither conventional nor 
daytime BP were associated with LVMI, no differences were noted in the correlation 
coefficients between night-time BP and LVMI and conventional BP and LVMI (p=0.23) or 
between night-time BP and LVMI and daytime BP and LVMI (p=0.50). No associations 
were noted between night-day differences in BP or night-to-day ratio of BP and LVMI in 
either women or men. 
 
3.3.5 Conventional BP-independent relationship between ambulatory BP and 
LVMI. 
 
Figure 3.3 summarizes the relationships between 24-hour, daytime or night-time 
systolic and diastolic BP and LVMI after adjusting for sex, age, BMI, antihypertensive 
treatment and the presence of diabetes mellitus/abnormal blood glucose control, as well 
as conventional BP, with non-independence of family members include as an adjustor 
when determining probability values. Neither 24-hour, daytime, nor night-time systolic or 
diastolic BP were associated with LVMI independent of conventional BP.  
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Table 3.5. Correlations between blood pressure and left ventricular mass index in sex-
specific groups. 
           Systolic BP             Diastolic BP 
    Correlation        p value  Correlation           p value 
                    coefficients (r)             coefficients (r) 
_______________________________________________________________________ 
  Adjusted* correlations with left ventricular mass index in women (n=187) 
Conventional BP     0.31       <0.0001     0.16           =0.04 
24-hour BP      0.17†             =0.022     0.03           =0.72 
Daytime BP      0.20†              <0.007     0.05           =0.47 
Night-time BP      0.12#                  =0.11     0.03           =0.70 
Night-day     -0.11        =0.12     -0.02           =0.68 
Night/day     -0.10        =0.17     -0.03           =0.62 
   
Adjusted* correlations with left ventricular mass index in men (n=110) 
Conventional BP     0.07         =0.41     -0.07           =0.49 
24-hour BP      0.18†                 =0.07      0.04           =0.72 
Daytime BP      0.14†        =0.17      0.004          =0.97 
Night-time BP      0.23#        =0.02      0.09           =0.37 
Night-day      0.14         =0.17      0.10           =0.33 
Night/day      0.18                    =0.21      0.08           =0.45 
 
*adjusted for age, body mass index, and the presence of diabetes mellitus/abnormal 
blood glucose control (+ for 24-hour BP in indexes of nocturnal decreases in BP). 
Probability values were calculated with additional adjustments for non-independence of 
family members. # p>0.05 vs daytime values † p>0.05 vs conventional BP values. 
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3.3.6 Conventional BP-independent relationship between ambulatory BP and 
LVMI in sex-specific groups. 
 
Figure 3.4 summarizes the relationships obtained in sex-specific groups between 
24-hour, daytime or night-time systolic and diastolic BP and LVMI after adjusting for age, 
BMI, antihypertensive treatment and the presence of diabetes mellitus/abnormal blood 
glucose control, as well as conventional BP, with non-independence of family members 
include as an adjustor when determining probability values. In men, although neither 24-
hour nor daytime systolic or diastolic BP were associated with LVMI independent of 
conventional BP, night-time systolic BP (r=0.21, p<0.05), but not night-time diastolic BP 
was independently associated with LVMI. In women, no conventional BP-independent 
relationship between ambulatory BP and LVMI was noted. In men, sensitivity analysis 
conducted in untreated subjects also showed a conventional BP-independent relationship 
between night-time systolic BP (p<0.03) and LVMI. Comparisons of the regression 
relations between daytime and night-time systolic BP showed no differences in these 
relations in men (p=0.37 for comparisons of regression relations).  
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Figure 3.3. Conventional BP-independent relationships between left ventricular mass indexed 
to body surface area (LVMI) and either 24-hour or daytime systolic (SBP) or diastolic (DBP) 
blood pressure in all subjects and in untreated subjects as indicated by partial correlation 
coefficients and 95% confidence intervals. The relationships were adjusted for conventional BP, 
sex, age, body mass index, antihypertensive treatment (in all subjects), and the presence of 
diabetes mellitus/abnormal blood glucose control. Probability values were obtained with an 
additional adjustment for non-independence of family members. 
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Figure 3.4. Conventional BP-independent relationships between left ventricular mass 
indexed to body surface area (LVMI) and either 24-hour or daytime systolic (SBP) or 
diastolic (DBP) blood pressure in sex-specific groups as indicated by partial correlation 
coefficients and 95% confidence intervals. The relationships were adjusted for 
conventional BP, age, body mass index, antihypertensive treatment (in all subjects), and 
the presence of diabetes mellitus/abnormal blood glucose control. Probability values were 
obtained with an additional adjustment for non-independence of family members. 
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3.4 DISCUSSION 
 
The main findings of the present study conducted in a large, randomly selected 
population sample of African ancestry living in Africa with a high frequency of obesity 
(~40%) and both treated (~22%) and untreated (~18%) hypertension, where 
conventional, 24-hour, daytime and night-time BP were all associated with LVM index 
independent of confounders, were as follows. Indexes of nocturnal decreases in BP were 
not associated with LVM index; daytime BP was as closely associated with LVM index as 
was nocturnal BP; conventional BP was as closely associated with LVM index as 24-
hour, daytime and night-time BP, and ambulatory BP was not associated with LVM index 
independent of conventional BP. However, on sensitivity analysis conducted in sex-
specific groups, night-time BP was associated with LVM index independent of 
conventional BP in men, but not in women. 
Previous studies conducted exclusively in subjects of European or Asian descent 
have indicated that an attenuated nocturnal decrease in BP or nocturnal BP per se is 
associated with lacunar infarcts (Yamamoto et al 1998), cardiovascular outcomes in the 
elderly with isolated systolic hypertension (Staessen et al 1999), cardiovascular outcomes 
in hypertensives in general (Verdecchia et al 1994, Zweiker et al 1994), cardiovascular 
outcomes in the general population (Ohkubo et al 1997, Kikuya et al 2005) and vascular 
events in type II diabetes mellitus (Nakano et al 1998) independent of conventional BP 
values. However, in groups of African descent, there are few studies that have evaluated 
the role of diurnal variations in BP as potential determinants of cardiovascular target 
organ effects or outcomes. 
In general, studies evaluating a potential role of diurnal variations in BP in groups 
of African descent have focussed on target organ effects, such as LVM. However, in this 
regard, there is no consensus as to the role of diurnal variations in BP on LVM in groups 
of African descent as these studies have been conducted in small samples, with 
disparate study designs and definitions of day and night BP and have had inconsistent 
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outcomes. Murphy et al (1991) and Fumo et al (1992) observed a greater night-time BP 
and a higher LVM in small study samples (22-44) of subjects of African ancestry. In 39 
African-American men and 49 African-American women, in comparison to a group of 
subjects of European ancestry (n=83), ethnic differences in LV wall thickness were 
abolished by adjustments for sleep BP (Hinderliter et al 2004). Moreover, in 46 
hypertensives of African descent, nocturnal decreases in systolic BP were associated 
with LVM index, but not in a group of 46 hypertensives of European ancestry (Mayet et al 
1998). A greater frequency of subjects with an attenuated nocturnal decrease in BP was 
noted in subjects of African descent with concentric LV remodelling (Olutade et al 1998) 
and night-time systolic BP and indices of nocturnal decreases in BP were associated with 
concentric LV hypertrophy (El-Gharbawy et al 2001). In contrast, Chaturvedi et al (1994), 
demonstrated in 78 men and 89 women of African descent that daytime, but not night-
time BP was associated with LVM index. Moreover, in 94 African-Americans of a mean 
age of 14 years, neither day nor night BP was associated with LVM index (Harshfield et al 
2002) and in a mixed group of Caucasian and African-Americans, day-night differences in 
BP were not associated with LVM (Palmieri et al 1999). The present study conducted in a 
relatively large population sample (n=297) provides evidence to suggest that nocturnal 
BP may predict LVM index beyond conventional BP in men, but not in women. 
The relationship between indices of nocturnal decreases in BP and LVM has been 
extensively studied in groups of European ancestry. In this regard, there is also 
considerable controversy as to whether an attenuated nocturnal decrease in BP is 
associated with LVM, with some studies showing a relationship (Verdecchia et al 1990, 
Verdecchia et al 1992, Schmieder et al 1995), whilst others have reported on no 
relationship (Schulte et al 1993, Boley et al 1997, Roman et al 1997). These 
discrepancies may be attributed to a sex-specific effect, where nocturnal decreases in BP 
affect LVM in women (Verdecchia et al 1992, Schmieder et al 1995). In contrast, in the 
present study I demonstrated a conventional BP-independent relationship between 
nocturnal BP and LVM index in males as opposed to females. The discrepancy between 
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this and previous studies (Verdecchia et al 1992, Schmieder et al 1995) may relate to the 
considerably higher sample size employed in the present study as compared to previous 
studies or that different ethnic groups were studied. Importantly, however, the results of 
the present study provide substantially stronger evidence to indicate that nocturnal 
decreases in BP are not related to LVM index, but that nocturnal BP may provide 
information beyond conventional BP when predicting LVM index in males. 
In the present study ambulatory BP was not more closely associated with LVM 
index than conventional BP. A number of previous studies have shown significantly better 
correlations of ambulatory BP values with LVM index than conventional BP (reviewed by 
Fagard et al 19951, Verdecchia et al 1999, Fagard and Staessen 2002). In this regard 
there are a number of explanations for the discrepancy between the impact of ambulatory 
and conventional BP on LVM including the lack of standardization of conventional BP 
measurements and inappropriate quality control (Fagard et al 19951, Fagard and 
Staessen 2002). In the present study, conventional BP was measured by a single trained 
nursing sister, thus avoiding the potential differences in measurement produced by 
different observers, and reducing the chances of isolated office hypertension. Nurse-
recorded clinic BP values have recently been demonstrated to correlate equally as well 
with LVM as ambulatory BP (Nystrom et al 2005). Moreover, our group have recently 
demonstrated that on-treatment changes in LVM are as closely correlated with nurse-
recorded conventional BP as ambulatory BP in newly diagnosed hypertensives of African 
origins (Skudicky et al 2002, chapter 5). 
The clinical relevance of the present study relates to identifying a potential 
explanation for the conventional-BP independent increase in LVM that appears to exist in 
groups of African descent as compared to other ethnic groups (Skelton et al 2003, Lorber 
et al 2003, Kizer et al 2004, Rodriguez et al 2004, Drazner et al 2005), a change that may 
translate into a higher prevalence of CVD. In this regard, the present study supports the 
notion that nocturnal BP may account for a significant proportion of the variability in LVM 
index beyond conventional BP in men, but not in women. 
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The limitations of the present study include the fact that this is a cross-sectional 
and not a prospective study. Additional prospective analysis is presently underway. 
Further, the smaller study sample of men as compared to women could have limited the 
outcomes in men. In this regard, although in men nocturnal BP was associated with LVM 
index independent of conventional BP, I could not demonstrate a statistically significant 
difference between nocturnal BP and LVM index and conventional BP and LVM index 
relations. Furthermore, I could not demonstrate a statistically significant difference 
between nocturnal BP and LVM index and daytime BP and LVM index relations in this 
gender group. 
In conclusion, the results of this first large study assessing the impact of diurnal 
variations in BP on LVM in groups of African descent suggest that in the general 
population, indexes of nocturnal decreases in BP are not associated with LVM index; 
daytime BP is as closely associated with LVM index as is nocturnal BP; conventional BP 
is as closely associated with LVM index as 24-hour, daytime and night-time BP, and 
ambulatory BP is not associated with LVM index independent of conventional BP. 
However, night-time BP may be associated with LVM index independent of conventional 
BP in men, but not in women. The mechanisms of this gender-specific effect of nocturnal 
BP on LVM index require further investigation. 
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                                               Chapter 4 
 
 
Blood Pressure-Independent Relationship Between Arterial 
Stiffness and Left Ventricular Mass in Subjects of African 
Ancestry. 
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ABSTRACT 
As compared to Caucasians, groups of African as compared to European ancestry 
have an increased arterial stiffness, a change that may impact on central rather than 
peripheral (brachial artery) blood pressures (BP). In groups of European descent it is 
uncertain whether indices of arterial stiffness predict left ventricular mass index (LVMI) 
beyond blood pressure (BP). I therefore determined whether the relationship between an 
index of arterial stiffness (pulse wave velocity [PWV]) or wave reflection (central 
augmentation index [AIc]) and LVM is independent of conventional BP in randomly 
recruited subjects of African ancestry (n=399). Applanation tonometry was performed at 
the carotid, radial and femoral arteries and AIc and aortic PWV derived from these 
measures. LVM indexed for body surface area (LVMI) was determined using 
echocardiography. Univariate analysis demonstrated a relationship between PWV and 
LVMI (r=0.28, p<0.0001) and between AIc and LVMI (r=0.19, p<0.001), but on sex-
specific analysis, the relationship between PWV and LVMI was present in women (r=0.49, 
p<0.0001), but not in men (r=0.06, p=0.54), whereas the relationship between AIc and 
LVMI was noted in both gender groups. After adjusting for age, body mass index, 
antihypertensive treatment, the presence or absence of diabetes mellitus or abnormal 
blood glucose control (HbA1c), non-independence of family members and either 
conventional systolic BP or pulse pressure, PWV (r=0.25, p<0.0005), but not AIc (p=0.40-
0.86) was independently associated with LVMI in females. In males, neither PWV nor AIc 
were associated with LVMI independent of conventional BP and other confounders. In 
conclusion, PWV may refine the ability to predict LVMI beyond conventional BP in groups 
of African descent, but this effect is sex-specific being limited to females only. 
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4.1 INTRODUCTION 
 
 As indicated in chapter one of the present thesis, groups of African ancestry have 
a higher LVM than groups of European descent, changes that are independent of 
conventional BP (Skelton et al 2003, Lorber et al 2003, Kizer et al 2004, Rodriguez et al 
2004, Drazner et al 2005, chapter 2). As LVM is a strong independent predictor of CVD 
(Casale et al 1986; Levy et al 1990; Koren et al 1991; Levy et al 1994; Verdecchia et al 
1996; Ghali et al 1998; Devereux et al 20042; Okin et al 2004), these ethnic differences 
could translate into a greater prevalence of CVD in groups of African descent. Therefore, 
it is particularly important to identify the determinants of LVM in groups of African 
ancestry. In this regard, the exact mechanisms responsible for an increased LVM in 
groups of African ancestry have not been identified. In chapter three I provide evidence to 
suggest that in men, a relationship between nocturnal, but not daytime BP and LVM index 
may in-part contribute toward a conventional BP-independent increase in LVM index. 
However, further factors need to be identified to account for conventional BP-independent 
changes in LVM index in groups of African ancestry, particularly in women. 
Importantly, arterial stiffness appears to be higher in people of African ancestry as 
compared to Caucasians (Din-Dzietham et al 2004; Shiburi et al 2006; Chaturvedi et al 
2004) and arterial stiffness is associated with LVM (Tatchum–Talom et al 1995; 
Kobayashi et al 1996; Bouthier et al 1985; Boutouyrie et al 1995; Roman et al 1996; Chen 
et al 1998; Roman et al 2000; Baguet et al 2000; Iketani et al 2000; Deague et al 2001, 
Gates et al 2003; Lekakis et al 2004). The impact of arterial stiffness on LVM may be 
independent of either conventional or ambulatory BP measured at the brachial artery as 
an increased arterial stiffness produces early reflected waves which influence central 
aortic pressures, a pressure that is not accurately measured by brachial artery BP 
measurements (Karamanoglu et al 1993, Williams et al 2006). However, few studies 
(Lekakis et al 2004, Leoncini et al 2006) have demonstrated a BP-independent 
relationship between indices of arterial stiffness and LVMI, with one study involving only a 
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small study sample (Lekakis et al 2004), and the other utilising the less well understood 
ambulatory arterial stiffness index (Leoncini et al 2006). In contrast, the majority of 
studies have failed to demonstrate a conventional BP-independent relationship between 
indices of arterial stiffness index and LVMI (Bouthier et al 1985; Boutouyrie et al 1995; 
Roman et al 1996; Chen et al 1998; Roman et al 2000; Baguet et al 2000; Iketani et al 
2000; Deague et al 2001, Gates et al 2003). No studies have evaluated the BP-
independent relationship between arterial stiffness and LVMI in either sex-specific groups 
or in groups of African descent. I therefore aimed to determine whether LVM is 
associated with indices of arterial stiffness and wave reflection independent of 
conventional BP in a relatively large, randomly selected population sample of African 
descent previously demonstrated by our group to have thresholds for arterial stiffness that 
exceed those of population groups of European descent (Shiburi et al 2006). 
 
4.2 METHODS 
 
 Selection of the study group, the questionnaire data obtained, the anthropometric 
assessments and blood analysis, the conventional BP data obtained, and the 
echocardiographic assessments have been described in chapter 2. Of the 399 
participants with high quality echocardiograms, PWV could not be measured in 72 
subjects, because they had a bradycardia or were too obese. 
 
4.2.1 Pulse wave analysis. 
 
Pulse wave velocity and AI were measured as previously described (Nichols and 
O’Rourke 1998). After subjects rested for 15 minutes in the supine position, the radial 
waveform was recorded at the dominant arm by applanation tonometry during an 8-
second period. A high-fidelity SPC-301 micromanometer (Millar Instrument, Inc., Houston, 
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Texas), interfaced with a computer running the SphygmoCor software, version 6.21 
(AtCor Medical Pty. Ltd., West Ryde, New South Wales, Australia) was used to determine 
PWV and AI (Figure 4.1). Recordings (Figure 4.2) were discarded when the systolic or 
diastolic variability of consecutive waveforms exceeded 5%, or when the amplitude of the 
pulse wave signal was less than 80 mV. The pulse wave was calibrated by auscultatory 
measurement of the brachial BP immediately before the recordings. From the radial 
signal the SphygmoCor software calculates the aortic pulse wave by means of a validated 
(Nichols and O’Rourke 1998) generalized transfer function. The aortic (central arterial) 
AI(AIc) and peripheral AI were determined as the difference between the second and the 
first systolic shoulder (Figure 4.2) given as a percentage of the aortic pulse pressure. 
Aortic PWV was measured by sequential recordings of the arterial pressure waveform at 
the carotid and the femoral arteries. Distances from the suprasternal notch to the carotid 
sampling site (distance A) and from the suprasternal notch to the femoral artery (distance 
B) were measured. Pulse wave velocity distance was calculated as distance B minus 
distance A. Pulse transit time, calculated as the mean time difference between sites A 
and B (Figure 4.2) was determined from the average of 10 consecutive beats. Aortic PWV 
was calculated as the ratio of the distance in meters to the transit time in seconds. 
 
4.2.3 Statistical Analysis. 
 
The software and the database management for this study have been described 
in chapter 2. Means and proportions were compared by the large-sample z-test and the 
χ2-statistic, respectively. Linear regression analysis was used to determine the 
relationships between BP, PWV and AI with LVMI. Regression relations were adjusted for 
age, gender, BMI, antihypertensive treatment, the presence or absence of diabetes 
mellitus/impaired blood glucose control (HbA1c>7.0%) and either systolic BP or pulse 
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  A Applanation tonometer 
  B ECG electrodes 
  C SphygmoCor device  
 
 
 
 
 
Figure 4.1 Illustrates the hardware used to determine pulse wave velocity and 
augmentation index. 
A 
B 
C 
 - 88 -
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.2. Illustrates an example of the applanation tonometry recordings obtained to 
determine augmentation index (AI) (upper panel) and pulse wave velocity (PWV)(lower 
panel). The figures in the upper panel show pulse waves obtained from the femoral and 
carotid artery indicating the points (first and second shoulders) from which augmentation 
index is derived. The arrows in the lower panel indicate the time differences between 
electrical events and the arterial pressure changes in the carotid and femoral arteries 
used to calculate PWV. See text for a further description. 
Carotid pulse   
Femoral pulse  
Radial  Aortic  
ECG   
ECG   
First shoulder 
First shoulder 
Second 
shoulder 
Second 
shoulder 
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pressure. For statistical analysis of the relations and the derivation of probability values, 
further adjustments were made for non-independence of family members. Sensitivity 
analysis was conducted in participants not receiving antihypertensive therapy and in sex-
specific groups. 
 
4.3 RESULTS 
 
4.3.1 Characteristics of the participants. 
 
Table 4.1 gives the demographic and clinical characteristics of the study group. 
More women than men participated. In general the group had a high BMI and 66% of 
participants were either overweight or obese. The increased adiposity was especially 
prevalent in women. More men than women smoked and reported intake of alcoholic 
beverages. More women than men were receiving antihypertensive medication at the 
time of the study, but a similar proportion had no previous history of receiving such 
medication (81.9 versus 77.4%; p=0.39). 
Table 4.1 also gives the central and peripheral haemodynamic values of the study 
group. Apart from heart rate which was lower in men, there were no gender differences in 
central and peripheral haemodynamic values. 
Table 4.2 lists the echocardiographic measurements. Men had larger LV 
dimensions and a greater LVM and LVM index than women. 
  
4.3.2 Association between indices of arterial stiffness/wave reflection and blood 
pressure. 
 
PWV and AIc were correlated with each other (r=0.30, p<0.0001). Importantly, 
both PWV (r=0.64, p<0.0001) and AIc (r=0.43, p<0.0001) were strongly correlated with  
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Table 4.1. Demographic, anthropometric, and clinical characteristics. 
 
  All subjects            Women        Men 
_______________________________________________________________________ 
Number             327   204       123              
Age (years)        43.1 ± 18.4         42.8 ± 18.0 43.5 ± 19.0  
BMI (kg/m2)         28.5± 6.8          30.3± 7.0 25.4± 5.1** 
% overweight/obese          28/38                  25/49                     32/20**            
Regular tobacco intake (% subjects)        13                3       30** 
Regular alcohol intake (% subjects)         22              14       36** 
% with DM or with an HbA1c>7.0%         9     8       10 
HbA1C (%)         6.08±1.2         6.07±1.09            6.11±1.41 
% with hypertension                                   41   43       40 
Current antihypertensive medication (%)  23    28       14* 
Conventional SBP/DBP (mm Hg)   130±22/84±12    129±23/83±12     132±21/85±12 
Pulse pressure (mm Hg)         46±15           45±15  48±15 
Peripheral augmentation index (%)           84±22           85±24  81±20 
Central augmentation index (%)        27±14           27±14             26±13 
Aortic pulse wave velocity (m/sec)           6.82±3.23         6.76±3.18 6.92±3.34 
Pulse rate (beats/min)          68±10  71±10   64±9** 
BMI, body mass index; DM, diabetes mellitus; HbA1C, glycosylated hemoglobin; 
SBP/DBP, systolic blood pressure/diastolic blood pressure. *p<0.05 , ** p<0.001 versus 
women. 
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Table 4.2. Echocardiographic characteristics. 
 
                                                                 All subjects      Women          Men 
Sample number    327         204             123     
LV end diastolic diameter (cm)       4.74±0.49    4.61±0.46       4.94±0.48** 
LV septal wall thickness (cm)        1.02±0.17    1.00±0.16       1.05±0.18* 
LV posterior wall thickness (cm)        0.98±0.15    0.96±0.14       1.01±0.16* 
LV mean wall thickness (cm)        1.00±0.16    0.98±0.15       1.03±0.16* 
LV mass (g)           170±51       159±43               189±56** 
LV mass index (g/m2)                      96±25        90±22          104±27** 
LV, left ventricle;  * p <0.01, ** p<0.001 versus women. 
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conventional systolic BP (Figure 4.3). Similarly, both PWV (r=0.62, p<0.0001) and AIc 
(r=0.35, p<0.0001) were strongly correlated with conventional pulse pressure. 
 
4.3.3 Association between blood pressure and LVMI. 
 
Consistent with data shown in chapter 3, after adjustments for age, gender, BMI,  
antihypertensive treatment, the presence or absence of diabetes mellitus or abnormal 
blood glucose control and for non-independence of family members; conventional systolic 
BP (r=0.23, p<0.0001) and pulse pressure (r=0.27, p<0.0001), but not diastolic BP were 
associated with LVMI. 
 
4.3.4 Association between indexes of arterial stiffness/wave reflection and LVMI. 
 
On univariate analysis PWV was correlated with LVMI (Figure 4.4). Furthermore, 
both central and peripheral AI were correlated with LVMI (AIc, r=0.19, p=0.0006; AIp, 
r=0.19, p=0.0007). On univariate analysis PWV was correlated with LVMI in women, but 
not in men (Figure 4.4). In contrast, AIc and AIp were correlated with LVMI in both men 
(AIc; r=0.24, p=0.008, AIp; r=0.26, p=0.004) and in women (AIc; r=0.20, p=0.004, AIp; 
r=0.20, p=0.004).   
After adjustments for age, BMI, antihypertensive treatment, the presence or 
absence of diabetes mellitus/impaired blood glucose control (HbA1c>7.0%), non-
independence of family members and either systolic BP or pulse pressure, PWV was 
associated with LVMI in women, but not in men (Figure 4.5). On sensitivity analysis, a 
strong and independent relationship between PWV and LVMI was similarly noted in 
untreated women, but not in untreated men (Figure 4.5). However, neither central (r=-
0.06, p=0.40) nor peripheral (r=-0.03, p=0.67) AI were associated with LVMI after 
adjustments for conventional systolic BP and other confounders in women. However, a 
modest, and independent relationship between central (r=0.20, p=0.012) or peripheral 
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Figure 4.3. Relationships between indexes of arterial stiffness and conventional systolic 
blood pressure (SBP). PWV, pulse wave velocity; AIc, central or aortic augmentation 
index.  See text for regression coefficients. 
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Figure 4.4. Relationship between pulse wave velocity (PWV) and left ventricular mass 
index (LVMI) in study subjects. The upper panel illustrates the relationship in all subjects 
and the lower panel the relationships in women (left panel) and men (right panel). 
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Figure 4.5. Blood pressure (BP)-independent relations between pulse wave velocity 
(PWV) and left ventricular mass index (LVMI) in sex-specific groups. Correlation 
coefficients (partial r) and 95% confidence intervals (CI) for the relations are shown in all 
subjects and in subjects not receiving antihypertensive therapy. SBP, systolic BP; PP, 
pulse pressure. Partial r values were obtained after adjustments for age, BMI, 
antihypertensive treatment (in all subjects), the presence or absence of diabetes mellitus 
or abnormal blood glucose control and either SBP or PP. Probability values were 
obtained with an additional adjustment for non-independence of family members. 
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(r=0.20, p<0.02) AI and LVMI was noted in men, an effect that was nevertheless absent 
in untreated subjects. 
 
4.3 DISCUSSION 
 
 The main finding of the present study is that in a relatively large, randomly 
selected population sample of African descent with a high prevalence of excess adiposity 
(~65%) and both treated (~23%) and untreated (~18%) hypertension, PWV was 
associated with LVM index independent of conventional BP and other confounders in 
women, but not in men. This effect was reproduced in untreated subjects. 
The present results provide the first evidence at a population level that in groups 
of African descent an index of arterial stiffness provides information beyond that of 
peripheral brachial BP measurements when predicting LVM index. The outcome of the 
present study is consistent with two studies conducted in groups of European ancestry 
(Lekakis et al 2004, Leoncini et al 2006) demonstrating the importance of a measure of 
arterial stiffness as a brachial artery BP-independent predictor of LVM. However, one of 
these studies (Lekakis et al 2004) involved only 48 hypertensive patients. Moreover, in 
the other study (Leoncini et al 2006) the less well established ambulatory arterial stiffness 
index was employed as a measure of arterial stiffness. In this regard, the extent to which 
the information derived from the ambulatory arterial stiffness index is comparable with 
that of pulse wave analysis is uncertain as the correlation coefficient between the two is 
~0.5 (Li et al 2006). 
The outcome of the present study is in contrast to previous studies (Bouthier et al 
1985; Roman et al 1996; Chen et al 1998; Roman et al 2000; Baguet et al 2000; Deague 
et al 2001) that have observed no additional predictive power of measures of arterial 
stiffness in relation to LVM beyond that provided by conventional BP measurements in 
groups of European ancestry. Two studies conducted in groups of European ancestry 
(Bouthier et al 1985, Baguet et al 2000) in which PWV was used as an index of arterial 
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stiffness, included only a small sample of hypertensive patients. In these studies 
(Bouthier et al 1985, Baguet et al 2000), insufficient sample sizes and a narrow range of 
BP values only encompassing the upper tail of the distribution in the population at large 
might have reduced the power of previous studies to detect an independent association 
between LVM index and PWV. One large population-based study failed to show a BP-
independent effect of PWV on LVM index (Deague et al 2001), but no gender-specific 
analysis was conducted. In this regard, in the present study we noted a marked gender-
specific effect of PWV on LVM index. Other previous studies conducted in groups 
presumably of European descent with large sample sizes that have failed to demonstrate 
a BP-independent effect of indices of arterial stiffness on LVM (Roman et al 1996; Chen 
et al 1998; Roman et al 2000) have employed different measurements to derive indices of 
arterial stiffness. Whether the information derived from other indices is comparable with 
that of pulse wave analysis is uncertain.  
In the present study, although PWV was associated with LVM index independent 
of BP, AI was not, confirming that AI and PWV cannot be used as surrogates of each 
other (Lemogoum et al 2004). The lack of BP-independent effect of central AI on LVM 
index is consistent with previous studies (Deague et al 2001). There are a number of 
potential explanations for the contrasting effects of PWV and AI on LVM index. These 
might relate to the dependence of central AI, but not PWV, on ventricular ejection time 
and heart rate (Wilkinson et al 2002). Further, unlike PWV, AI also depends on the 
distance of the reflection points to the heart. It is possible that in a large population 
sample, subjects with a higher PWV might have reflection points further from the heart. 
The strengths and potential limitations of the present study should be 
underscored. The strong points of the study are the population-based approach, the 
relatively large sample size, and the use of conventional BP measurements that have 
previously been demonstrated to be as closely correlated with LVM index as ambulatory 
BP values (see chapter 3). The limitations are the cross-sectional, rather than longitudinal 
nature of the study design, and the relatively small sample size for men (n=123) as 
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compared to women (n=204). However, the BP-independent relationship between PWV 
and LVM index in women was robust (partial r=0.26, p<0.0001), whilst no relationship 
was noted in men (partial r=-0.09, p=0.37). Moreover, on sensitivity analysis conducted in 
untreated subjects, the outcomes were similarly robust (r=0.32, p=0.0003 for women and 
r=-0.12, p=0.37 for men). Hence, it is unlikely that increasing the sample size for men 
would alter the outcomes of this study. 
 In conclusion, the present study suggests that measures of arterial stiffness offer 
information beyond that of conventional BP measured at the brachial artery when 
predicting LVM index in a group of African descent, albeit that this effect is gender-
specific. 
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     Chapter 5 
 
 
Relationship between Treatment-induced Changes in Left 
Ventricular Mass and Ambulatory Versus Conventional Blood 
Pressure in Hypertensive Patients of African Descent. 
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ABSTRACT 
 
There is substantial controversy as to whether conventional, daytime or nocturnal 
BP best predicts the regression of LVM. Studies that have been conducted to-date have 
been exclusively performed in groups of European descent. However, as groups of 
African descent have an attenuated nocturnal decline in BP, antihypertensive-induced 
decreases in LVM may depend more on changes in ambulatory than on conventional BP 
in this ethnic group. In a single-center study, the extent to which changes in conventional 
and ambulatory BP predicted regression of LVM index in response to antihypertensive 
treatment in previously untreated and treated patients of African ancestry with sustained 
hypertension was explored. In this study 173 patients who, off treatment, had a daytime 
diastolic BP ranging from 90 to 114 mm Hg were enrolled. Antihypertensive drugs were 
titrated and combined to reduce the daytime diastolic BP below 90 mm Hg. 
Echocardiograms were obtained at baseline and follow-up. Mean systolic/diastolic clinic 
BP, 24-hour BP, and LVM index were similar in previously untreated (n=64) and 
previously treated (n=109) patients and averaged 171/102 mm Hg, 151/97 mm Hg, and 
118 g/m
2
, respectively. At 4 months, these values had decreased (P<0.001) by 26/12 mm 
Hg, 23/14 mm Hg, and 14 g/m
2 
in previously untreated patients and by 22/9 mm Hg, 
21/13 mm Hg, and 19 g/m
2 
in previously treated patients. In the previously untreated 
patients, the regression in LVM index correlated to a similar degree (p<0.09) with the 
decreases in the conventional (r=0.34; p<0.005) and the 24-hour (r=0.26; p<0.04) systolic 
BP. In the previously treated patients, the corresponding correlations were 0.02 (p<0.82) 
and =0.10 (p<0.32), respectively. Compared with the 24-hour systolic BP, automated 
oscillometric measurements of systolic BP obtained at the clinic yielded similar results. 
Thus, in previously untreated patients of African ancestry with sustained hypertension 
followed at a single center, reductions in clinic and ambulatory systolic pressure in 
response to antihypertensive treatment equally predicted the regression in LVM index. 
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5.1    INTRODUCTION 
 
As indicated in chapters 1 and 2, LVM is a strong independent predictor of CVD 
(Casale et al 1986; Levy et al 1990; Koren et al 1991; Levy et al 1994; Verdecchia et al 
1996; Ghali et al 1998; Devereux et al 20042; Okin et al 2004). Recent studies (Fagard et 
al 19973 and Fagard et al 2000) and three meta-analyses (Schlaich et al 1998, Dahlof et 
al 1992, Jennings and Wong 1997) on antihypertensive treatment have demonstrated that 
reductions in LVM correlate with decreases in BP. However, controversy still exists with 
regard to the type of BP measurement (conventional, automated, or ambulatory) that best 
correlates with changes in LVM induced by antihypertensive treatment (reviewed by 
Fagard et al 19973). 
Some studies have indicated that ambulatory BP is more closely associated with 
the regression of LVH in hypertension (reviewed by Fagard et al 19973). In most previous 
studies the investigators did not exclude previously treated or white-coat hypertensive 
patients. With respect to white coat hypertension, in older patients with isolated systolic 
hypertension, active treatment compared with placebo reduced electrocardiographic 
voltages only in patients with sustained hypertension and not in those with white-coat 
hypertension (Fagard et al 2000). Moreover, previous studies were multi-centre studies, 
thus increasing the difficulty in standardizing clinic measurements of BP. Further, all 
previous studies assessing the relationship between on-treatment decreases in BP and 
LVM have been conducted in groups of European descent (reviewed by Fagard et al 
19973). As groups of African descent have an attenuated nocturnal decline in BP (Profant 
and Dimsdale 1999, Wang et al 2006), this raises the question of the relevance of the 
outcomes of previous studies to groups of African descent? In groups of African descent, 
ambulatory BP is unable to predict LVM index beyond conventional BP, except perhaps 
in men (chapter 3). Whether antihypertensive-induced decreases in LVM may depend 
more on ambulatory than on conventional BP in groups of African ancestry requires 
further study. 
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The Baragwanath Hypertension Study was a single-center, randomized trial that 
compared several drug classes to initiate treatment in patients of African ancestry with 
sustained hypertension confirmed by ambulatory BP monitoring (Sareli et al 2001). In the 
present analysis, to what extent changes in conventional and automated BP readings at 
the clinic and in the ambulatory BP, predict regression of LVM index in response to 
antihypertensive treatment in previously untreated or treated patients with sustained 
hypertension was assessed. 
 
5.2 METHODS 
 
5.2.1 Subjects and Procedures 
 
The Baragwanath Hypertension Study was a single-center, randomized, open-
label trial conducted at the Chris Hani-Baragwanath Hospital from 1994 through 1997. 
Men and women of African descent were enrolled if they were 18 to 70 years of age and 
free of clinically significant cardiovascular or noncardiovascular disorders. Women of 
reproductive age had to use adequate contraception. All patients gave informed written 
consent. 
Patients diagnosed as being hypertensive after a 2-week placebo run-in period 
and with a count of returned placebo tablets within 80% to 120% of the expected number 
qualified for randomization if, in addition, their daytime diastolic BP was 90 to 114 mm Hg. 
Eligible patients were randomized to nifedipine gastrointestinal therapeutic system (GITS) 
30 mg/d, verapamil slow release (SR240 mg/d, hydrochlorothiazide 12.5 mg/d, or 
enalapril 10 mg/d (Sareli et al 2001). Patients were followed up at monthly intervals. The 
target BP was a daytime diastolic pressure of <90 mm Hg. If at the first monthly follow-up 
visit the target was not reached, the daily dose of the first-line drug was increased, as 
follows: nifedipine GITS to 60 mg, verapamil SR to 360 mg, hydrochlorothiazide to 25 mg, 
and enalapril to 20 mg. At 2 months, patients of the nifedipine GITS group who had not 
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achieved the target BP were additionally randomized to 1 of the following 4 treatment 
strategies: the addition of enalapril (10 mg/d), carvedilol (25 mg/d), or verapamil SR (120 
mg/d) or increasing the daily dose of nifedipine GITS to 90 mg. In the uncontrolled 
patients of the verapamil SR group, the daily dose of the calcium-channel blocker could 
be increased to 480 mg. Patients not controlled on hydrochlorothiazide 25 mg/d received 
reserpine 0.125 mg/d, and those not controlled on enalapril 20 mg/d were given 
hydrochlorothiazide 12.5 mg/d. 
All patients randomized in the Baragwanath Trial underwent echocardiography at 
baseline. However, only patients in whom high-quality echocardiograms could be 
obtained were eligible for inclusion in the echocardiographic substudy. 
 
5.2.2 Blood pressure measurements  
 
At baseline and at each of four follow-up visits, BP was assessed with three 
techniques. First, after the patient had rested in the sitting position for 10 minutes, the 
study nurse measured the conventional BP three times consecutively according to the 
recommendations of the American Heart Association (Frohlich et al 1998). The same 
nurse performed the conventional BP readings in all patients. Subsequently, the sitting 
BP was recorded ten times consecutively at three-minute intervals using calibrated 
Dinamap 1846 SX oscillometric monitors (Critikon Inc) (Borrow et al 1982). For analysis, 
the three conventional and ten Dinamap automated BP measurements were averaged. 
Furthermore, oscillometric SpaceLabs 90207 devices (O’Brien et al 1991) 
(SpaceLabs Inc) were programmed to obtain BP readings every fifteen minutes from 6:00 
AM to 10:00 PM and every thirty minutes from 10:00 PM to 6:00 AM. The intraindividual 
BP means were weighted by the time interval between successive BP readings. For 
analysis, the daytime period was defined as the time interval from 6:00 AM to 6:00 PM 
and nighttime ranged from 10:00 PM to 4:00 AM. Previous studies in hypertensive 
patients of African descent have shown that this definition excludes the rapid BP changes 
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in the morning and evening (Sareli et al 2001). 
 
5.2.3 Echocardiography  
 
At randomization and at 4 months, M-mode, 2-dimensional, pulse and color 
Doppler echocardiograms were obtained with a Hewlett-Packard Sonos 2500 system 
using a 2.5-MHz transducer as described in chapter 2. Briefly, M-mode echocardiography 
of the left ventricle was performed in the short-axis view. M-mode variables were 
analyzed according to the American Society of Echocardiography Convention (Sahn et al 
1978) and included left ventricular end-diastolic and end-systolic diameters and septal 
and posterior wall thickness. All measurements were recorded on videotape and 
analyzed by the same experienced echocardiographer who was unaware of the BP and 
the clinic data of the patients. For statistical analysis, measurements were averaged over 
three heart cycles. Doppler estimation of the stroke volume was assessed as previously 
described (Dubin et al 1990). LVM was adjusted for body size according to an 
anatomically validated regression method (Devereux et al 1986). Replicate 
measurements of LVM index showed that in the present study population, the 
interobserver and intraobserver coefficients of variation were 12.4% and 11.4%, 
respectively. 
 
5.2.4 Statistical Analysis  
 
Database management and statistical analysis were performed with SAS 
software, version 6.12 (SAS Institute Inc). Previously untreated and treated patients were 
compared using Student’s t test and the  
2 
statistic for continuous measurements and 
class variables, respectively. Single and stepwise multiple regression analyses were used 
to analyze the relationship between changes in LVM or LVM index and variou
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explanatory variables, including the treatment-induced BP changes. Multivariate ANOVA 
was performed to test the null hypothesis of no differences between the parameters of 
regression equations (SAS Institute Inc, 1987). 
 
5.3 RESULTS 
 
5.3.1 Demographic Characteristics 
 
Of the 409 patients randomized in the trial, 233 (57%) were eligible for inclusion in 
the present substudy because echo-cardiograms of sufficient quality had been obtained. 
Of the latter patients, 23 (10%) had been withdrawn at 4 months and 37 (16%) did not 
have all measurements at baseline or at 4 months required for the statistical 
measurements. Thus, this study includes 173 patients who, compared with the 236 
nonparticipants, had similar BP values at entry (Table 5.1). However, nonparticipants 
were older, more obese, and included slightly more previously treated patients (46% 
versus 37%, respectively, p=0.052)  
The 173 patients (41 men and 132 women) were 51   10 years of age. Their body-
mass index averaged 30.3  6.2 kg/m
2
. Of the 173 patients, 109 had previously been 
treated, and 85 patients had been on monotherapy either with diuretics (n=48), 
angiotensin-converting enzyme inhibitors (n=20),  -methyldopa (n=9), or calcium channel 
blockers (n=8). Furthermore, 17 patients had been on multiple drugs, including diuretics 
in 11 patients, and 7 patients could not report which drug treatment they had been taking 
before the screening visit. Compared with the untreated patients, the previously treated 
patients included more women and had higher mean body-mass index (Table 5.1). At 
entry, clinic, Dinamap and ambulatory BP values (Table 5.2) as well as all 
echocardiographic measurements (Table 5.3) were similar in previously untreated and 
treated patients (p>0.04). 
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Table 5.1. Clinical Characteristics at Randomization of Participants and Nonparticipants 
        Participants 
    Nonparticipants  Previously  Previuosly  All 
     Untreated  Treated                      Included 
No   236      64                 109              173 
Age,y   5510    4911     529          5110* 
Female sex, n (%) 181 (77) 40 (62.5)  92 (84.4)  132 (76) 
BMI (kg/m2)  31.87  28.46   31.46            30.36.2 
Systolic/Diastolic BP (mm Hg) 
Conventional  17318/1037 1707/1039       17221/1029             17221/1029 
Dinamap  1668/998 162 16/1007       16521/1008     16521/1008 
24-Hour  15015/967 14915/967       15315/977     15315/977 
Daytime  15514/1027 15315/1027       15814/1037     15814/1037 
Nighttime  13918/8510 140 18/8610       14320/8711     14320/8711 
Values are mean
*p<0.01 and †p=0.03, significance of the difference between participants and nonparticipants,  
 p=0.002, significance of the difference betweenpreviuosly untrated and previously treated 
patients. 
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Table 5.2. Conventional, Dinamap, and Ambulatory BP at Baseline and at 4 Months. 
BP, mm Hg  Baseline  4 Months  Change 
 
 
Previously untreated (n=64) 
 
Conventional       17017/103 9        14421/9111  -26 25/-1214 
Dinamap       16216/1007        13719/8810  -25 21/-1211 
24-hour       14915/967        12614/9218  -23 15/-149         
Daytime       15315/1027        13014/878  -2316/-159 
Nighttime        14018/8610        1197/7310  -2116/-1310 
 
Previously treated (n=109) 
 
Conventional         17221/1029       15022/9311  -2227/-914 
Dinamap         16521/1008       14320/9011  -2226/-1012 
24-hour         15315/977       13214/859  -2117/-1310 
Daytime         15814/1037        13515/900  -2217/-1310 
Nighttime         143±20/87±11       124±17/75±10  -19±19/-12±12 
 
All changes in blood pressure were significant (p<0.001) 
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Table 5.3. Echocardiographic Data at Baseline and at 4 Months. 
 
Characteristic  Baseline 4 Months Change p-value 
 
 
Previuosly untreated (n=64) 
 
 LVEDD, mm   47.0±4.9 46.4±4.6 -0.6±5.1 0.34 
 
 PWT,mm   11.1±0.21 10.3±1.7 -0.7±2.1 0.007 
 
IVS, mm   11.9±2.3 11.0±1.7 -0.9±2.2 0.003  
 
MWT, mm   11.5±2.1 10.7±1.4 -0.8±1.9 0.001 
 
LVM, g   205±55 181±40 -24.4±42.9 <0.001 
 
LVMI, g/m2   118±33 104±23 -14.3±26.1 <0.001 
 
Stroke Volume, ml  73±16  74±18  0.099  0.32 
 
Previuosly treated (n=109) 
 
LVEDD, mm   45.7±6.3 43.9±5.8 -1.8±6.4 0.004 
 
PWT, mm   11.5±2.3 10.7±1.8 -0.8±2.3 <0.001 
 
IVS, mm   12.6±2.0 11.6±1.9 -1.0±2.0 <0.001 
 
MWT, mm   12.0±1.9 11.2±1.6 -0.9±1.8 <0.001 
 
LVM, g   212±70 178±55 -33.7±52.6 <0.001 
 
LVMI, g/m2   118±34 99±26.1 -18.6±29.1 <0.001 
 
Stroke volume, ml  73±17  73±16  -0.00008 0.96 
LVEDD: left ventricular end-diastolic diameter; PWT: posterior wall end-distolic thickness; 
IVS: interventricular septum end-diastolic thickness; and MWT: end-diastolic mean wall 
thickness
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5.3.2 Results in Previously Untreated Patients 
 
The number of patients who remained on monotherapy was 27 of 39 in the 
nifedipine group, 6 of 9 in the verapamil SR group, 2 of 8 in the enalapril group, and 4 of 8 
in the hydrochlorothiazide group. 
 At 4 months, compared with baseline, BP measured at the clinic by the study 
nurse or by the Dinamap device had significantly (p<0.001) decreased (Table 5.2). In 
addition, there was a parallel shift (p<0.001) of the systolic and diastolic ambulatory BP 
profiles to lower values (Figure 5.1 and Table 5.2). The treatment-induced changes in the 
BP recorded oscillometrically, either at the clinic or over 24 hours, were significantly 
correlated with the correspondingchanges in the conventionally measured office readings 
(Figure 5.2).  
After 4 months of antihypertensive therapy, LVM and LVM index had decreased 
(p<0.001) by 24 g and 14 g/m2, respectively (Table 5.3). This was achieved through a 
reduction in wall thickness with no significant change in left ventricular end-diastolic 
diameter. Both before and after standardization for body surface area, there was a 
positive linear relationship between the decrease in LVM index and the reduction in 
systolic BP as assessed by conventional or automated measurement at the clinic or by 
24-hourambulatory monitoring (Table 5.4). The corresponding relationship for diastolic 
pressure was not statistically significant (Table 5.4). Considering conventional, Dinamap, 
and 24-hour BP measurements, there were no significant differences in the regression 
parameters relating the changes in LVM to those in BP (p  0.09). These findings 
remained unaltered when LVM index was used as an outcome variable (Figures 5.3 and 
5.4). In addition, measurement of the 24-hour or Dinamap BP did not significantly 
increase the accuracy of the prediction of the changes in LVM (p>0.40) or LVM index 
(p>0.37) over and beyond that already provided by conventional systolic pressure. 
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Figure 5.1. Systolic and diastolic blood pressure profiles (BP) at baseline (open symbols) 
and at 4 months of treatment (closed symbols) in hypertensive patients of African 
descent. Values are hourly BP means with 95% confidence intervals. Results are given 
separately for previously untreated and treated patients. 
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Figure 5.2. Relationships in previously untreated hypertensive patients of African descent 
between changes in 24-hour (d 24) or Dinamap (d Din) measurements of systolic blood 
pressure (SBP and diastolic BP (DBP) and the corresponding changes in BP measured 
using conventional techniques (d Con). 
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Figure 5.3. Partial correlation coefficients with 95% confidence intervals between 
changes in left ventricular mass index (LVMI) and changes in blood pressure (BP) after 4 
months of treatment in previously untreated and previously treated hypertensives of 
African ancestry. 
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Figure 5.4. Relationships between the changes in left ventricular mass index (LVMI) and 
in systolic blood pressure (SBP) as assessed by three techniques of BP measurement in 
previously untreated hypertensive patients of African descent. D Con, conventional 
measurements; d Din, Dinamap measurements; d 24, 24-hour measurements. 
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Table 5.4. Regression coefficients between changes in LVM index and in BP over 4 
months. 
 
   Systolic Pressure   Diastolic Pressure 
  
        Regression Coefficient   Regression Coefficient 
(95% CI)  p   (95% CI) p 
 
Previuosly untreated 
(n=64)  
Conventional  0.37 (0.14-0.61) 0.004  0.14 (-0.32-060) 0.56 
Dinamap  0.34 (0.05-0.63) 0.03  0.42 (-0.12-0.97) 0.13 
24-hour  0.46 (0.03-0.89) 0.04  0.60 (-0.013-1.34) 0.11 
Daytime  0.34 (-0.05-0.73) 0.10  0.42 (-0.027-1.10) 0.24 
Nighttime  0.40 (-0.01-0.81) 0.06  0.55 (-0.06-1.17) 0.08 
Previuosly treated 
(n=109)  
Conventional  0.02 (-0.18-0.23) 0.82  -0.05 (-0.45-0.34 0.80 
Dinamap  -0.06 (-0.28-0.15) 0.57  -0.21 (-0.66-1.24) 0.37 
24-hour  -0.17 (0.48-0.14) 0.32  -0.17 (-0.73-0.39) 0.56 
Daytime  -0.19 (-0.50-0.12) 0.23  -0.22 (-0.75-0.30) 0.41 
Nighttime  -0.09 (-0.38-0.20) 0.54  -0.53 (-0.39-0.48) 0.98 
 - 115 - 
5.3.3 Results in Previously Treated Patients  
 
The number of patients that remained on monotherapy was 40 of 65 in the 
nifedipine-treated group, 14 of 17 in the verapamil SR-treated group, 3 of 14 in the 
enalapril-treated group, and 5 of 13 in the hydrochlorothiazide-treated arm. There were 
no significant differences in the use of study medications between previously untreated 
and treated patients (p>0.42). Furthermore, at 4 months the clinic, Dinamap and 
ambulatory BP (Table 5.2 and Figure 5.1) had fallen to the same extent as in the 
previously untreated group. After 4 months of antihypertensive therapy with the study 
medications, LVM and LVM index had decreased by 34 g (p<0.001) and 19 g/m2 
(p<0.001), respectively (Table 5.3). This was achieved through a reduction in wall 
thickness and left ventricular end-diastolic diameter. Treatment-induced changes in all 
echocardiographic measurements were similar (p>0.18) in previously untreated and 
treated patients (Table 5.3). However, in contrast to the previously untreated group, in 
treated patients, all correlations between the changes in LVM index and any type of BP 
measurement failed to reach statistical significance (Table 5.4 and Figure 5.3). 
Adjustment for previous treatment with diuretics or other drugs did not alter these 
findings. 
 
5.3 DISCUSSION 
 
The Baragwanath Hypertension Study was a single-center trial that investigated 
the efficacy of various drug classes to initiate antihypertensive treatment in patients of 
African dsecent (Sareli et al 2001). The same trained research nurse obtained all 
conventional BP readings. Only patients with sustained hypertension were enrolled. The 
study medications were titrated or combined to reduce the daytime diastolic BP to a level 
below 90 mm Hg. Four months of antihypertensive treatment significantly lowered clinic, 
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24-hour, daytime, and nighttime BP, which led to a significant decrease in wall thickness, 
LVM, and LVM index. 
Significant and positive correlations between the changes in LVM index and all 
types of systolic BP in response to treatment in previously untreated patients were noted, 
whereas in previously treated patients these correlations were nonsignificant. 
Furthermore, in untreated patients, regression of LVM index was not significantly better 
correlated with the reduction in 24-hour, daytime, or nighttime systolic pressure than with 
the decrease in the conventional systolic pressure. The latter observations are at 
variance with two previous studies. In the Study on Ambulatory Monitoring of Blood 
Pressure and Lisinopril Evaluation (SAMPLE) (Mancia et al 1997), after 12 months of 
follow-up of 184 patients, the decreases in systolic/diastolic pressure were 26/18 mm Hg 
for the clinic pressure and 18/12 mm Hg for the 24-hour pressure. LVM index decreased 
from 158 to 133 g/m
2
. The reduction in LVM index was not correlated with the changes in 
the clinic BP (r=0.11/0.11), but it was significantly (p<0.01) correlated with the changes in 
the 24-hour BP (r=0.42/0.38). In the study by Fagard3 et al (1997) during 6 months of 
follow-up of 54 patients, the reductions in systolic/diastolic BP were 22/16 mm Hg for the 
conventional pressure, 19/12 mm Hg for Dinamap measurements performed at the clinic, 
and 17/11 mm Hg for the 24-hour BP. LVM decreased from 237 to 212 g. Changes in 
LVM were significantly related to changes in systolic BP. The correlation coefficients, 
adjusted for sex and body size, amounted to 0.39 and 0.40 for the conventional and 
automated measurements of clinic systolic pressures, respectively, and to 0.55 for the 24-
hour systolic pressure. The 24-hour systolic pressure added 7.4% (p<0.05) and 6.2% 
(p=0.06) to the variance of the changes in LVM explained in terms of the conventional 
and automated measurements of clinic systolic pressures, respectively. 
The discordance between the findings of the present study and two previous 
studies (Mancia et al 1997, Fagard et al 19973) may depend on various factors, such as 
the characteristics of the study participants, duration of follow-up under treatment with 
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study medications, precision and standardization of the conventional BP readings, and 
recruitment of previously treated patients. Earlier studies have demonstrated that under 
antihypertensive treatment, LVM decreases to a similar extent in Caucasian patients and 
patients of African descent (Skoularigis et al 1994, Radevski et al 2000). Furthermore, 
previous studies have demonstrated that three months of antihypertensive treatment is 
sufficient to maximally reduce LVM (Bielen et al 1992, Fagard et al 19971). However, in 
the Losartan Intervention For Endpoint Reduction (LIFE) study (Devereux et al 2002) the 
maximum effect on LVH of antihypertensive treatment was not achieved for at least two 
years. In the SAMPLE study, the 12-month change in LVM index correlated equally with 
the change in the 24-hour systolic pressure in previously untreated (r=0.49) and 
previously treated (r=0.39) patients, whereas such relationships were not observed for the 
changes in the clinic BP (Mancia et al 1997). However, the clinic BP in the SAMPLE 
study was the average of only two conventional readings, which were obtained by 
different observers across 11 centers. Conventional BP readings are more difficult to 
standardize in multicenter studies. In the present study, only one study nurse measured 
the clinic BP at baseline and follow-up in all patients. The strength of the reported 
associations of LVM index with conventional BP readings has varied greatly, with 
correlation coefficients ranging from close to zero (Balansard et al 1991) to approximately 
0.5 (Fagard et al 1992). Fagard2 et al (1997) produced convincing evidence suggesting 
that differences among studies may be partly attributable to the variable degrees of 
standardization and the divergent number of conventional BP readings. 
In the Baragwanath Trial, all patients had a daytime diastolic BP ranging from 90 
to 114 mm Hg. Patients with white-coat hypertension were therefore excluded. In the two 
previous studies comparing the strength of the relationships between ambulatory and 
conventional BP and LVM (Fagard3 et al 1997, Mancia et al 1997), patients were 
exclusively selected on the basis of conventional BP readings at the clinic. Furthermore, 
depending on the number of clinic visits, the number of conventional BP readings 
averaged to diagnose hypertension, and the level of the conventional BP, the prevalence 
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of white-coat hypertension among patients with elevated clinic pressure on conventional 
measurement may range from 5% (Pickering et al 1988) to >70% (Myers and Reeves 
1991). In white-coat hypertensive patients, the clinic BP does not reflect the usual BP load 
and therefore may be expected to be only weakly correlated or not correlated with LVM. 
We hypothesize that the high degree of standardization of the conventional BP 
measurements in the clinic and the exclusion of white-coat hypertensive patients explain 
why in our previously untreated patients, in contrast to earlier studies, the correlations 
between the changes in LVM and in systolic BP were of similar magnitude for all types of 
BP measurement. 
The limitations of this study are the study sample size, in that sex-specific analysis 
may have revealed a more important effect of ambulatory as compared to conventional 
BP in men, but not women.    
 In conclusion, the results of the present study indicate that in hypertensives of 
African ancestry, decreases in LVM induced by antihypertensive treatment are correlated 
with changes in conventional BP equally as well as changes in ambulatory BP. Moreover, 
there were no differences in the ability of day and night BP to predict changes in LVM in 
this ethnic group. These data are consistent with the ability of conventional BP to predict 
LVM as closely as ambulatory BP in cross-sectional studies in this ethnic group.   
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Chapter 6 
 
 
A Reduction in Left Ventricular Mass is More Closely 
Associated with Blood Pressure than with the Use of an 
Angiotensin-Converting Enzyme Inhibitor in Patients of 
African Descent. 
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ABSTRACT 
In the reduction of left ventricular mass (LVM), the relative importance of blood 
pressure (BP) lowering versus the class of antihypertensive employed in groups of 
African ancestry remains uncertain. In a single-centre, randomized trial I explored the 
independent associations between LVM and both ambulatory BP and treatment with an 
angiotensin-converting enzyme inhibitor (ACEI) over a 25-month follow-up period. 
Patients of African ancestry (n=185 at enrollment) with a mean daytime diastolic BP 
ranging from 90-114 mm Hg off-treatment were randomized to receive either enalapril, 
calcium channel blockers (nifedipine or slow release verapamil), or hydrochlorothiazide 
as initial therapy. Doses were increased and additional therapy, including enalapril, added 
to achieve a target daytime diastolic BP below 90 mm Hg. At 4, 13 and 25 months of 
therapy 66, 71 and 72 % of patients had BP values within target ranges. LVM index 
decreased from 118± 33 g/m2 at baseline to 101±25, 101±23, and 96±22 g/m2 at 4, 13 
and 25 months of therapy (p<0.001 compared to baseline). Accounting for effects of 
either conventional or ambulatory BP at each time point, the use of enalapril was 
associated with neither LVM index, nor with LV relative wall thickness over the treatment 
period. However, in-treatment conventional systolic BP was associated with both LVM 
index (p=0.01) and LV relative wall thickness (p=0.03) and systolic night-time BP was 
associated with both LVM index (p=0.01) and LV relative wall thickness (p=0.005). In 
conclusion, in the treatment of hypertension in groups of African origins, the use of an 
ACE inhibitor confers no additional benefits on LVM beyond that produced by effects on 
BP. 
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6.1 INTRODUCTION 
 
 As indicated in all preceding chapters, left ventricular hypertrophy (LVH) and 
concentric remodeling are strong predictors of cardiovascular morbidity and mortality in 
hypertensive patients (Casale et al 1986; Koren et al 1991; Verdecchia et al 1996; Ghali 
et al 1998) and in the general population (Levy et al 1990; Levy et al 1994). Moreover, 
several studies in hypertensive patients have demonstrated that regression of 
hypertensive LVH is associated with improved prognosis (Levy et al 1994; Muiesan et al 
1995; Verdecchia et al 1998; Mathew et al 2001; Devereux et al 20042). Thus, in the 
treatment of hypertension, regression of LVH and normalization of LV geometry are 
desirable clinical end-points. 
Small sample sizes, a short duration of follow-up and echocardiographic 
measurements unblinded for the patient’s treatment status limit the validity of many 
previous studies designed to assess the impact of antihypertensive agents on the 
regression of LVH (Dahlöf et al 1992; Schmieder et al 1998; Klingbeil et al 2003; Neaton 
et al 1993; Gottdiener et al 1997). Quantitative reviews of the literature, of which one 
included open and uncontrolled studies, have suggested that angiotensin-converting 
enzyme (ACE) inhibitors (Dahlöf et al 1992; Schmieder et al 1998) and angiotensin II 
receptor blockers (Dahlöf 2001) might be particularly effective in regressing LVH, whilst -
adrenoreceptor blockers would be least effective. In the Losartan Intervention For 
Endpoint Reduction in Hypertension (LIFE) trial conducted in hypertensive patients with 
electrocardiographic evidence of LVH, the angiotensin II receptor blocker, losartan, was 
more effective at regressing LVH than the -adrenoreceptor blocker, atenolol, an effect 
that was independent of office BP (Devereux et al 20041; Okin et al  2003). However, in a 
small cohort of other ethnic groups, mostly consisting of patients of African ancestry, a 
significant decrease in LVM was not achieved with losartan (Devereux et al 20041). 
The lack of ability of losartan to decrease LVM to a greater extent than atenolol in 
patients of African descent in the LIFE study (Devereux et al 20041) was also mirrored by 
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an inability of losartan to produce greater effects on CV outcomes as compared to 
atenolol in African-Americans patients (Julius et al 2004). Indeed the overall analysis on 
CV outcomes favored atenolol as opposed to losartan (Julius et al 2004). The ethnic-
specific effects of agents that block the RAS on CV outcomes were also noted in the 
Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). 
In the ALLHAT study, in which 35% of the patients enrolled were African-Americans, a 
significant interaction between ethnic group and treatment was noted when comparing 
the ACE-I, lisinopril, to the diuretic treatment group with respect to stroke and CVD, with 
lisinopril achieving a worse outcome in patients of African ancestry (Julius et al 2004). 
The lack of appreciable benefit on target organ effects of ACE-I therapy over that 
of other therapeutic classes in patients of African descent, was also noted in the 
Baragwanath Hypertension Study, a single-centre randomized trial that compared several 
drug classes (Sareli et al 2001). In this study (Sareli et al 2001) the use of an ACE-I 
conferred no appreciable benefit over that of other antihypertensive classes of agents in 
reducing LVM over a four-month treatment period. However, maximal decreases in LVM 
may require treatment for up to two years (Devereux et al 2002). Consequently, the aim 
of the present study was to assess the independent associations between LVM and both 
ambulatory BP and treatment with an ACE-I over a 25-month follow-up period in the 
Baragwanath Hypertension Study. 
 
6.2 METHODS 
 
6.2.1 Study design and subjects. 
 
The Committee for Research on Human Subjects of the University of the 
Witwatersrand approved the study (clearance number M940106). Patients gave informed 
written consent. The Baragwanath Hypertension Study was a single centre, prospective, 
randomized, open-label, actively controlled study, conducted at the Chris Hani-
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Baragwanath Hospital from 1994 until 1998. The study design, and inclusion and 
exclusion criteria have been described in detail (chapter 6) (Sareli et al 2001). The 
antihypertensive therapy; assessment of the patient’s adherence to the prescribed 
medication, and the number of follow-up visits to achieve BP control employed in the 
study, have also been previously reported (chapter 6, Sareli et al 2001). Briefly, patients 
diagnosed as being hypertensive after a 2-week placebo run-in period and with a count of 
returned placebo tablets within 80 to 120% of the expected number qualified for 
randomization, if daytime diastolic BP was 90-114 mm Hg. 
Eligible patients were randomized to receive either nifedipine 30 mg/day as a 
gastrointestinal therapeutic system (GITS) formulation, verapamil slow release (SR) 240 
mg/day, hydrochlorothiazide 12.5 mg/day, or enalapril 10 mg/day (Sareli et al 2001). 
Patients were followed up at monthly intervals and if the target BP (daytime diastolic 
BP<90 mm Hg) was not achieved, the daily dose of the initial agent was increased to 60 
mg/day for nifedipine GITS, 360 mg/day for verapamil SR, 25 mg/day for 
hydrochlorothiazide, and 20 mg/day for enalapril. At 2 months if patients had not achieved 
target BP, patients receiving nifedipine GITS were randomized to one of four treatment 
strategies involving either the addition of enalapril (10 mg/day), carvedilol (25 mg/day), or 
verapamil SR (120 mg/day) or increasing the daily dose of nifedipine GITS to 90 mg/day. 
In patients with uncontrolled BP originally assigned to receive verapamil SR, the dose 
was increased to 480 mg/day and then these patients subsequently received 
hydrochlorothiazide 12.5 mg/day with the possible addition of enalapril 10mg/day. Those 
originally receiving hydrochlorothiazide 25 mg/day with uncontrolled BP received 
reserpine 0.125 mg/day with the possible addition of enalapril 10mg/day if necessary to 
achieve the target BP. Those originally on treatment on enalapril 20 mg/day and with 
uncontrolled BP subsequently received hydrochlorothiazide followed by nifedipine GITS if 
indicated. 
Of the 409 patients randomized, 233 patients had high quality echocardiograms at 
baseline and were therefore eligible for inclusion in the current echocardiography 
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substudy. Of the latter patients, 23 (10%) had been withdrawn at 4 months and 25 did not 
have measurements at 4, 13 and 25 months. The remaining 185 participants studied had 
similar BP values at entry and the same proportion of previously treated patients (61% 
versus 56%, p=0.32). However, the remaining participants were younger (5110 versus 
569 years, p<0.0001) and less obese (body mass index = 306 versus 328 kg.m2, 
p<0.02) (chapter 6) (Skudicky et al 2002). 
 
6.2.2 Blood pressure measurements and echocardiography. 
 
Conventional and oscillometric clinic BP, ambulatory BP and echocardiographic 
measurements were performed at baseline and repeated at 4, 13 and 25 months using 
methods described in chapters 2-5. Echocardiograms were analyzed according to the 
American Society of Echocardiography convention (Sahn et al 1978). All measurements 
were recorded on videotape by experienced technologists and analyzed by an 
investigator who was unaware of the BP, treatment arm and clinical data of the patients. 
Intra- and inter-observer variability for LVM has been reported on (chapter 5). LVM was 
derived according to an anatomically validated formula (Devereux et al 1986) and 
indexed for body surface area. Left ventricular relative wall thickness (RWT) was 
calculated as previously described (Ghali et al 1998). Left ventricular hypertrophy was 
diagnosed if LVMI was >120 g/m2 in males and >100 g/m2 in females. These criteria were 
used to define LVH, instead of the thresholds defined in chapter 2, as they are based on 
mortality data rather than on data obtained from healthy populations. Concentric LVH was 
diagnosed in persons with LVH and RWT>0.44 for men and women (Ganau et al 1992). 
Patients with LVH, but without a concentric LV were classified as having eccentric LVH. 
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6.2.3 Data analysis. 
 
Database management and statistical analyses were performed with SAS 
software, version 9.1 (SAS Institute Inc, Cary, NC). All data are expressed as mean±SD. 
Proportions were compared using Fisher’s exact test. An ANOVA was used to compare 
data at baseline between groups. The within-group and between-group changes in 
continuous measurements during follow-up were analysed using the PROC MIXED 
procedure as implemented in the SAS package. The maximum likelihood approach 
accounts for randomly missing observations and allows adjustments for baseline values 
and other covariates (age, gender and body mass index). To assess the BP-independent 
impact of ACE inhibitors on the on-treatment LVMI  and LV RWT, patients were grouped 
according to whether they were receiving 1) enalapril either as initial therapy or at follow-
up (group 1); 2) hydrochlorothiazide as initial therapy or at follow-up, but without enalapril 
(group 2); 3) nifedipine GITS as initial therapy or at follow up, but without enalapril (group 
3), and 4) verapamil SR as initial therapy or at follow up, but without enalapril (group 4). 
In further analysis all patients who had received calcium channel blockers both initially 
and during follow-up were combined (groups 3 and 4). 
 
6.3 RESULTS 
 
6.3.2 Study group characteristics. 
 
Of the 185 patients, 173 had optimal echocardiographic data at 4 months. 
Subsequently, 36 patients were lost to follow-up, 11 were withdrawn for poor blood 
pressure control, 15 withdrew consent, 2 died, 3 became pregnant, 4 were withdrawn for 
adverse events and 21 patients did not have optimal echocardiographic recordings at 25 
months. The study group largely consisted of women with a high body mass index (Table 
6.1). Most patients had no prior record of antihypertensive medication use (Table 6.1). 
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The baseline demographic and clinical characteristics of the group (n=81, 44%) still 
remaining to follow-up at 25 months were similar to the total group included in the 
echocardiography substudy (Table 6.1). 
 
6.3.3 Blood pressure and antihypertensive medication. 
 
The majority of patients received two or more agents (Table 6.2). The number of 
patients receiving enalapril either as initial therapy or at follow-up (group 1); 
hydrochlorothiazide as initial therapy or at follow-up, but without enalapril (group 2); and 
either nifedipine or verapamil SR as initial therapy or at follow up, but without enalapril 
(groups 3 and 4), are given in Table 6.3. 
Maximal ambulatory BP control was largely achieved by 4 months of therapy 
(Tables 6.2 and 6.3). No further decline in mean ambulatory BP or improvement in the 
control rate of the ambulatory BP occurred from 4 until 25 months (Table 6.2). However, 
beyond month 4 we observed a further decline in the conventional clinic based pressures 
(Table 6.2). At 4 months, patients who had received either nifedipine or 
hydrochlorothiazide, achieved lower 24-hour, daytime and nocturnal systolic and diastolic 
BP than those who had been randomized to enalapril or subsequently received enalapril 
therapy (Table 6.3). Although patients receiving verapamil SR as initial therapy also had a 
higher ambulatory BP at 4 months, the difference was not statistically significant from the 
nifedipine and hydrochlorothiazide treated groups. With the addition of subsequent 
therapy, all groups achieved similar BP values (Table 6.3). 
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Table 6.1. Baseline demographic and clinical characteristics of the patients. 
 
           All patients with      Patients remaining 
       echocardiograph data     at the end of study 
Number                                                            185    81 
Age (years)     51±10          52± 11 
Women (number [%])             143 (77%)        69 (85%) 
Weight (kg)      76±15          77±15 
Body mass index (kg/m2)     30±6          31±6 
Total cholesterol (mmol/L)    5.1±1.2       5.2±1.2 
Glucose (mmol/L)     5.3±2.5       5.6±3.1 
Potassium (mmol/L)     4.1±0.4       4.0±0.4 
Creatinine (mmol/L)      65±26        67±29 
Antihypertensive medication  
before enrollment (n, %)                        112 (61%)     50 (62%) 
_______________________________________________________________________ 
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Table 6.2. Blood pressures (BP), antihypertensive use and proportion of patients with BP control during follow-up.  
 
Months     0           4     13                       25 
n                                                        185                                173                                 111                                     81 
Conventional BP (mm Hg)  171±19/102±8             148±219/92±11*          135±18/85±10 *     134±21/87±10*† 
24 hour BP (mm Hg)    151±15/97±7                 130±15/84±9*      126±12/80±8*    128±14/81±8* 
Daytime BP (mm Hg)   155±15/102±8               133±15/88±10*      130±13/85±9*   132±15/86±9* 
Night-time BP (mm Hg)   144±19/88±10                124±17/76±11*      123±13/76±8*   124±16/76±9* 
% (sample size) with 
daytime BP < 140/90 mm Hg  0   61 (106)  68 (76)          62 (50) 
daytime BP <90 mm Hg  0   66 (114)  71 (79)          72 (58) 
% two or more agents              0             42              48     53 
% calcium channel blockers             0             76   82    80 
% diuretics               0             28   32         41 
% ACEIs               0             18   23         31 
% -blockers                0              6    7          9 
*p<0.001 versus baseline, † p<0.001 versus 4 months. 
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Table 6.3. Blood pressure at baseline and follow-up by treatment group. 
 
Months   0           4     13                       25 
 Patients receiving enalapril (group1) 
Sample number    47   45     29    25 
Median Dose (mg)                                         10                                20                                 20                                         20 
Conventional BP (mm Hg)  169±23/102±11 147±23/92±13*      133±18/85±9*   133±21/86±10* 
24 hour BP (mm Hg)   153±16/98±7  136±17/88±10*†      126±12/81±8*   128±16/80±9* 
daytime BP (mm Hg)   156±17/103±8  138±16/92±11*†      129±12/85±9*   132±14/86±8* 
night-time BP (mm Hg)  145±18/89±9  130±19/81±12*†      123±13/76±8*   123±18/74±10* 
______________________________________________________________________________________________________ 
     Patients receiving hydrochorothiazide, but not enalapril (group 2) 
Sample number    21   20     15    11 
Median Dose (mg)                                       12.5                               25                                 25                                         25  
Conventional BP (mm Hg)  170±18/103±7  142±19/88±11*      138±24/86±12*   128±11/86±9* 
24 hour BP (mm Hg)   147±11/95±7  128±13/82±8*       126±12/80±7*   125±14/79±7* 
daytime BP (mm Hg)   149±11/99±6  131±14/86±9*       129±14/84±9*   129±14/84±8* 
night-time BP (mm Hg)  140±15/84±10  121±14/73±10*      123±13/76±8*   121±14/74±6*  
 
*p<0.001 versus baseline values; † p<0.05 versus group 2 and 3. 
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Table 6.3 continued. Blood pressure at baseline and follow-up by treatment group. 
Months   0           4     13                       25 
Patients receiving nifedipine, but not enalapril (group 3)  
Sample number    92   86     55    34 
Median Dose (mg)                                         30                                60                                 60                                         60  
Conventional BP (mm Hg)  174±17/102±8  148±21/92±10*      132±17/85±8*   135±22/85±11* 
24 hour BP (mm Hg)   152±14/97±7  126±11/81±7*       126±13/80±8*   128±14/81±7* 
daytime BP (mm Hg)   156±14/103±7  129±12/86±8*       130±14/85±8*   131±15/86±8* 
night-time BP (mm Hg)  144±19/89±11  119±13/74±9*       122±14/75±7*   123±14/76±8* 
____________________________________________________________________________________________________ 
 Patients receiving verapamil, but not enalapril (group 4) 
Sample number    25   22     12            11 
Median Dose (mg)                                        240                              360                               360                                     240 
Conventional BP (mm Hg)  169±18/102±7  153±21/97±11*      146±15/89±13*   145±23/91±10* 
24 hour BP (mm Hg)   151±17/96±7  135±18/85±10*      130±12/81±11*   134±15/85±12* 
daytime BP (mm Hg)   152±17/100±8  134±22/87±13*      132±13/84±12*   137±17/89±14* 
night-time BP (mm Hg)  144±21/89±10  135±18/81±9*       128±12/78±11*   133±19/80±12* 
 
*p<0.001 versus baseline values. 
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6.3.4 LV mass and relative wall thickness. 
 
In the study group at baseline 50 % of patients had concentric LVH (n=92), and 
15% eccentric LVH (n=28). There was a significant change in LVMI over time (Table 6.4, 
p<0.001). After 4 months of antihypertensive therapy, LVM and LVMI had decreased by 
30±49 g and 17± 28 g/m2, respectively (Table 6.4). However, from 4 months onwards 
there was no further statistically significant change in LVMI (Table 6.4). Decreases in LVM 
were achieved largely by a reduction in the posterior and septal wall thickness, as well as 
by a modest change in LV end diastolic internal diameter (Table 6.4). At 4 months, 40 
patients (23 %) had concentric LVH, and 19 patients (11%) had eccentric LVH. Despite 
maintaining BP control over the subsequent 21 months of therapy, at the end of the study 
20 patients (25%) had concentric LVH, and 10 patients (12.5%) still had eccentric LVH. 
 
6.3.5 Predictors of LV mass and relative wall thickness on treatment. 
 
Changes in LVMI over time tended to be modestly greater in the group of patients 
receiving hydrochlorothiazide as initial therapy or at follow-up, and who did not receive 
enalapril as additive therapy, as compared to the other groups (Table 6.5). However, 
these apparent differences failed to achieve significance (Table 6.5). Indeed, during 
follow-up, treatment arm was not associated with either LVMI or LV relative wall thickness 
(Table 6.6). However, conventional and nighttime systolic BP were independently 
associated with in-treatment LVMI (Table 6.6). Moreover, conventional, 24 hour, daytime 
and nighttime systolic BP were associated with in-treatment LV relative wall thickness 
(Table 6.6). Neither daytime, nor 24 hour BP, were independently associated with in-
treatment LVM (Table 6.6). Both baseline LVMI and LV relative wall thickness were strong 
determinants of follow-up LVMI and LV relative wall thickness, respectively (Table 6.6). 
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Table 6.4. Echocardiograph measurements at baseline and follow-up. 
 
Months          0           4         13                      25 
Number                                                    185                     173                  111                   81 
LV end diastolic diameter (mm)          45.9±6.0             44.8±5.5*         45.1±5.2           44.4±5.2* 
LV end systolic diameter (mm)           30.2±5.4             28.8±4.9        28.5±5.4         28.9±4.5* 
LV posterior wall thickness (mm)       11.4±2.4            10.6±1.8       10.5±1.8           10.5±3.2 
LV septal wall thickness (mm)            12.4±2.3            11.4±1.9       11.5±2.1           11.3±2.2 
FS (%)       35±7               36±7*             38±11*                35±8 
EF (%)       63±9               65±10             67±9*                 64±12 
LVM (g)                                               210±64               179±50         180±43            170±42 
LVMI (g/m2 )                                        118±33               101±25         101±23            96±22 
RWT   (ratio)                                        0.51±0.14           0.48±0.11	       0.47±0.11	       0.47±0.12	
LVH [%, (n)]                                          65 (120)             34 (59)             43 (48)           38 (31) 
______________________________________________________________________________________________________ 
LV, left ventricle; FS, LV endocardial fractional shortening; EF, LV ejection fraction; LVM, LV mass; LVMI, LV mass adjusted to height; RWT, 
relative wall thickness; *p<0.05 p<0.001 versus baseline values 
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Table 6.5.  Echocardiographic measurements at baseline and follow-up by treatment group. 
Months               0           4     13                        25 
 Patients receiving enalapril (group1) 
Sample number   47   45     29    25 
LVEDD (mm)                              46.2±5.9                         45.9 ± 5.9                      45.7 ± 5.2                              45.0± 5.* 
LVESD (mm)       30.1±5.2                     28.5±5.5*                     28.4±4.7*                   28.1±5.2* 
PWT (mm)        11.4±2.1          10.7±2.0                      10.3±1.9*                   10.4±2.0* 
IVS (mm)                   12.6±2.1          11.4±2.0†                     11.2±2.6†                   11.9±2.2* 
FS (%)                                         35.4±6.1                37.8±7.3*                     40.2±11.3*                             37.4±6.0 
EF (%)                                         64.4±8.4                 67.6±9.3*                    66.9±9.5                               68.2±7.7 
LVM (g)                                       214.6±73.1                     188.3±55.7†               177.2±41.0†                        181.2±43.5† 
LVMI (g/m2)                              119± 38                          104±30†                      100±27†                              100±23† 
RWT (ratio)                                 0.50±0.11                      0.48±0.12                      0.46±0.13                            0.47±0.12 
______________________________________________________________________________________________________ 
     Patients receiving hydrochorothiazide, but not enalapril (group 2) 
Sample number           21   20     15    11 
LVEDD (mm)                              47.0±5.6                      44.7 ± 5.9                    44.9 ± 4.8                              43.9± 5.7 
LVESD (mm)       31.3±5.1       29.3±4.9                    29.0±3.0                    29.3±4.1 
PWT (mm)       11.1±2.7       10.0±1.5*                    10.6±2.2                    9.7±1.2* 
IVS (mm)                  12.1±2.5       11.5±1.9                    11.2±1.8*                    10.3±1.4* 
FS (%)                                         33.5±8.6              34.2±6.1                      31.6±10.3                             33.1±7.1 
EF (%)                                         62.2±12.2               63.3±9.1                       63.7±9.8*                               61.6±9.5 
LVM (g)                                       208.0±62.4                   172.3±47.6*                 176.1±34.3*                          149.8±29.7† 
LVMI (g/m2)                                   115±32                        94±21*                          98±22*                                  85±18† 
RWT (ratio)                                 0.48±0.15                     0.45±0.10                   0.48±0.13                               0.45±0.11 
______________________________________________________________________________________________________ 
†p<0.001, * p<0.05 versus baseline values. LVEDD, left ventricular end diastolic diameter; LVESD, LV end systolic diameter; PWT, LV 
posterior wall thickness; IVS, Interventricular septal wall thickness. See table 4 for other abbreviations. 
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Table 6.5 continued. Echocardiographic measurements at baseline and follow-up by treatment group. 
Months           0                      4     13                         25 
Patients receiving nifedipine, but not enalapril (group 3)  
Sample number          92   86     55    34 
LVEDD (mm)                              46.2±6.3                      44.8 ± 5.6*                      44.8 ± 5.3                              44.3± 5.2 
LVESD (mm)       30.5±5.1       29.1±4.8*                    28.5±6.3*                    29.3±4.5 
PWT (mm)       11.5±2.3       10.5±1.6†                    10.3±1.6†                    10.2±2.0† 
IVS (mm)                  12.3±2.4       11.3±1.9†                    11.6±1.9*                    11.3±2.5* 
FS (%)                                         34.8±6.9              35.7±7.2                      39.0±10.6*                             33.7±9.0 
EF (%)                                         63.4±8.9               64.3±9.7                       67.0±9.2*                               61.1±14.8 
LVM (g)                                       211.2±63.5                   177.0±50.4†                 176.5±43.5†                          169.0±44.3† 
LVMI (g/m2)                                   120±33                        101±24†                       101±22†                                98±24† 
RWT (ratio)                                  0.51±0.14                     0.48±0.10*                     0.47±0.10*                             0.47±0.13* 
____________________________________________________________________________________________________ 
 Patients receiving verapamil, but not enalapril (group 4) 
Sample number          25             22     12              11 
LVEDD (mm)                              43.0±5.1                      42.5 ± 3.5                      45.1 ± 5.3                              43.9± 4.5 
LVESD (mm)       28.7±7.1       27.7±4.1                    27.8±5.5                    28.3±4.0 
PWT (mm)       11.8±2.9       11.2±1.8                    11.2±1.8                    10.8±2.0 
IVS (mm)                  12.8±2.0       11.7±1.7*                    12.2±1.7                    11.2±2.1* 
FS (%)                                         34.6±6.7              34.8±7.9                       38.2±7.0                                35.5±5.8 
EF (%)                                         63.8±8.9              63.8±10.3                      68.9±7.7*                               64.1±8.5 
LVM (g)                                       195.5±47.2                 173.5±34.2*                  198.1±52.8                            171.3±37.8* 
LVMI (g/m2)                                  110±23                        99±19*                          108±26                                   98±16* 
RWT (ratio)                                 0.56±0.20                    0.53±0.10                    0.50±0.10                               0.50±0.11 
 
†p<0.001, * p<0.05 versus baseline values. 
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Table 6.6. Predictors of on-treatment left ventricular (LV) mass indexed for body surface area and relative wall thickness (RWT). 
                                 LVMI  (g/m2)                                  RWT (ratio) 
Characteristics         Estimate±SEM           p-value       Estimate±SEM        p-value                     
       Model with Conventional BP 
BMI  (g/m2)                                      -0.27± 0.22                           0.23                         0.21±0.11                0.072     
Age  (years)                                                         0.09±0.13                 0.85   0.17±0.12      0.008 
Gender  (female)                                       5.3±3.3                 0.11   0.74±1.72      0.66                 
Treatment group                                      -1.6±4.3                 0.71   -1.48±2.28      0.52               
Baseline LVMI /RWT                                           0.35±0.04              <0.0001              0.14±0.05                      0.003                    
Systolic BP (mm Hg)                                           0.13±0.05                  0.010  0.06±0.03      0.033                   
        
                                                                                     Model with 24-hour BP 
BMI  (g/m2)                                      -0.26± 0.22                           0.24                         0.21±0.11                0.072     
Age  (years)                                                         0.09±0.13                 0.50   0.20±0.07      0.005 
Gender  (female)                                       5.7±3.3                 0.09   0.76±1.71      0.66                 
Treatment group                                       -2.9±4.4                 0.51   -3.8±2.6      0.56               
Baseline LVMI /RWT                                           0.35±0.04              <0.0001              0.13±0.05                      0.007                    
Systolic BP (mm Hg)                                           0.15±0.08                  0.07   0.12±0.04      0.005                   
       Model with day BP 
BMI  (g/m2)                                     -0.24± 0.22                            0.29                         0.22±0.12                0.06     
Age  (years)                                                         0.10±0.13                 0.46   0.20±0.07      0.005 
Gender  (female)                                       5.7±3.3                 0.09              0.85±0.72      0.62                 
Treatment group                                       -3.3±4.4                 0.45   -4.04±2.6      0.49               
Baseline LVMI/RWT                                             0.35±0.04              <0.0001             0.13±0.05      0.006                    
Systolic BP (mm Hg)                                            0.06±0.08                           0.41   0.09±0.04      0.017                                                                               
       Model with night BP 
BMI  (g/m2)                                    -0.32± 0.22                             0.16                         0.20±0.12                 0.097     
Age  (years)                                                       0.09±0.13                 0.50   0.19±0.07      0.006 
Gender  (female)                                     5.8±3.3                 0.08   0.83±1.70      0.62                 
Treatment group                                      -1.9±4.4                 0.66   -3.33±2.65      0.65               
Baseline LVMI /RWT                                          0.34±0.04               <0.0001              0.13±0.05          0.007                    
Systolic BP (mm Hg)                                          0.19±0.07                              0.010                        0.11±0.04                       0.005 
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Combining the groups of patients receiving either nifedipine or verapamil SR as initial 
therapy or at follow up, and who did not receive either enalapril as additive therapy, 
revealed the same effects (data not shown). 
 
6.4 DISCUSSION 
 
The main finding of the present study is that in hypertensive patients of African 
descent treated and followed up for 25 months, several indices of LVH remained 
positively and independently associated with conventional and nocturnal systolic BP. The 
use of the ACE inhibitor, enalapril, conferred no appreciable additional benefit on indices 
of LVH, over that mediated by the decrease in the conventional and nocturnal BP, and its 
effects did not differ from those of treatment regimens not including an ACE inhibitor. 
In the present study the overall reduction in LV mass was ~15% after 4 months 
and ~17% after 25 months of therapy. Quantitative reviews of randomised, controlled 
studies of antihypertensive agents of the same class studied by us have reported on 
reductions of LV mass between 8 and 12% over an average treatment period of ~27 
weeks (Schmieder et al 1998) and also between ~8 and 16% over an unspecified period 
(Fagard3 1995). More recent original randomized, controlled studies have reported on 
reductions in LVM of ~11.5% (Devereux et al 20041) and ~11-12.7% (Devereux et al 
2001) over one year of treatment and ~16% after 2 years of study (Devereux et al 20041, 
Devereux et al 2002). The apparently greater reduction in LVM noted over a shorter 
treatment period in the present as compared to previous studies (Schmieder et al 1998, 
Devereux et al 20041, Fagard3 1995; Devereux et al 2001; Devereux et al 2002) could be 
explained by a higher proportion of patients being treated to target diastolic (72%) and 
systolic (62%) BP, than in other studies (for example ~40% of patients were treated to 
target BP in the LIFE study [Dahlöf et al 20021]). 
Few studies, all with small sample sizes, have reported on reductions in LVM on-
treatment in mild-to-moderate hypertension in patients of only African descent 
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(Skoularigis et al 1994, Middlemost et al 1994, Roman et al 1998). The longest period of 
follow-up in these studies was three months (Skoularigis et al 1994). Nevertheless, the 
degree of change in LVM index reported on in the present study is consistent with that 
previously shown to occur after three months of treatment (~16-19%) (Skoularigis et al 
1994, Middlemost et al 1994). In these studies (Skoularigis et al 1994, Middlemost et al 
1994) ambulatory BP was also used to define BP control and subsequently uptitrate or 
assign additional therapy. In a previous study conducted where a large proportion of the 
study sample consisted of African-Americans, LVM decreased at most by ~7% over six 
months of treatment (Roman et al 1998). A potential explanation for the difference 
between the present study and this prior study (Roman et al 1998) is not apparent. 
The present study is the first large-scale study to formally explore the relative 
importance of drug class versus BP lowering as determinants of in-treatment LVM 
reduction in a group of African ancestry. In this regard, LVM decreased to a similar 
degree in all study groups and was associated with a decline in nocturnal BP. In contrast 
to the present study, a meta-analysis of 109 studies including open and uncontrolled 
studies, has suggested that treatment-induced reductions in LVM were greater with ACE 
inhibitors than with other drug classes despite similar reductions in conventional BP 
(Dahlöf et al 1992). However, subsequent quantitative reviews of studies of a high 
scientific quality have not supported the contention that ACE inhibitors are more effective 
than calcium channel blockers or diuretics at reducing LVM (Schmieder et al 1998, 
Fagard3 1995). More recent original studies comparing ACE inhibitor and calcium channel 
blocker therapy also showed similar reductions in LVM between these drug classes 
(Devereux et al 2001). The quantitative effects of ACE inhibitors and calcium channel 
blockers on LVM reported on in the present study are consistent with those previously 
shown to occur in hypertensive patients of African descent after 3 months of treatment 
with enalapril (~19%) and nifedipine (~16%)(Skoularigis et al 1994, Middlemost et al 
1994). 
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The attenuated effect of calcium channel blockers on LVM reduction reported on 
in early quantitative reviews (Dahlöf et al 1992), and large-scale studies (Gottdiener et al 
1997) may be ascribed to the use of non-dihydropyridine rather than dihydropyridine 
calcium channel blockers. Indeed, in the present study, the non-dihydropyridine calcium 
channel blocker, verapamil, reduced LVM by only ~7% over a 25-month treatment period. 
However, although not statistically different, LVM index tended to be lower at baseline 
and mean ambulatory BP higher on-treatment in the verapamil-treated as compared to 
the other groups. Moreover, study group was not associated with in-treatment LVM when 
accounting for baseline LVM index or in-treatment conventional or ambulatory BP in the 
statistical model. 
In-treatment reductions in LVM may be achieved by decreases in LV wall 
thickness and internal dimensions. In the present study, both LV wall thickness and LV 
end diastolic diameter were reduced at all time points studied and in each of the 
treatment groups. However, as indicated by the decrease in LV relative wall thickness at 
each time point in all study groups, the change in LV wall thickness was comparatively 
greater than that for LV end diastolic diameter. These changes therefore support the 
notion that on-treatment reductions in LVM are largely achieved by alterations in wall 
thickness rather than internal diameters. 
A limitation of the present study is that after 25 months of treatment less than half 
the sample remained in the study. However, this was adjusted for using a proc mixed 
model in the statistical analysis. A second potential limitation of this study was that it was 
conducted with an open-label design. Nevertheless, ambulatory BP was employed to 
account for observer bias in BP measurements, and echocardiographic measurements 
were analyzed by an investigator unaware of the BP, treatment arm and the clinical data 
of the patients. Third, statistical analysis was performed on groups to which patients had 
not necessarily been randomised. This approach was required in order to assess the BP-
independent impact of ACE inhibitors on LVM in patients assigned both at randomisation 
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and during follow-up to receive ACE inhibitors. Fourth, although a high proportion of 
patients had LVH, this study was not specifically conducted in patients with LVH.  
The present study provides insight into new studies being conducted to explore 
the comparative benefits of antihypertensive agents on target organ damage in patients 
with mild-to-moderate hypertension. In the light of the development of novel 
antihypertensive agents designed to block the actions of the renin-angiotensin system 
(Gradman et al 2005), additional benefits conferred on LVM regression are expected to 
be mediated largely through reductions in BP in groups of African ancestry at least. 
In conclusion, the results of the present study indicate that in the treatment of 
mild-to-moderate hypertension in groups of African descent, the use of an ACE inhibitor 
confers no additional benefits on LVM beyond that produced by effects on BP alone. 
These data would support the notion that therapeutic class of antihypertensive agent is 
not as important as BP in the reduction of LVM in mild-to-moderate hypertension in 
groups of African ancestry. 
  
 
- 140 - 
 
 
 
 
      Chapter 7 
 
 
Changes in Ambulatory Blood Pressure Predict Regression 
of Left Ventricular Hypertrophy in Patients of African Ancestry 
Receiving Agents Influencing the Renin-Angiotensin System. 
  
 
- 141 - 
 
ABSTRACT 
Agents that target the renin-angiotensin system (RAS) appear to produce BP-
independent effects on LVM. Hypertensives of African ancestry have distinct BP 
responses to antihypertensives that target the RAS. Whether decreases in BP associated 
with the use of agents that specifically target the RAS predict regression of LVH in 
patients of African ancestry is uncertain. Patients with a mean daytime diastolic 
ambulatory BP (ABP)>90 mm Hg and LVH on echocardiography received candesartan 
cilexetil 8-16 mg once daily for 2 months followed by the addition of hydrochlorothiazide 
12.5 mg daily for a further month and subsequently ramipril 2.5-5 mg daily for another 2 
months if diastolic ABP remained>90 mm Hg. The impact of changes in ABP on 
alterations in LVM index (LVMI) was assessed. Of the 86 patients starting, 47 completed 
the study. Candesartan monotherapy produced only modest decreases in ABP (from 
153+17/95+6 to 151±18/93±7 at 2 months, p<0.05). The addition of a diuretic resulted in 
a striking decrease in ABP (to 139±21/87±9 at 3 months, p<0.0001 versus baseline), an 
effect that was only partially augmented by the addition of ramipril (p<0.05). LVMI 
decreased from 122±20 to 111±23 g/m2 (p<0.005) with treatment. Adjusting for gender, 
changes in systolic ABP (daytime, r=0.46, p=0.006) were predictive of changes in LVMI. 
In conclusion, these results suggest that in hypertensive patients of African ancestry 
receiving therapy targeting the RAS and a diuretic agent, changes in systolic BP may be 
an appropriate surrogate for target organ effects. 
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7.1 INTRODUCTION 
 
As underscored throughout the present thesis, LVH is an independent predictor of 
CV mortality and morbidity in patients with hypertension (Levy et al 1990, Koren et al 
1991). A decrease in LVM following the use of antihypertensive therapy is associated with 
beneficial effects on the vasculature, the incidence of arrhythmic events, cardiac 
dysfunction and morbidity and mortality in hypertensive patients, effects that have 
frequently been reported to be independent of conventional BP (Hansson et al 1991; 
Gonzalez-Fernandez et al 1993; Grandi et al 1989; Dahlof et al 20022). Hence, regression 
of LVM is a crucial clinical indicator of beneficial effects of antihypertensive agents. As 
highlighted in chapter 1 and in the previous chapter, recent evidence suggests that 
regression of LVH and the associated improvements in CV outcomes following the use of 
angiotensin II (AII) receptor antagonists and angiotensin converting-enzyme inhibitors 
(ACE-I) is to some extent independent of BP changes in hypertensive patients (Dahlof et 
al  2002 2, Okin et al  2003, Malmqvist et al 2001). The outcome of these studies (Dahlof 
et al  2002 2, Okin et al  2003, Malmqvist et al 2001) raises the question of whether 
changes in BP following the use of AII receptor antagonist and ACE-Is, are an 
appropriate clinical index of modifications in target organ damage in hypertensives. 
Recent evidence in patients of European ancestry indicates that changes in BP 
following the use of an AII receptor blocker are indeed associated with reductions in LVM 
in patients with LVH (Nystrom et al 2002). Whether this effect is noted in all populations, 
in particular populations of African ancestry whose BP responses to blockers of the renin-
angiotensin system (RAS) are quite distinct from other groups (Sareli et al 2001, 
Woodiwiss et al 2006), has not been determined. Indeed, previous data from our group 
suggests that the use of an ACE-I may result in a reduction in LVM in hypertensives of 
African ancestry in association with little change in BP (Middlemost et al 1994). Although, 
in the previous chapter of the present thesis I was able to demonstrate that the use of an 
ACE-I produced no appreciable benefit over that of BP changes in mediating a reduction 
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of LVM over a 25 month treatment period, in this study, patients were not selected for the 
presence of LVH. Consequently, further studies are required to ascertain whether 
potential class-specific effects of RAS blockers on LVM mask BP effects on the 
regression of LVH in groups of African ancestry. The question of whether decreases in 
BP predict regression of LVH is of particular importance in groups of African ancestry who 
have a higher prevalence of LVH (Danzer et al 2005) and in whom electrocardiograph 
criteria are poor indicators of LVH (Lee et al 1992), thus necessitating the use of other 
clinical indicators of regression of LVH. 
In the present study I therefore assessed the relationship between changes in BP 
and alterations in LVM following the use of agents that target the RAS (an AII receptor 
blocker and an ACE-I) used together with a diuretic agent, in hypertensives of African 
ancestry with LVH. Both an AII receptor blocker and an ACE-I were studied as a degree 
of synergy exists in this combination (Mogensen et al 2000). 
 
7.2 METHODS 
 
7.2.1 Patients, study design and blood pressure measurement 
 
This was a single center, prospective, open-label study, conducted at Chris Hani-
Baragwanath Hospital from 1999 through to 2001. Men and women aged 21-to-70 years, 
without significant concomitant cardiovascular or non-cardiovascular disease, but who 
nevertheless had LVH as determined from echocardiograms, were recruited. Women of 
reproductive age had to apply appropriate contraception. All patients gave written 
informed consent before inclusion into the study. 
Patients were initially screened using a Dinamap 1846 SX vital signs monitor 
(Critikon Inc, Tampa, FL) as previously described (Borrow et al 1982). If the mean 
diastolic BP was >90 mm Hg (10 measurements over 30 minutes taken in a sitting 
position) the patients underwent echocardiography to determine the presence of LVH. 
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LVH was defined as a LVM indexed to body surface area (LVMI) >120 g/m2 in males and 
>100 g/m2 in females. These criteria were used to define LVH, instead of the thresholds 
defined in chapter 2, as they are based on mortality data rather than on data obtained 
from healthy populations. Patients fulfilling inclusion and exclusion criteria underwent a 
two-week washout period followed by a two-week placebo run-in phase. Patients whose 
mean diastolic BP remained >90 mm Hg on Dinamap measurements then had 24 hour 
ambulatory BP monitoring performed using a SpaceLabs model 90207 oscillometric 
device (SpaceLabs Inc, Redmond, WA), programmed to obtain readings every 15 
minutes from 6.00 to 18.00h and every 20 minutes from 18.00 to 6.00h (O'Brien et al 
1991) . Patients whose mean ambulatory daytime diastolic BP was 90 mm Hg and 110 
mm Hg and mean daytime systolic BP was 180 mm Hg were subsequently considered 
eligible. Patients were excluded if their medication compliance during the placebo run-in 
phase was poor (<80% or >120% of the expected tablet count). 
Eligible patients received candesartan cilexetil 8 mg once daily and if after a 
month BP control was not achieved (office diastolic BP >90mmHg) the dose of 
candesartan cilexetil was increased to 16 mg. At the end of the first two month period of 
the study ambulatory BP monitoring was again performed and patients whose mean 
daytime diastolic BP was <90 mm Hg continued on the same therapy. If daytime diastolic 
BP <90 mm Hg was not achieved at the end of the initial two month treatment period, 
hydrochlorothiazide (HCTZ) 12.5 mg once daily was added and ambulatory BP 
monitoring again performed after another month. If daytime diastolic BP was still 90 mm 
Hg, patients were given ramipril 2.5 mg daily for a month, and the dose increased to 5 mg 
daily if required. After 5 months final ambulatory BP monitoring and echocardiography 
were performed. Patients were withdrawn from the study if at any follow-up visit the mean 
daytime ambulatory BP exceeded 220/114 mm Hg, or if they experienced any serious 
adverse event whilst receiving combination therapy. 
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7.2.2 Echocardiography 
 
Two-Dimensional targeted M-mode echocardiograms were obtained with a 
Hewlett Packard Sonos 2500 system using a 2.5 MHz transducer using techniques 
described in chapter 2. The echocardiograms were analyzed according to the American 
Society of Echocardiography recommendations (Sahn et al 1978). Left ventricular mass 
was derived according to an anatomically validated regression method that corrects LVM 
estimates obtained from recommended measurements (Devereux et al 1986). In the 
present study LVM was indexed for body surface area to ensure that LVH was 
hypertensive and not adiposity-induced. Replicated LVM values obtained by the two 
persons performing the measurements required to calculate LVMI showed that the inter- 
and intra-observer coefficients of variation were 12.4% and 11.4% respectively. 
 
7.2.3 Data analysis 
 
Database management and statistical analysis were performed with SAS 
software, version 8.2 (SAS Institute Inc, Cary, NC). Within-group differences in 
continuous measurements were tested with repeated measures analysis of covariance 
with gender as a covariate. Proportions were compared using the Fisher’s exact test. 
Stepwise multiple regression models were used to determine predictors of LVMI and 
Pearson correlation coefficients between ambulatory BP measurements and LVMI were 
calculated. 
 
7.3 RESULTS 
 
7.3.1 Baseline characteristics, withdrawals, adverse events and medication 
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Of 167 patients screened for the study, 86 patients who fulfilled inclusion and 
exclusion criteria were entered into the study. From the group recruited, 47 patients 
completed five months of treatment who were included in the analysis. Importantly, the 
characteristics of the 47 patients who completed the study were similar to the group 
initially recruited (Table 7.1). Twenty-one of the initial 86 patients recruited were 
withdrawn because of mean daytime ambulatory BP values that exceeded 200/114 mm 
Hg on subsequent visits, 7 defaulted, 1 died of a motor vehicle accident, 1 suffered a non-
fatal stroke, 2 patients developed anemia and 4 patients an ACEI-related cough. Three 
patients did not have optimal echocardiograms at the end of the study. During the course 
of the study 8 patients suffered headaches, 7 articulation aches, and 5 backaches. The 
study group was mostly female with a high body mass index (Table 7.1). No significant 
changes in mean values of biochemical parameters at the end of treatment period were 
noted. 
Of the 47 patients included in the analysis, at the end of the treatment period 3 
patients remained on monotherapy with 16 mg candesartan daily, 12 patients were 
receiving 16 mg candesartan and 12.5 mg HCTZ daily, 10 patients were receiving 16 mg 
candesartan, 12.5 mg HCTZ and 2.5 mg ramipril daily, and the remaining 22 patients 
were receiving maximum doses of all three agents. 
 
7.3.2 Blood pressure response 
 
In those patients included in the final analysis a continuous decline in BP was 
noted over the time course of the study (Table 7.2). Monotherapy with candesartan 
produced only modest BP effects (Table 7.2). After two months of candesartan 
monotherapy only 2 of 47 patients had achieved BP control, defined as mean daytime 
ambulatory BP <140/90 mm Hg. However, the addition of HCTZ at two months resulted in 
a striking decrease in ambulatory BP as determined at 3 months (Table 7.2). Thirty four 
% of patients (16 of 47) achieved controlled BP values after 3 months of therapy. The  
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Table 7.1:  Baseline characteristics 
Initially recruited  Completed 
  n=86      n=47 
_______________________________________________________________________ 
Gender (% female)     81        83 
Age (years)                    53.5±10.2              53.3±9.4 
Duration of hypertension (years)         4.5±6.3   4.4 + 6.2 
Newly diagnosed (%)     31        32 
Body mass index (kg/m2)         31.5 + 6.5   31.4 + 6.6 
Serum K+ (mmol/l)           3.6±0.4   3.7 + 0.4 
Serum glucose (mmol/l)          5.0 + 2.1   5.1 + 2.3 
Total cholesterol (mmol/l)          5.0 + 1.1   5.1 + 1.1 
Serum creatinine (µmol/l)          72 + 15   73 + 16 
Blood Pressure 
Clinic* SBP/DBP (mm Hg)   160 + 18/98 + 6      158 + 16/97 + 7 
24 hour ambulatory SBP/DBP (mm Hg) 154 + 16/95 + 6      153 + 17/95 + 6 
_______________________________________________________________________ 
SBP, systolic blood pressure; DBP, diastolic blood pressure. 
* Oscillometric measurement. 
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Table 7.2. Effect of antihypertensive therapy with agents that target the RAS and diuretics on blood pressures in hypertensives of African 
ancestry. 
Baseline                  2 months                  3 months                5 months                 Change in BP        
                                                                                                                                     at 5 months 
_______________________________________________________________________________________________________________ 
Clinic# SBP/DBP (mm Hg)   158+16/97+7          152+22*/88+8**       140+25/84+11**     132+23/81+10**†     -25+20/-16+11 
24 hour ambulatory SBP/DBP (mm Hg) 153+17/95+6          151+18/93+7*        139+21/87+9**   135+20/83+10**†   -18+16/-11+ 9 
Day ambulatory SBP/DBP (mm Hg)  159+17/100+5        156+17/98+6*        144+22/92+10**   139+20/88+10**†    -19+17/-12+10 
Night ambulatory SBP/DBP (mm Hg) 148+19/89+10        145+21/87+10        133+20/87+10**   130+ 20/79+10**†     -18+17/-11+11 
_______________________________________________________________________________________________________________ 
* p<0.05, ** p<0.0001 versus baseline; † p<0.05 versus 3 months except for night ambulatory SBP. # oscillometric BP. 
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addition of ramipril only modestly accentuated the decline in BP (Table 7.2). However, 
with the addition of ramipril, 60% of patients (28 of 47) achieved BP control by the end 
of the study. 
 
7.3.3 Left ventricular mass 
 
After 5 months of therapy a decrease in LVMI occurred (Table 7.3). Regression 
of LVH was achieved by a reduction in LV wall thickness and not by a decrease in 
LVEDD (Table 7.2). Decreases in ambulatory 24 hour, daytime and nighttime systolic 
BP noted at 5 months were correlated with reductions in LVMI (Figures 7.1 and 7.2). In 
addition, the decrease in 24 hour, daytime and nighttime systolic BP noted at 5 months, 
were independent predictors of reductions in LVMI adjusted for gender (24 hour systolic 
ABP, r=0.46 [Figure 7.2]; daytime systolic ABP, r=0.46, p=0.006 and nighttime systolic 
ABP, r=0.44, p=0.009). Neither changes in ambulatory 24 hour, daytime nor nighttime 
diastolic BP values were significantly correlated with decreases in LVMI (Figure 7.1), 
although a trend effect for a correlation between changes in 24 hour diastolic BP and 
change in LVMI was noted. 
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Table 7.3. Effect of antihypertensive therapy with agents that target the renin-angiotensin 
system and diuretics on echocardiograph measurements in hypertensives of African 
ancestry with left ventricular hypertrophy. 
 
    Baseline   5 months    Change in values 
_______________________________________________________________________ 
LVESD (mm)   32.1 + 6.4  32.1 + 4.9  -0.02 + 0.5 
LVEDD (mm)   45.8 + 5.4  47.9 + 5.5   2.1 + 3.7* 
PWED (mm)   11.5 + 1.5  10.1 + 1.8*  -1.4 + 1.5* 
IVS (mm)   13.1 + 2.3  11.8 + 1.9  -1.3 + 2.4* 
FS (%)    32 + 6   33 + 6    1.1 + 7.2  
EF (%)    60 + 9   61 + 8    1.5 + 9.8 
LVM (g)   216 + 43  193 + 45  -23 + 40* 
LVMI (g/m2)   122 + 20  111 + 23*  -11 + 25* 
RWT (ratio)   0.51 + 0.10  0.43 + 0.10*  -0.08 + 0.08* 
_______________________________________________________________________ 
LVESD, left ventricular end systolic diameter; LVEDD left ventricular end diastolic 
diameter; PWED, posterior wall thickness at end diastole; IVS, interventricular (septal) 
wall thickness at end diastole; FS, endocardial fractional shortening; EF, ejection fraction; 
LVM, left ventricular mass; LVMI, LVM index; RWT, relative wall thickness.* p<0.001 
compared to baseline. 
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Figure 7.1. Partial correlation coefficients between change in ambulatory (ABP) blood 
pressure and change in left ventricular mass index following 5 months of antihypertensive 
therapy with agents that target the renin-angiotensin system together with diuretics given 
to hypertensive patients of African ancestry with left ventricular hypertrophy. 
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Figure 7. 2. Relationship between change in 24 hour ambulatory systolic blood pressure 
and change in left ventricular mass index following 5 months of antihypertensive therapy 
with agents that target the renin-angiotensin system together with diuretics given to 
hypertensive patients of African ancestry with left ventricular hypertrophy. The correlation 
coefficient is provided in figure 7.1. 
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7.4 DISCUSSION 
 
The main findings of the present study are that in hypertensive patients of African 
ancestry with LVH, changes in ambulatory systolic BP mediated by co-administration of 
an angiotensin II receptor blocker, candesartan, together with HCTZ (12.5 mg) and the 
ACE-I, ramipril (in 68 % of patients) predict regression of  LVH. 
Although decreases in LVM are associated with BP changes in patients of 
European ancestry receiving antihypertensive agents that target the RAS (Nystrom et al 
2002), prior data from our group suggest that decreases in LVM in patients of African 
origins receiving ACE-Is can occur with little change in BP (Middlemost et al 1994). The 
question of whether agents that target the RAS mediate effects on LVM in patients of 
African ancestry that can be predicted by BP changes is of particular importance as the 
predominant RAS profiles are quite distinct in patients of African ancestry (Luft et al 1991) 
and BP responses to RAS inhibitors are unique in comparison to other population groups 
(Sareli et al 2001, Woodiwiss et al 2006). The present study provides clear evidence that 
in hypertensive patients of African ancestry with LVH, receiving therapeutic agents 
targeting the RAS, change in ambulatory BP is associated with regression of LVM. 
This is the first study to show that in subjects of African ancestry who have a high 
prevalence of LVH (Drazner et al 2005), BP changes following the use of 
antihypertensive agents predict regression of LVH irrespective of whether previous 
therapy had been utilized. Prior studies conducted in this population group have 
demonstrated that change in ambulatory BP predicts decreases in LVM in newly 
diagnosed, but not in previously treated patients irrespective of whether LVH was present 
(Skudicky et al 2002, chapter 5). Although data in previously treated patients of African 
descent (Skudicky et al 2002, chapter 6) cast doubt on the importance of BP 
measurements as an appropriate clinical index of target organ effects (specifically LVH) in 
previously treated patients of this population group, to-date no study has been conducted 
to assess the impact of changes in BP on LVM in previously treated patients with LVH.  
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Data from the present study indicate that alterations in BP are indeed an appropriate 
index of beneficial effects on LVM in previously treated patients (69% of the study group) 
with LVH. 
A potential limitation of the present study is that approximately 45% of patients 
had to be withdrawn, of which the majority (26%) were withdrawn because daytime 
ambulatory BP values exceeded 200/114 mm Hg. These data are entirely consistent with 
the relatively low number of patients of African ancestry that respond to antihypertensive 
agents that target the RAS (Sareli et al 2001, Woodiwiss et al 2006). Importantly, 
however, it is also acknowledged that therapeutic agents that target the RAS are 
efficacious in a proportion of hypertensive patients of African ancestry when used 
together with diuretic agents (Middlemost et al 1994), as in the present study. The aim of 
the present study was not to evaluate the efficacy of agents that target the RAS when 
combined with a diuretic on BP in hypertensive subjects of African ancestry. The question 
I wished to answer is whether decreases in LVM index are indeed associated with 
changes in BP mediated by these agents in those patients of African ancestry who 
respond to these agents. In this regard, in those patients who did not require withdrawal 
from the study, a marked antihypertensive response was noted, thus allowing for an 
evaluation of the relationship between LVH regression and BP changes. 
 As the major change in BP noted in the present study occurred with the addition of 
the diuretic agent, it may be argued that the relationship between changes in BP and 
LVM index noted in the present study are attributed to diuretic effects alone and have little 
to do with RAS blockade. However, diuretic agents at this dose, when used as 
monotherapy, do not mediate such profound decreases in systolic BP (~12 mm Hg on 
average in 24-hour systolic BP) in this ethnic group (Skoularigis et al 1995, Sareli et al 
2001). Therefore, the impact of antihypertensive therapy on BP and LVM index can only 
be attributed to combination therapy and thus in-part to RAS blockade. 
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In summary, the results of the present study indicate that changes in BP are 
indeed associated with regression of LVH in patients of African ancestry receiving 
therapeutic agents that target the RAS together with a diuretic agent. These results 
suggest that BP measurements may be used as a clinical indicator of regression of LVH 
in hypertensive patients of African ancestry receiving these agents. 
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Chapter 8 
 
 
Effect of Slow-release Indapamide and an ACE-I as 
Compared to Amlodipine on 24-hour Blood Pressure and Left 
Ventricular Mass Reduction in Hypertensive Patients of 
African Ancestry. 
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ABSTRACT 
In the treatment of hypertension in subjects of African origins, there is question as 
to whether diuretic therapy, followed by the addition of an angiotensin-converting enzyme 
inhibitor (ACE-I) is as effective as calcium channel blockers on BP and LVM. In the 
present study I therefore compared the effects of slow release (SR) indapamide with the 
addition of an ACE-I to that of the calcium channel blocker, amlodipine, when used as 
initial therapy, on BP and LVM over 6 months of treatment in this ethnic group. Patients 
with mean daytime ambulatory diastolic BP (DADBP) ≥90 mm Hg and ≤110 mm Hg 
(n=125, age 53 + 11, 68% female) were randomized to receive open-label indapamide 
SR 1.5 mg or amlodipine 5 mg. If DADBP at 1 month was ≥ 90 mm Hg, perindopril 4 mg 
was added to indapamide SR or the dose of amlodipine was increased to 10 mg. After 1 
month, there was an equivalent decline in systolic and diastolic BP in the two groups 
(p<0.0001). In the indapamide SR treated group (n=62) the daytime BP decreased from 
153±12/101±6 to 138±15/92±10 and in the amlodipine treated group (n=58) it decreased 
from 152±13/99±5 to 138±12/91±8. At 6 months DABP decreased to 130±15/86±8 and to 
129±11/85±5 mm Hg for the indapamide SR (n=42) and amlodipine (n=44) treated 
groups respectively. Both groups showed equivalent regression in LVM index. These data 
suggest that in hypertensive patients of African ancestry initiating therapy with the 
diuretic, indapamide SR and then adding the ACE-I, perindopril 4 mg is equally as 
effective as amlodipine therapy at reducing BP and modifying target organ damage. 
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8.1 INTRODUCTION 
 
As compared to other ethnic groups, in groups of African descent, agents that 
block the renin angiotensin system (RAS), such as angiotensin-converting enzyme 
inhibitors (ACE-I) and angiotensin II receptor blockers are not as effective at reducing BP 
(Cushman et al 2000, The ALLHAT Officers and Coordinators for the ALLHAT 
Collaborative Research Group 2002, chapter 7) or decreasing LVM (Devereux et al 
20041, Sareli et al 2001, Radevski et al 1999; Skoularigis et al 1994). In many patients 
this does not pose a treatment dilemma as the South African Hypertension Society and 
the Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation 
and Treatment of High Blood Pressure (JNC 7) guidelines recommend thiazide diuretics 
and not RAS blockers as initial therapy for the treatment of uncomplicated hypertension 
(Hypertension Society of Southern Africa, [Seedat et al 2006], The Joint National 
Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure 
2003). However, there are many compelling indications for the use of RAS blockers in the 
treatment of hypertension, one of which is hypertension with LVH (Hypertension Society 
of Southern Africa, [Seedat et al 2006], The Joint National Committee on Prevention, 
Detection, Evaluation, and Treatment of High Blood Pressure 2003). As LVH is likely to 
be highly prevalent in groups of African descent (see chapters 1 and 2), the ethnic-
specific effects of RAS blockers may pose a management decision problem. However, a 
potential solution to this dilemma is to initiate treatment with a diuretic in patients of 
African ancestry requiring RAS blockers, and then add a RAS blocker, a combination that 
is thought to be no less efficacious than in other ethnic groups. However, low-dose 
thiazide diuretic agents do not achieve ambulatory BP control in patients of African 
descent (Skoularigis et al 1995). Moreover, in a multi-arm combination trial, a 
dihydropyridine calcium channel blocker (CCB), when used as monotherapy, was shown 
to be more efficacious than other classes of antihypertensive agents including low dose 
hydrochlorothiazide (HCTZ) (12.5-25 mg daily), a thiazide diuretic, as determined from 24  
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hour ambulatory BP monitoring in patients of African ancestry (Sareli et al 2001). Thus, it 
appears at least from a BP perspective, that efficacious first-line therapy in groups of 
African descent may not be diuretic agents, but rather CCBs. 
Nevertheless, using ambulatory BP monitoring to assess efficacy, our group have 
recently demonstrated that monotherapy with the diuretic indapamide was superior to low 
dose HCTZ (Radevski et al 2002) in the management of hypertension in patients of 
African descent with mild-to-moderate hypertension. Whether indapamide used as initial 
therapy, with an ACE-I added as additional therapy, mediates equivalent antihypertensive 
actions and beneficial effects on LVM when compared to dihydropyridine CCB therapy in 
groups of African descent has not been evaluated. Therefore, in the present study I 
compared the effect of slow-release (SR) indapamide followed by the addition of an ACE-
I, perindopril, to that of the dihydropyridine CCB, amlodipine, on ambulatory BP and LVM 
in patients of African descent with mild-to-moderate hypertension. 
 
8.2 METHODS 
 
8.2.1 Study population 
 
This was a single-center, open-label, randomized, prospective study, conducted at 
Chris Hani Baragwanath Hospital, from 2001 through 2002. Men and women, aged 21-70 
years, without significant concomitant cardiovascular or non-cardiovascular disease were 
recruited. Women of reproductive age had to apply adequate contraception. All patients 
gave written informed consent before inclusion into the study. 
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8.2.2 Blood Pressure measurements and targets 
 
Patients were initially screened using the Dinamap 1846 SX vital signs monitors 
(Critikon Inc, Tampa, FL) using an approach previously described (Borrow et al 1982). 
Eligible patients were enrolled in a wash-out placebo run-in phase of 2 weeks. Thereafter, 
a 24 hour ambulatory BP monitoring was performed using SpaceLabs 90207 oscillometric 
monitor (SpaceLabs Inc, Redmond, WA), programmed to obtain readings every 15 
minutes from 06H00 to 18H00 and every 20 minutes from 18H00 to 06H00 (O’Brien et al 
1991). If the mean daytime ambulatory diastolic BP was ≥90 mm Hg and ≤114 mm Hg, 
patients were randomized to one of two treatment arms: indapamide SR 1.5 mg once 
daily (Natrilix SR, Servier Lab), or amlodipine 5 mg once daily (Norvasc, Pfizer). Patients 
were excluded if their compliance during the placebo run-in phase was poor (<80% or 
>120% of the expected tablet count). Throughout the study conventional BP was 
measured according to the American Heart Association guidelines (Frohlich et al 1998). 
After one month of therapy, if the BP target was not achieved (daytime ambulatory 
diastolic BP ≥ 85 mm Hg), perindopril 4 mg o/d (Coversyl, Servier Lab) was added to the 
diuretic treated group or amlodipine was increased to 10 mg in the CCB treated group. 
Thereafter, patients continued on the same therapy for a further 5 months with visits at 
monthly intervals. After 2 months if a mean daytime diastolic ambulatory BP of less 100 
mm Hg and a decrease in the mean daytime diastolic ambulatory BP ≥ 10 mm Hg were 
not achieved, the patients were withdrawn from the study. Throughout the study patients 
that experienced any serious adverse events or had a daytime systolic ambulatory BP > 
180 mm Hg and a daytime ambulatory diastolic BP> 110 mm Hg were also withdrawn. 
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8.2.3 Echocardiography 
 
Two-dimensional targeted M-mode echocardiograms were obtained as described 
in chapter 2 with a Hewlett Packard Sonos 2500 system using a 2.5 MHz transducer at 
the end of the two-week washout phase, and after 2 and 6 months of therapy. The 
echocardiograms were analyzed according to the American Society of Echocardiography 
recommendations (Sahn et al 1978). Left ventricular mass was derived according to an 
anatomically validated regression method that corrects LVM estimates obtained from the 
recommended measurements (Devereux et al 1986). Left ventricular mass was indexed 
to body surface area to ensure that blood pressure, rather than adiposity-induced effects 
were noted. Replicated measurements of LVMI showed that the inter- and intra-observer 
coefficients of variation were 12.4% and 11.4% respectively. 
 
Statistical analysis 
 
Database management and statistical analysis were performed with SAS 
software, version 8.2 (SAS Institute Inc, Cary, NC). Between and within-group differences 
in continuous measurements were tested with multiple repeated measurements analysis 
of variance, adjusting for baseline BP values. Proportions were compared using the Chi 
square test or Fisher exact when necessary. 
 
8.3 Results 
 
Of the 283 patients screened for the study, 125 were randomized, 61 patients 
received amlodipine 5 mg/once daily (od) and 64 patients received indapamide SR 1.5 
mg o/d as initial treatment. The baseline study groups were mostly female with a high 
mean body mass index (BMI) (Table 8.1). There were no statistical differences between  
  
- 162 - 
 
 
Table 8.1. Baseline demographic characteristics of the study groups 
Amlodipine (n=61)    Indapamide SR (n=64) 
_______________________________________________________________________ 
Gender (n/% female)        43 (71)   42 (66) 
Age (years)       53.7 ± 10.5            51.6 ± 10.7 
Body weight (kg)      78.9 ± 14.6   77.8  ± 16.2   
Body mass index (kg/m2)      30.8 ± 6.5   29.9 ± 6.8 
Serum K+ (mmol/l)         3.7 ± 0.7   3.7 ± 0.9 
Serum glucose (mmol/l)        5.1 ± 1.6   5.3 ± 2.7 
Total cholesterol (mmol/l)        5.1 ± 1.0   5.2 ± 1.2 
Serum creatinine (µmol/l)         80 ± 18   84 ± 18 
Blood Pressure 
Conventional SBP/DBP (mm Hg)       151 ± 16 / 94 ± 8          153 ± 14 / 95 ± 8 
Heart rate (beats/min)   74 ± 10   74 ± 11 
24 hour ambulatory SBP/DBP (mm Hg)   148 ± 14 / 94 ± 6          148 ± 12 / 95 ± 6 
Daytime SBP/DBP (mm Hg)          152 ± 13 / 99 ± 5           153 ± 12 / 101 ± 6* 
Night-time SBP/DBP (mm Hg)         144 ± 16 / 89 ± 7           143 ± 15 / 90 ± 8 
_______________________________________________________________________ 
SBP, systolic blood pressure; DBP, diastolic blood pressure. * p =0.03 for daytime 
diastolic BP between the two groups. 
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baseline characteristics, except for the daytime diastolic ambulatory BP between the two 
groups (Table 8.1). From the cohort, 44 patients in the amlodipine treated group and 42 
patients in the indapamide SR treated group completed 6 months of treatment. Thirteen 
patients were withdrawn and 4 defaulted in the amlodipine treated group and 17 were 
withdrawn, and 5 patients defaulted in the indapamide SR treated group. Major adverse 
events requiring withdrawal were: angioneurotic oedema (1 patient) due to perindopril, 
severe dizziness (1 patient) due to indapamide SR; and pedal oedema (6 patients) and 
generalized oedema (1 patient). 
 
8.3.1 Blood pressure and heart rate 
 
The reduction in BP at 1 month of therapy was similar in both groups (Table 8.2). 
The decline in ambulatory daytime SBP/DBP after 1 month of therapy was 14/8 mm Hg in 
the amlodipine treated group and 15/9 mm Hg in the indapamide SR treated group (Table 
8.2). At 1 month BP control rates were similar in both groups. Using a target daytime 
diastolic ambulatory BP<85 mm Hg, 16% (9/58) and 23% (14/62) control rates were 
achieved for amlodipine and indapamide SR respectively. The daytime ambulatory 
systolic BP was <140 mm Hg in 55% (32/58) of patients in the amlodipine treated group 
and 61% (38/62) of patients in the indapamide SR treated group. The daytime ambulatory 
systolic and diastolic BP was less than 140/90 mm Hg in 35 % (20/58) of patients in the 
amlodipine treated group and 42% (26/62) of patients in the indapamide SR treated 
group. 
At both 2 and at 6 months, the decrease in BP and BP values achieved were 
similar between the groups (Table 8.2). Although the baseline daytime ambulatory 
diastolic BP was slightly higher in the indapamide SR treated group, at the end of the 
study, the indapamide SR treated group achieved BP control (daytime ambulatory  
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Table 8.2. Conventional, Dinamap and ambulatory blood pressures at baseline, 1 month and 6 months of therapy 
 
                    Baseline         1 month        6 months 
_____________________________________________________________________________________________________________________ 
Amlodipine, n=            61              58    44 
Conventional SBP/DBP (mm Hg)†    153 ± 15 / 97 ± 8   138 ± 15 / 90 ± 8*  127 ± 13 / 81 ± 8* 
Dinamap SBP/DBP (mm Hg)             151 ± 16 / 94 ± 8  136 ± 14 / 87 ± 8*  124 ± 15 / 79 ± 7* 
24-hour SBP/DBP (mm Hg)             148 ± 14 / 94 ± 6  134 ± 12 / 86 ± 8*  126 ± 11 / 81 ± 6* 
Daytime SBP/DBP (mm Hg)             152 ± 13 / 99 ± 5  138 ± 12 / 91 ± 8*  129 ±11 / 85 ± 5* 
Indapamide SR, n=    64                                              62                                42 
Conventional SBP/DBP (mm Hg)†      153 ± 14 / 97 ± 7*                  135 ± 15 / 88 ± 8*                   128 ± 14 / 85 ± 8* 
Dinamap SBP/DBP (mm Hg)              153  ± 14 / 95 ±7*                  135 ± 18 / 86 ±12*                  127 ± 18 / 81 ±10* 
24-Hour SBP/DBP (mm Hg)                148 ± 12 / 95  ± 6*                134 ± 15 / 87 ± 9*                   126 ± 16 / 81 ± 8* 
Daytime SBP/DBP (mm Hg)                153 ± 12 / 101 ±6*                138 ± 15 / 92 ±10*                 130 ± 15 / 86 ± 8* 
Nighttime SBP/DBP (mm Hg)              143 ± 15 / 90 ± 8*                 130 ± 15 / 83 ± 9*                  123 ± 17 / 77 ± 9* 
____________________________________________________________________________________________________________________ 
SBP/DBP; systolic blood pressure/diastolic blood pressure. * p < 0.0001 (between baseline and 1 month / 6 months) † Blood pressure was 
measured according to the recommendation of the American Heart Association. 
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 diastolic BP<85 mmHg) in 52% of patients (22/42), which was similar to that in the 
amlodipine treated group, where BP control was achieved in 52% (23/44) of patients. In 
those patients who remained on initial therapy, in the indapamide SR treated group only 3 
(7%) of patients remained controlled and in the amlodipine treated group only 4 (9%) 
patients remained controlled. After 6 months of therapy the daytime ambulatory systolic 
BP was less than 140 mm Hg in 86 % (38/44) of patients in the amlodipine treated group 
and 76% (32/42) of patients in the indapamide SR treated group. The daytime ambulatory 
systolic and diastolic BP was less than 140/90 mm Hg in 75 % (33/44) of patients in the 
amlodipine treated group and 67% (28/42) of patients in the indapamide SR treated 
group. The mean daytime and nighttime heart rate was similar in both groups and did not 
change significantly throughout the study (data not shown). 
 
8.3.2 Left ventricular mass and remodelling. 
 
The decline in systolic BP was associated with regression of LVMI after 2 and 6 
months of therapy (Figure 8.1). This regression was achieved by a reduction in posterior 
ventricular and inter-ventricular septal wall thickness (PWED, IVS) and not by a decrease 
in end diastolic diameter (LVEDD) (Table 8.3). Furthermore, a reversal of LV concentric 
remodelling was noted as evidenced by a reduction in RWT (Figure 8.2). The reduction in 
LVMI and in RWT was similar in both groups after 2 and 6 months of therapy (Figures 8.1 
and 8.2). 
 
8.3.3 Biochemistry 
 
No significant changes in biochemical parameters were noted with treatment 
except for a similar decrease in cholesterol concentrations in both groups (data not 
shown) following atorvastatin administration to four patients in the indapamide SR treated  
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Figure 8.1. Left ventricular mass index reduction after 2 and 6 months of therapy. † p< 
0.0001 (2 months versus baseline); * p < 0.001 (6 months versus  2 months). 
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Figure 8.2. Relative wall thickness reduction after 2 and 6 months of therapy.   † p< 
0.0001 (2 months versus baseline); * p < 0.001 (6 months versus 2 months). 
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Table 8.3. Echocardiographic data at baseline and after 2 and 6 months of 
treatment  
    
Baseline           2 months       6 months 
_______________________________________________________________________ 
Amlodipine (n=36) 
24-hour SBP/DBP (mm Hg) 147 + 12/ 93 + 6      126 + 9/ 82 + 5†      125 + 10/ 80 + 5 
LVEDD (mm)               49.1+ 5.2        49.9 + 4.6        48.8 + 3.5 
PWED (mm)             10.0 + 1.2        9.4 + 1.0†         8.7 + 0.8* 
IVSD (mm)            10.5 + 1.6        9.8 + 1.3†         9.1 + 0.9* 
LVM (g)            191 + 54        178 + 49†        154 + 27* 
Indapamide SR (n=37) 
24 H SBP/DBP (mmHg)     147 + 13/ 94 + 6        128 + 11/ 82 + 6†      128 + 16/ 82 + 9 
LVEDD (mm)            49.0 + 4.3         48.8 + 4.1         48.4 + 3.5 
PWED (mm)            10.3 + 1.4          9.5 + 1.2†          8.9+ 1.1* 
IVSD (mm)            11.1 + 1.8         10.0 + 1.4†         9.4 + 1.2* 
LVM (g)             200 + 54          176 + 49†         158 + 37* 
 
SBP/DBP, systolic blood pressure/diastolic blood pressure 
LVEDD, left ventricular end diastolic diameter 
PWED, posterior ventricular wall thickness 
IVS, inter-ventricular septal wall thickness 
LVM, left ventricular mass 
*p< 0.001 (2-6 months) † p < 0.0001 (baseline-2 months) 
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group and to seven patients in the amlodipine treated group. Potassium supplementation 
was required in two patients in each group. 
 
8.4 DISCUSSION 
 
The major findings of the present study are that in patients of African ancestry with 
mild-to-moderate hypertension: 1) monotherapy with indapamide SR  (1.5 mg o/d) 
decreases ambulatory and office BP to a similar extent as compared to amlodipine (5 mg 
o/d) after one month of therapy, 2) the combination of indapamide SR (1.5 mg) and 
perindopril (4 mg o/d) was equally as effective as amlodipine (10 mg o/d) at lowering BP 
after 2 and 6 months of therapy and 3) the decline in BP following therapy was associated 
with continued regression of LVM index and a decrease in RWT to an equivalent extent in 
both treatment groups. 
The present study is the first to compare the efficacy of the sustained release 
indapamide (thiazide diuretic) to that of the dihydropyridine CCB, amlodipine on 
ambulatory BP in subjects of African ancestry with mild-to-moderate hypertension. 
Equivalent efficacy was achieved. This is in contrast to the greater antihypertensive 
efficacy of CCB (including dihydropyridines) agents as compared to low dose HCTZ 
(12.5-25 mg daily) used in this ethnic group (Skoularigis et al 1995, Sareli et al 2001). 
The data in the present study are consistent with the comparable efficacy of indapamide 
SR 1.5 mg with amlodipine 5 mg at reducing systolic BP in elderly patients of mainly 
European ancestry with isolated systolic hypertension (Emeriau et al 2001). 
In the present study initial monotherapy failed to achieve control of BP to accepted 
therapeutic targets as determined by ABPM in the majority of patients. Similarly, in the 
ALLHAT study (The ALLHAT Officers and Coordinators for the ALLHAT Collaborative 
Research Group 2002) in which 35% of patients were of African ancestry and the initial 
office BP values in untreated patients in the diuretic (chlorthalidone) and the CCB   
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(amlodipine) treatment arms were 156/89 mm Hg and 157/90 mm Hg respectively, (as 
compared to a baseline office BP in the present study of 153/97 mm Hg), although the 
dose of chlorthalidone was up-titrated to 25 mg daily and the dose of amlodipine was 
increased to 10 mg daily, 63% of the patients required the addition of a  blocker, atenolol 
to achieve an office target BP of < 140/90 mm Hg. 
In the present study the equivalent effect on BP employing both therapeutic 
approaches was associated with similar reductions in LVM index and RWT. The 
significant reduction of RWT in both treatment groups underscores the favorable effect of 
antihypertensive therapy on LV remodeling. 
In summary this study supports the notion that initiating antihypertensive therapy 
with the diuretic indapamide and then subsequently adding an ACE-I produces similar 
antihypertensive effects and beneficial effects on LVM as a long-acting CCB in patients of 
African descent. In conclusion, the results of the present study support the use of 
indapamide as initial therapy, with an ACE-I added as additional therapy, in hypertensive 
patients of African ancestry who may require an ACE-I for compelling reasons, such as 
LVH. 
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As reviewed in chapter 1 of the present thesis, it is now well established that LVH 
is a risk factor for CVD (such as stroke, MI, cardiac death, heart failure etc.) beyond 
classical cardiovascular risk factors such as conventional BP. Importantly, there is 
substantial evidence from studies with large sample sizes to suggest that LVM is higher in 
African-Americans than in European-Americans (Skelton et al 2003, Lorber et al 2003, 
Kizer et al 2004, Rodriguez et al 2004, Drazner et al 2005) a difference that may translate 
into a higher prevalence of CVD. However, whether LVM is similarly elevated in groups of 
African descent living in Africa has not been determined. Consequently, in the initial part 
of the present thesis (chapter 2) I aimed to establish whether in healthy South Africans of 
African ancestry, thresholds for LVM are indeed higher than those previously described 
for studies defining thresholds for LVM in communities of European ancestry. 
In chapter 2 of the present thesis, in order to identify the thresholds for LVM in 
healthy individuals, I first established the most appropriate allometric signals that adjust 
for growth effects on LVM for the community of African descent living in South Africa that 
I studied. In 141 healthy individuals obtained from a random sample of nuclear families 
comprising 399 participants of African ancestry older than 16 years of age and living in 
metropolitan areas of Johannesburg, I determined that LVM adjusted for body surface 
area to the first power was an appropriate allometric signal to adjust for growth effects on 
LVM. The allometric signals that adjust for growth effects on LVM established in other 
populations considerably overadjusted for LVM in the group that I studied with marked 
negative relations noted between LVM indexed to height2.7 or body surface area1.5 and 
either height or body surface area. I subsequently determined the threshold values for 
LVM adjusted for body surface area and compared these against data described in other 
population groups. After adjusting for body surface area to the first power I noted upper 
thresholds of LVM index of 134 g/m2 for men and 112 g/m2 for women in clinically normal 
individuals in a community of African descent living in South Africa. As compared to  
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thresholds described for other population samples these thresholds were noted to be only 
~10 g/m2 higher in healthy men of African descent living in South Africa, and only ~5 g/m2 
higher in healthy women of African descent living in South Africa. 
24-Hour BP may be more closely associated with LVM than conventional BP, as it 
reflects BP load over a substantially greater time period. This may be particularly 
important in groups of African ancestry. Indeed, as compared to European-Americans, 
African-Americans have an attenuated nocturnal decrease in BP (Profant and Dimsdale 
1999, Wang et al 2006). Although data obtained from small studies suggest that this 
translates into a greater degree of target organ damage in groups of African ancestry 
(reviewed in chapters 1 and 3), these studies have largely had inconsistent outcomes. No 
large study has assessed whether ambulatory BP is a better predictor than conventional 
BP or a predictor independent of conventional BP in groups of African descent. Moreover, 
whether nocturnal decreases in BP play a substantial role in contributing to LVM in 
groups of African descent, or whether nocturnal BP is more important that daytime BP in 
contributing to LVM in groups of African ancestry has not been assessed in large studies 
with complete ambulatory BP profiles. These questions were addressed in chapter 3 of 
the present thesis. In this regard, I was able to show that after adjustments were made for 
sex, age, body mass index, non-independence of family members, antihypertensive 
treatment, and the presence of diabetes mellitus or an HbA1c>7.0%, neither the ratio of 
night-to-day BP, nor differences in night-to-day BP were associated with LVM indexed for 
body surface area. Moreover, after adjustments, conventional, 24-hour, daytime and 
night-time systolic BP (SBP) were all associated with LVM index, with equivalent relations 
noted for conventional (r=0.21, p<0.0005) and 24 hour (r=0.17, p<0.005) SBP and for 
daytime (r=0.17, p<0.005) and night-time (r=0.16, p<0.01) SBP. Diastolic BP was not 
independently related to LVM index. With conventional BP included as a covariate, 
neither 24-hour, daytime nor night-time BP were independently associated with  
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LVM index in the whole group. However, in sex-specific analysis, night-time BP was 
associated with LVM index independent of conventional BP in men (n=110, r=0.21, 
p<0.05). These data therefore provide some evidence to indicate that in persons of 
African descent, nocturnal BP may predict LVM index beyond conventional BP in men, 
but not in women. However, an increased sample of men is required to confirm these 
data. 
Left ventricular mass is partly determined by arterial stiffness, which may impact 
on central rather than peripheral (brachial artery) BP. Arterial stiffness may therefore 
predict LVM independent of brachial artery BP values. However, as indicated in chapter 
4, in this regard the present evidence is controversial. However, arterial stiffness is 
greater in groups of African as compared to European ancestry (Din-Dzietham et al 2004; 
Shiburi et al 2006; Chaturvedi et al 2004) and there are no studies evaluating the brachial 
artery-independent effect of arterial stiffness on LVM in groups of African ancestry. In the 
present thesis I therefore determined whether the relationship between an index of 
arterial stiffness (pulse wave velocity [PWV]) or wave reflection (augmentation index [AI]) 
and LVM is independent of conventional BP in randomly recruited subjects of African 
ancestry (chapter 4). Applanation tonometry was performed at the carotid, radial and 
femoral arteries and central AI and aortic PWV (carotid-femoral) derived from these 
measures. LVM indexed for body surface area was determined using echocardiography. 
Univariate analysis demonstrated a relationship between PWV and LVM index (r=0.28, 
p<0.0001) and between AIc and LVM index (r=0.19, p<0.001), but on sex-specific 
analysis, the relationship between PWV and LVM index was present in women (r=0.49, 
p<0.0001), but not in men (r=0.06, p=0.54), whereas the relationship between AIc and 
LVM index was noted in both gender groups. After adjusting for body mass index, 
antihypertensive treatment, the presence or absence of diabetes mellitus or abnormal 
blood glucose control (HbA1c), non-independence of family members and either 
conventional systolic BP or pulse pressure, PWV (r=0.25, p<0.0005), but not AIc (p=0.40- 
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0.86) was independently associated with LVM index in females. In males, neither PWV 
nor AIc were associated with LVM index independent of conventional BP and other 
confounders. These data therefore suggest that PWV may refine the ability to predict 
LVM index beyond conventional BP in groups of African descent, but this effect is sex-
specific being limited to females only. 
As reviewed in chapter 1, a reduction of LVM is established as a desirable 
therapeutic goal in hypertension. However, there is substantial controversy as to whether 
conventional BP or ambulatory BP measurements should be used to assess changes in 
LVM index with antihypertensive therapy. Studies that have assessed this question have 
been conducted exclusively in groups of European descent. However, as groups of 
African descent have an attenuated nocturnal decline in BP (Profant and Dimsdale 1999, 
Wang et al 2006) and antihypertensive-induced decreases in LVM may therefore depend 
more on changes in ambulatory rather than conventional BP in this ethnic group. In the 
present thesis, I explored the extent to which changes in conventional and ambulatory BP 
predict regression of LVM index in response to antihypertensive treatment in previously 
untreated and treated patients of African ancestry with sustained hypertension (chapter 
5). In this study 173 patients who, off treatment, had a daytime diastolic BP ranging from 
90 to 114 mm Hg were enrolled. Antihypertensive drugs were titrated and combined to 
reduce the daytime diastolic BP below 90 mm Hg. Echocardiograms were obtained at 
baseline and follow-up. Mean systolic/diastolic clinic BP, 24-hour BP, and LVM index 
were similar in previously untreated (n=64) and previously treated (n=109) patients and 
averaged 171/102 mm Hg, 151/97 mm Hg, and 118 g/m2, respectively. At 4 months, 
these values had decreased (p<0.001) by 26/12 mm Hg, 23/14 mm Hg, and 14 g/m2 in 
previously untreated patients and by 22/9 mm Hg, 21/13 mm Hg, and 19 g/m2 in 
previously treated patients. In the previously untreated patients, the regression in LVM 
index correlated to a similar degree (p<0.09) with the decreases in the conventional 
(r=0.34; p<0.005) and the 24-hour (r=0.26; p<0.04) systolic BP. In the previously treated  
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patients, the corresponding correlations were 0.02 (p<0.82) and =0.10 (p<0.32), 
respectively. Compared with the 24-hour systolic BP, automated oscillometric 
measurements of systolic BP obtained at the clinic yielded similar results. These data 
indicated that in previously untreated patients of African ancestry with sustained 
hypertension followed at a single center, reductions in clinic and ambulatory systolic 
pressure in response to antihypertensive treatment equally predicted the regression in 
LVM index. Despite these conclusions, the limited sample size of untreated hypertensives 
prevented me from performing sex-specific analysis. Consequently, whether this effect is 
specific for women, and whether the conventional BP-independent relationship between 
nocturnal systolic BP and LVM index noted in men as described in chapter 3, translates 
into a greater importance for ambulatory as compared to conventional BP when 
predicting treatment-induced changes in LVM index requires further study. 
Recent evidence indicates that antihypertensive agents that target the RAS 
regress LVH more effectively than some other classes of antihypertensive agents, despite 
similar conventional BP effects (Devereux et al 20041, Zanchetti et al 2002). However, in 
these studies only a relatively small number of patients of African descent were recruited. 
In a sub-analysis in those patients of African ancestry that were recruited, RAS blockers 
did not show a BP-independent effect on LVM index (Devereux et al 20041). These data 
are consistent with small studies conducted in groups of African ancestry in South Africa 
conducted over relatiovely short periods (reviewed in chapter 1). However, the regression 
of LVH may only be achieved after 2 years of therapy. Thus, in the reduction of LVM, the 
relative importance of BP lowering versus the class of antihypertensive employed in 
groups of African ancestry remains uncertain. In chapter 6 I describe a single-centre, 
randomized trial where I explored the independent associations between LVM and both 
ambulatory BP and treatment with an ACE-I over a 25-month follow-up period. Patients of 
African ancestry (n=185 at enrollment) with a mean daytime diastolic BP ranging from 90-
114 mm Hg off-treatment were randomized to receive either enalapril, calcium channel  
  
- 177 - 
 
 
blockers (nifedipine or slow release verapamil), or hydrochlorothiazide as initial therapy. 
Doses were increased and additional therapy, including enalapril, added to achieve a 
target daytime diastolic BP below 90 mm Hg. At 4, 13 and 25 months of therapy 66, 71 
and 72 % of patients had BP values within target ranges. LVM index decreased from 
118±33 g/m2 at baseline to 101±25, 101±23, and 96±22 g/m2 at 4, 13 and 25 months of 
therapy (p<0.001 compared to baseline). Accounting for effects on either ambulatory or 
conventional BP at each time point, the use of enalapril was associated with neither LVM 
index, nor with LV relative wall thickness over the treatment period. However, in-
treatment systolic conventional and night-time BP were associated with both LVMI 
(conventional; p= 0.01, night-time; p=0.01) and LV relative wall thickness (conventional; 
p=0.03, night-time; p=0.005). Although 24 hour and daytime BP were not associated with 
LVM index, both 24-hour (p=0.005) and daytime (p=0.017) BP were associated with in-
treatment LV relative wall thickness. These data indicated that in the treatment of 
hypertension in groups of African origins, the use of an ACE-I confers no additional 
benefits on LVM beyond that produced by effects on BP. 
As indicated above, although antihypertensive agents that target the RAS produce 
conventional BP-independent effects on LVM in groups of European ancestry, in 
hypertensives of African ancestry, this does not appear to be the case. However, groups 
of African ancestry also have distinct BP responses to antihypertensive agents that target 
the RAS (Sareli et al 2001, Woodiwiss et al 2006). Moreover, although I was able to 
demonstrate that the use of an ACE-I produced no appreciable benefit over that of BP 
changes in mediating a reduction of LVM over a 25-month treatment period, in this study, 
patients were not selected for the presence of LVH. Whether decreases in BP associated 
with the use of agents that specifically target the RAS predict regression of LVH in 
patients of African ancestry is therefore uncertain. In chapter 7 I addressed this question. 
In this chapter I describe a single-centre study where patients of African ancestry with a 
mean daytime diastolic ambulatory BP (ABP)>90 mm Hg and LVH on echocardiography  
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received candesartan cilexetil 8-16 mg once daily for 2 months followed by the addition of 
hydrochlorothiazide 12.5 mg daily for a further month and subsequently ramipril 2.5-5 mg 
daily for another 2 months if diastolic ABP remained>90 mm Hg. The impact of changes 
in ABP on alterations in LVM index was assessed. Of the 86 patients starting, 47 
completed the study. Candesartan monotherapy produced only modest decreases in ABP 
(from 153+17/95+6 to 151±18/93±7 mm Hg at 2 months, p<0.05). The addition of a 
diuretic resulted in a striking decrease in ABP (to 139±21/87±9 mm Hg at 3 months, 
p<0.0001 versus baseline), an effect that was only partially augmented by the addition of 
ramipril (p<0.05). LVM index decreased from 122±20 to 111±23 g/m2 (p<0.005) with 
treatment. Adjusting for gender, changes in systolic ABP (daytime, r=0.46, p=0.006) were 
predictive of changes in LVM index. These results suggested that in hypertensive patients 
of African ancestry receiving therapy targeting the RAS and a diuretic agent, changes in 
systolic BP may be an appropriate surrogate for target organ effects. Clearly the 
outcomes of this study may have been largely driven by the impact of the diuretic agent 
on BP. However, diuretic agents at this dose, when used as monotherapy, do not mediate 
such profound decreases in systolic BP (~12 mm Hg on average in 24-hour systolic BP) 
in this ethnic group (Skoularigis et al 1995, Sareli et al 2001). Therefore, the impact of 
antihypertensive therapy on BP and LVM index can only be attributed to combination 
therapy and thus in-part to RAS blockade.  
 Although antihypertensive agents that target the RAS have a limited efficacy when 
used as monotherapy in patients of African ancestry (Sareli et al 2001, Woodiwiss et al 
2006, chapter 7), there are compelling indications for their use, including the presence of 
LVH (Hypertension Society of Southern Africa, [Seedat et al 2006], The Joint National 
Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure 
2003). Although when used alone RAS blockers have little antihypertensive efficacy in 
many patients of African descent, when used together with a diuretic agent, the synergy 
between these two classes of agents enhances the effects of either class used alone.  
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However, in the treatment of hypertension in subjects of African origins, there is question 
as to whether diuretic therapy, followed by the addition of an ACE-I is as effective as 
calcium channel blockers on BP and LVM. In chapter 8 I have described a study where I 
compared the effects of slow release (SR) indapamide (diuretic agent) with the addition of 
an ACE-I to that of the calcium channel blocker, amlodipine, when used as initial therapy, 
on BP and LVM over 6 months of treatment in patients of African descent. Patients with 
mean daytime ambulatory diastolic BP (DADBP) ≥90 mm Hg and ≤110 mm Hg (n=125, 
age 53 + 11, 68% female) were randomized to receive open-label indapamide SR 1.5 mg 
or amlodipine 5 mg. If DADBP at 1 month was ≥ 90 mm Hg, perindopril 4 mg was added 
to indapamide SR or the dose of amlodipine was increased to 10 mg. After 1 month, there 
was an equivalent decline in systolic and diastolic BP in the two groups (p<0.0001). In the 
indapamide SR treated group (n=62) the daytime BP decreased from 153±12/101±6 to 
138±15/92±10 mm Hg and in the amlodipine treated group (n=58) it decreased from 
152±13/99±5 to 138±12/91±8 mm Hg. At 6 months DABP decreased to 130±15/86±8 and 
to 129±11/85±5 mm Hg for the indapamide SR (n=42) and amlodipine (n=44) treated 
groups respectively. Both groups showed equivalent regression in LVM index. These data 
suggest that in hypertensive patients of African ancestry initiating therapy with the 
diuretic, indapamide SR and then adding the ACE-I, perindopril 4 mg, is equally as 
effective as amlodipine (calcium channel blocker) therapy at reducing BP and modifying 
target organ changes. 
The individual studies described in the present thesis have a number of limitations 
all of which have been acknowledged in the “discussion” section of the relevant chapters, 
and hence will not be elaborated on again. However, in addition, overall the present 
thesis is limited by the absence of additional studies or analyses that are presently still 
being conducted and go beyond the scope of the present thesis. First, I was unable to  
account for a large portion of the variability in LVM in the cross-sectional studies 
performed. Additional factors that may account for a considerable portion of the variability  
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of LVM in the population studied could include synergy as opposed to just additive effects 
between adiposity and BP; as well as an impact of genetic factors. Presently, the cross-
sectional study performed on nuclear families is under-sized to perform intrafamilial 
aggregation analysis on LVM index. Once this study is sufficiently powered to perform 
these analyses they will be conducted. Second, a prospective, intervention-based study 
assessing whether arterial stiffness changes are able to predict the regression of LVH 
independent of conventional BP is outstanding. This study is presently being planned and 
will be conducted once we have an understanding of the conventional BP-independent 
impact of arterial stiffness on other target organ changes, including urinary albumin-to-
creatinine ratios. 
Thus, in conclusion, the present thesis contributes to our knowledge of LVM in 
groups of African descent living in Africa in the following way. First, I have been able to 
demonstrate the appropriate allometric signals that adjust for growth effects on LVM in 
this group and that growth signal signals for other populations are inappropriate for the 
present population. Second, in groups of African ancestry living in Africa, nocturnal BP 
appears to have a conventional BP-independent effect on LVM in men, but not in women, 
but this requires confirmation in a larger group of men. In contrast, in this same 
population group, arterial stiffness appears to have a conventional BP-independent effect 
on LVM in women, but not in men. Third, in this population, reductions in LVM produced 
by antihypertensive therapy appear to be equally as closely related to conventional as 
ambulatory BP, but further studies are required in men. Fourth, in contrast to findings in 
groups of European ancestry, where RAS blockers produce unique benefits on LVM 
beyond conventional BP reductions, in groups of African ancestry in Africa, RAS blockers 
produce no BP-independent effects on reductions in LVM. Moreover, in this population, 
decreases in LVM in patients with LVH produced by RAS blockers are related to BP  
changes. Last, despite the ineffectiveness of RAS blockers on BP when used as 
monotherapy, RAS blockers together with diuretics are equally as efficacious in  
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decreasing BP and LVM as compared to a class of antihypertensive agents with 
established efficacy in this population (calcium channel blockers). Hence when 
compelling indications for RAS blockade exist, RAS blocker-diuretic combinations are 
effective therapy in patients of African descent living in Africa. 
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APPENDIX 1 
 
Formulae for left ventricular (LVM) mass derived from echocardiography measurements. 
 
1). LV mass calculated according to the American Society of echocardiography 
convention without adjustments for potential over-corrections. 
 
LVM = 0.8 x [1.04 (LVEDD + IVS +PWT) 3 – (LVEDD) 3] 
 
where LVEDD = LV internal diameter, IVS =LV septal thickness, PWT = posterior 
wall thickness, all measured at diastole in centimeters. 
 
2. LV mass calculated according to the American Society of echocardiography 
convention with the Devereux correction adjusting for over-corrections. 
 
LVM = 0.8 x [1.04 (LVEDD + IVS +PWT) 3 – (LVEDD) 3] + 0.6g 
 
3. LV mass calculated according to the Penn Method  
 
LVM
 
= [1.04 (LVEDD + IVS +PWT) 3 – (LVEDD) 3] - 13.6g 
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